Methodology

Sources & Methodology

The public technical contract for Milligram’s data and reasoning layer. Every pharmacokinetic parameter we ship is anchored to peer-reviewed literature; every computation is textbook math; every quantitative claim resolves to a published paper. This page lists the formulas, the constants, and the citations.

01 · Coverage by therapeutic class

Compounds are organised into 13 therapeutic classes. Pharmacokinetic depth scales with the published literature available — peptides with formal popPK studies receive the full quantitative parameter set; those with only animal or in-vitro data receive observational dose-range cohorts and qualitative mechanism profiles.

Each compound entry carries population pharmacokinetic parameters, route options, dose-range cohorts, mechanism summaries, evidence-quality grading, interaction flags, and a literature reference list. The reference set per compound averages 25 sources (range: 8–30+) and is enumerated in §12 below.

02 · Pharmacokinetic engine

Plasma concentration over time is computed from the user’s actual dose history using closed-form solutions to standard compartmental ordinary differential equations. The model class per compound (one-compartment vs two-compartment, oral first-order absorption vs depot subcutaneous flip-flop) is set per-entry from the published literature.

2.1 One-compartment Bateman (oral / fast-SubQ absorption)

For compounds with first-order absorption and first-order elimination, plasma concentration after a single dose follows the Bateman equation:

C(t) = (F · D · ka) / (Vd · (ka − ke)) · (e^(−ke·t) − e^(−ka·t))

where:
  ke = ln(2) / t½_elimination
  ka = ln(2) / t½_absorption
  F  = bioavailability (0–1)
  Vd = volume of distribution (L)
  D  = dose (mg)
  t  = hours since dose

The L’Hôpital limit is handled when |ka − ke| approaches zero. Reference: Gibaldi & Perrier, Pharmacokinetics, 2nd ed., §3.3.

2.2 Two-compartment biexponential (deep-tissue redistribution)

For compounds with significant deep-tissue redistribution (cabergoline, dutasteride, certain long-ester nandrolone preparations) the macro-constant biexponential form is used. Macro coefficients are stored per-compound from published clinical PK papers:

C(t) = D · F · (A · e^(−α·t) + B · e^(−β·t))

A, B   — macro coefficients (mg/L per mg dose)
α, β   — rate constants (h⁻¹)

Reference: Gibaldi & Perrier §3.3 (oral multi-compartment).

2.3 Multi-dose superposition

Plasma concentration under realistic dosing is the sum of single-dose contributions across the user’s actual logged history:

C_total(t) = Σᵢ C_i(t − tᵢ)

The summation window is bounded at ten elimination half-lives per compound (ten times the slower of α or β for two-compartment systems). Reference: Gibaldi & Perrier §10.5 (multi-dose superposition).

2.4 Steady-state concentration at interval τ

C_ss(t') = (F · D · ka) / (Vd · (ka − ke)) ·
           [(e^(−ke·t') / (1 − e^(−ke·τ)))
          − (e^(−ka·t') / (1 − e^(−ka·τ)))]

time-to-steady-state ≈ 4.5 × t½  (~94 % of asymptotic Cavg)

Reference: Rowland & Tozer, Clinical Pharmacokinetics, §10.5.

2.5 Effective-regimen Cavg (titration-aware)

Static half-life-only formulae read 100 % within a single dosing interval and fail to track real-world titration patterns (e.g. semaglutide 0.25 → 0.5 → 1.0 mg). The effective-regimen Cavg anchors the projected steady-state mean to the user’s actual recent dosing pattern over a sliding window:

Cavg_proj = F · D_eff / (CL · τ_eff),     CL = ke · Vd

D_eff   = mean dose (mg) over the trailing dosing window
τ_eff   = mean inter-dose interval over the same window
buildup% = min(100, max(0, C_now / Cavg_proj × 100))

Reference: Rowland & Tozer §10.5.

2.6 Non-linear pharmacokinetics

For compounds with saturable elimination or Michaelis–Menten kinetics, closed-form superposition is invalid. Numerical integration of the governing ODEs is performed using adaptive step-size Runge–Kutta methods with embedded error estimation. References: Press et al, Numerical Recipes, 3rd ed., ch. 17 (Runge–Kutta methods); Cash & Karp, ACM Transactions on Mathematical Software 16(3):201–222, 1990 (adaptive coefficients); Wagner 1973 (saturable Michaelis–Menten kinetics in pharmacokinetics).

2.7 Engine constants

03 · Reference-compound parameter set

The three GLP-1 receptor agonist class peptides — semaglutide, tirzepatide, retatrutide — carry the deepest published PK literature of any modern peptide. Quantitative outputs (Monte‑Carlo confidence bands, receptor occupancy, expected weight trajectory) are computed exclusively for these three compounds. For peptides outside this set, the reasoning layer degrades to qualitative copy with explicit hedging — never to fabricated numbers.

3.1 Molecular weights (concentration-unit conversion)

3.2 Population pharmacokinetic variability

Coefficient-of-variation values are taken directly from the published popPK papers and used in confidence-band Monte Carlo sampling. Sample sizes vary — semaglutide is the best-characterised, retatrutide the widest band reflecting Phase 1 sample sizes.

3.3 Allometric clearance scaling

iCL = pCL · (BW / 70)^exponent

tirzepatide:           0.8     (Schneck 2024 — explicit semi-mechanistic)
semaglutide / reta:    0.75    (textbook default; no published explicit number)

Used observationally only; never to recommend dose adjustment.

3.4 Confidence-band sampling

Steady-state Cmin / Cavg / Cmax are reported as percentile bands (p5 / p50 / p95) rather than point estimates, computed by log-normal Monte Carlo over the published popPK CV values (1,000 samples per call). Population PK parameter uncertainty (CV 25–50 %) dominates user-data uncertainty by 5–10×, so the band reflects the real precision available.

04 · Receptor pharmacology

For receptor-binding questions on the three reference compounds, occupancy at the user’s instantaneous plasma concentration is computed via the Hill–Langmuir equation against published EC₅₀ values from cAMP-response assays:

occupancy = [C] / ([C] + EC50)

Hill coefficient n = 1   (standard approximation for GPCR peptide agonism)

4.1 EC₅₀ panel (nanomolar)

4.2 Receptor reserve framing

Output is reported as “above the threshold for full receptor activation” rather than a binding-ratio percentage. The pharmacological rationale: receptor reserve / spare receptors mean EC₅₀ represents the cAMP-equivalent threshold for full downstream signal — not a saturation ceiling. Stating “X % receptor occupancy” misrepresents the underlying signal-transduction physiology.

4.3 Multi-agonist redundancy detection

For stacks containing more than one GLP-1RA-class agonist, per-receptor occupancy is summed across all modelable agonists. When a single compound’s occupancy already exceeds 0.95 on a given receptor, additional agonists are flagged as redundant on that channel — synergy is only achievable across compounds with non-overlapping receptor targets.

05 · Clinical-trial trajectory bands

Expected percent weight loss from baseline is derived from the published primary endpoint cohorts. Inter-week values are linear-interpolated between published anchors. Bands widen at long timepoints (spread scaled with √week) to reflect inter-subject variance accumulating with duration.

5.1 Semaglutide — STEP-1 / STEP-5

Wilding et al, NEJM 2021 (n=1,961, 68 wk, 2.4 mg/wk); Garvey et al, Nature Medicine 2022 (n=304, 104 wk extension).

5.2 Tirzepatide — SURMOUNT-1

Jastreboff et al, NEJM 2022 (n=2,539, 72 wk).

5.3 Retatrutide — Phase 2

Jastreboff et al, NEJM 2023 (n=338, 48 wk).

5.4 Confirmatory head-to-head

SURMOUNT-5 (Aronne et al, NEJM 2025) — tirzepatide 15 mg vs semaglutide 2.4 mg head-to-head: −20.2 % vs −13.7 % mean change in body weight.

5.5 Real-world cohort context

Retrospective real-world cohorts (Truveta and Epic Cosmos derivatives) report mean weight loss of 11–13 % at 12 months on semaglutide 1.7–2.4 mg — lower than trial means due to observational titration patterns and adherence drop-off versus the controlled trial environment.

5.6 Cardiovascular and renal outcomes context

Outcome-trial corroboration of the GLP-1RA class beyond weight: SUSTAIN-6 (Marso et al, NEJM 2016) — 26 % MACE reduction in T2D (n=3,297). SELECT (Lincoff et al, NEJM 2023) — 20 % MACE reduction in non-diabetic CVD population (n=17,604, mean 39.8 months). FLOW (Perkovic et al, NEJM 2024) — 24 % major kidney event reduction in T2D + CKD (n=3,533).

06 · Cardiovascular class effect

The expected resting heart rate and HRV deltas on GLP-1 receptor agonists are a class effect, observed across all three reference compounds rather than a compound-specific finding. From a 12-week wearable cohort:

Source: Brunetti et al, American Journal of Physiology – Heart, 12-wk wearable cohort, 2025.

07 · Renal function

For bloodwork interpretation involving renal function, two equations are computed in parallel: the FDA-preferred form for drug-dosing decisions (Cockcroft–Gault) and the current NKF/ASN clinical standard (CKD-EPI 2021, race-free). Both are used observationally — neither is used to suggest peptide dose adjustment. The three reference compounds clear by proteolysis and fatty-acid β-oxidation, not via renal pathways; FDA labels accordingly state no dose adjustment at any eGFR including ESRD.

7.1 Cockcroft–Gault (FDA-preferred drug-dosing form)

CrCl = ((140 − age) · weight_kg) / (72 · SCr_mg/dL)
       × 0.85    if female

returns mL/min

Reference: Cockcroft & Gault 1976.

7.2 CKD-EPI 2021 (NKF/ASN current standard)

eGFR = 142 · min(SCr/κ, 1)^α
            · max(SCr/κ, 1)^−1.200
            · 0.9938^age
            · 1.012   [if female]

κ = 0.7    (female)   /   0.9   (male)
α = −0.241 (female)   /   −0.302 (male)

returns mL/min/1.73 m²

Reference: Inker et al, NEJM 2021.

7.3 KDIGO 2024 stage labels

08 · Statistical methods

Correlations between any two named time series (sleep total vs resting heart rate, body weight vs week, mood vs cumulative dose count, biomarker vs biomarker) are computed via Pearson product-moment for linear continuous metrics and Spearman rank for ordinal or monotonic relationships. Sample size, p-value, and a low-confidence flag are returned at every call to enforce statistical discipline at the data layer.

8.1 Pearson product-moment correlation

r = Σ (x − x̄)(y − ȳ) / √(Σ(x − x̄)² · Σ(y − ȳ)²)

p-value via t-distribution, df = n − 2:
  t = r · √(df / (1 − r²))

8.2 Standard normal CDF approximation

The two-sided p-value computation passes the t-statistic through the Wilson–Hilferty cube-root transformation to a standard normal, then evaluates the cumulative distribution function via the Abramowitz & Stegun §26.2.17 polynomial approximation. Wilson–Hilferty produces accurate p-value estimates for n ≥ 7; below that threshold, the low-confidence flag fires regardless of the coefficient magnitude.

8.3 Spearman rank correlation

Each series is converted to average ranks (ties handled by averaging tied positions), then Pearson is computed on the ranks. Equivalent to standard Spearman ρ at consumer-app fidelity.

8.4 Statistical discipline at the data layer

Below n = 7, the low-confidence flag fires. The reasoning layer is constrained to refuse to name a coefficient under that condition, instead reporting that the sample is too small to claim a real pattern. The discipline is enforced in the data path itself, not at the narrative layer.

09 · Per-compound research profiles

114 compounds carry a long-form research profile in addition to the parametric data set. Each profile is structured around three voice tiers — clinical-published, community-aggregated, and named-individual — to keep the signal traceable per claim:

• Clinical-published research prose — every claim carries an inline numbered citation that resolves to an entry in the profile’s reference list (DOI, PubMed, NCT, FDA label, EMA assessment, WADA listing, drug monograph).
• Community-aggregated data — dose-range cohorts, three named real-world dosing protocols per compound (with frequency % and sample size), self-reported side-effect frequencies. Every aggregated number carries the n it was derived from.
• Named-individual quotes — clinicians, researchers, and named educators quoted with attribution and source URL.
• Sentiment summary — % positive across mentions over a stated time window, sample size disclosed.
• Regulatory status block — FDA approval dates, WADA listing, compounding-pharmacy regulation milestones, EMA / international regulatory references.
• Weekly timeline — week 1, weeks 2–3, weeks 4–6, weeks 8–12, off-cycle.
• Side-effect split — clinical (trial-derived) and forum (self-reported) frequencies displayed side-by-side, never conflated.
• Bloodwork markers — per-marker interpretation guidance with literature anchors.
• Practical notes — reconstitution math, optimal injection site, optimal timing, storage stability under defined temperature ranges.

9.1 Texture sample — semaglutide research prose

An excerpt showing the clinical-published voice tier, with inline numbered citations resolving to the profile’s sources array:

The full numbered references array per compound is enumerated below in §12 H.

10 · Reasoning layer

The reasoning layer sits on top of the data described above and is what users interact with when they ask a natural-language question. It exists to surface what the dataset already contains — not to generate new content from training data. Architecturally, the layer is structured around a single discipline: every quantitative claim must resolve to a deterministic computation against the literature-anchored parameter set. Where that computation cannot be performed, the layer is constrained to refuse rather than fabricate.

10.1 Computation, not pattern-matching

Numeric outputs surfaced in chat — plasma levels, receptor occupancy, expected weight trajectories, steady-state confidence bands, correlation coefficients across user metrics — are computed by the engines described in §02–§08, then returned to the response surface. The reasoning layer renders results; it does not estimate them. This is the structural reason the system can ground a claim like “sitting roughly 224× over the published GIPR EC₅₀” in a citable paper rather than a plausible-sounding training-data artefact.

10.2 Confidence bands surface as ranges

For population pharmacokinetic outputs, the underlying truth is a band, not a point. Population PK parameter uncertainty (CV 25–50 % on the three reference compounds) dominates user-data uncertainty by 5–10×. The reasoning layer is constrained to surface percentile ranges (p5 / p50 / p95) rather than collapse to a single estimate — the resulting answer reflects the precision actually available in the published literature, not the precision a confidently-phrased sentence might imply.

10.3 Statistical discipline enforced at the data layer

Correlation queries return coefficient, sample size, p-value, and a low-confidence flag. Below n = 7, the flag fires and the layer is structurally prevented from naming the coefficient in narrative output, instead reporting that the sample is too small to claim a real pattern. The discipline is enforced at the call boundary, not relied upon to be remembered at the narrative layer.

10.4 Reference vs investigational compounds

For the three GLP-1RA reference compounds (semaglutide, tirzepatide, retatrutide), full quantitative output is available — Monte Carlo confidence bands, receptor occupancy fractions, trajectory comparisons against trial cohorts. For peptides outside this set (BPC-157, GHK-Cu, MOTS-c, sermorelin, ipamorelin, tesamorelin, all SARM / AAS / PCT / supplement entries), the layer surfaces literature-anchored mechanism, observational dose-range cohorts, and per-compound research profile content only. The asymmetry is intentional: the reference set is where the literature supports quantitative answers; the investigational set is where it does not, and the layer reflects that boundary in the output.

10.5 Source traceability

Long-form responses on a specific compound resolve to the per-compound research profile described in §09 — including its three voice tiers (clinical-published, community-aggregated, named-individual) and its numbered reference list. Claims that originate from a research profile are traceable back to the citation that anchors them. The reasoning layer does not synthesise new clinical conclusions on top of profile content; it surfaces what is in the profile, with attribution preserved.

10.6 What the reasoning layer is constrained against

• Synthesising new clinical conclusions from training data alone — every numeric output anchors to the engines or the published reference set.
• Estimating pharmacokinetic parameters for compounds without published anchors — the layer surfaces qualitative mechanism and observational cohort framing only.
• Collapsing confidence bands to point estimates — population uncertainty is preserved in the response, not optimised away.
• Interpreting correlations below the statistical-significance threshold — the low-confidence flag is structural, not narrative.
• Providing medical advice or prescriptive recommendations — output is observational throughout.
• Conflating clinical (trial-derived) data with self-reported (forum-derived) data — the two are kept distinct end-to-end through the response surface.

The result is a chat surface that behaves more like a literature-anchored compute interface with prose framing than a generative writing interface with numbers attached. Where the literature is rich, the answer is rich; where the literature is sparse, the answer is sparse — and the user is told which they are looking at.

11 · Why this dataset is structurally exclusive

Real-world peptide and modulator use sits outside the formal clinical-trial system. Pharmaceutical companies cannot run randomised controlled trials on grey-market peptide protocols, off-label dosing patterns, or stacks combining multiple compounds — the regulatory status, supply chain, and prescribing pathway preclude controlled-study capture. Existing real-world evidence (RWE) datasets — Optum, Truveta, Epic Cosmos, Komodo — capture electronic health records and claims data, which means they capture prescribed use of approved peptides, missing the substantial off-label and grey-market population entirely.

Milligram’s data layer captures longitudinal dose history, biomarker uploads, weekly subjective ratings, wearable-derived heart-rate and sleep metrics, and progress photographs across this population — at a granularity and population coverage that no claims dataset replicates. The structural exclusivity is the population, not the methodology.

The framing on this page is observational throughout. The dataset describes what users do; it does not prescribe what they should do.

12 · Full reference list

Tier A through tier G are the named anchor references behind the engine, the receptor panel, the trajectory bands, and the regulatory backbone of the dataset. Tier H expands every per-compound literature reference list — 114 profiles, 2,833 references — collapsed by compound for navigation.

A. Pharmacokinetic foundations

• Gibaldi & Perrier — Pharmacokinetics, 2nd ed., §3.3 (oral multi-compartment) and §10.5 (multi-dose superposition). Marcel Dekker, 1982.
• Rowland & Tozer — Clinical Pharmacokinetics: Concepts and Applications, §10.5 (steady-state and Cavg). Lippincott Williams & Wilkins, 4th ed.

B. Numerical methods

• Press et al — Numerical Recipes: The Art of Scientific Computing, 3rd ed., ch. 17 (Runge–Kutta methods). Cambridge University Press, 2007.
• Cash & Karp — A variable-order Runge–Kutta method for initial-value problems. ACM Transactions on Mathematical Software 16(3):201–222, 1990.
• Wagner — Saturable Michaelis–Menten kinetics in pharmacokinetics. J Pharm Sci, 1973.
• Abramowitz & Stegun — Handbook of Mathematical Functions, §26.2.17 — polynomial approximation for the standard normal CDF.
• Toutain & Bousquet-Mélou — Bioavailability and its assessment: flip-flop kinetics. Journal of Veterinary Pharmacology and Therapeutics, 2004.

C. Reference-compound population PK and receptor pharmacology

• Overgaard et al, 2019 — Population pharmacokinetics of semaglutide. Clinical Pharmacokinetics. PMC6437231
• Schneck et al, 2024 — Population pharmacokinetics of tirzepatide. Clinical Pharmacokinetics. PMC10962491
• Coskun et al, 2022 — Retatrutide pharmacokinetics and triple GIP / GLP-1 / glucagon agonism. Cell Metabolism. doi:10.1016/j.cmet.2022.07.001
• Lau et al, 2015 — Discovery of the once-weekly GLP-1 analogue semaglutide. PMID 26308095
• Willard et al, 2020 — Tirzepatide GIPR / GLP-1R EC₅₀ panel and biased dual agonism. JCI Insight 140532. insight.jci.org/articles/view/140532

D. Clinical-trial pivots

• Wilding et al, 2021 — STEP-1 — Once-weekly semaglutide 2.4 mg in adults with overweight or obesity. NEJM, n=1,961, 68 wk. NEJMoa2032183
• Garvey et al, 2022 — STEP-5 — Semaglutide 2.4 mg in adults with obesity, 104-week extension. Nature Medicine, n=304. s41591-022-02026-4
• Marso et al, 2016 — SUSTAIN-6 — Semaglutide cardiovascular outcomes in type 2 diabetes. NEJM, n=3,297. NEJMoa1607141
• Lincoff et al, 2023 — SELECT — Semaglutide MACE reduction in non-diabetic cardiovascular disease population. NEJM, n=17,604. NEJMoa2307563
• Perkovic et al, 2024 — FLOW — Semaglutide kidney outcomes in T2D + CKD. NEJM, n=3,533. NEJMoa2403347
• Jastreboff et al, 2022 — SURMOUNT-1 — Tirzepatide in adults with obesity. NEJM, n=2,539, 72 wk. NEJMoa2206038
• Jastreboff et al, 2023 — Retatrutide Phase 2 — Triple agonist retatrutide Phase 2 in obesity. NEJM, n=338, 48 wk. NEJMoa2301972
• Aronne et al, 2025 — SURMOUNT-5 — Tirzepatide vs semaglutide head-to-head: 20.2 % vs 13.7 %. NEJM. NEJMoa2416394

E. Renal function

• Cockcroft & Gault, 1976 — Prediction of creatinine clearance from serum creatinine. FDA-preferred form for drug-dosing decisions.
• Inker et al, 2021 — New creatinine- and cystatin C-based equations to estimate GFR without race (CKD-EPI 2021). NEJM. NEJMoa2102953
• KDIGO 2024 — Kidney Disease Improving Global Outcomes — CKD evaluation and management guideline.

F. Cardiovascular wearable cohort

• Brunetti et al, 2025 — GLP-1RA effects on resting heart rate and HRV — 12-week wearable cohort. American Journal of Physiology – Heart.

G. Regulatory authorities and reference databases

• FDA — Drugs@FDA — Approved drug products with prescribing information. accessdata.fda.gov
• FDA — Drug Shortages and Compounding — Shortage list and 503A/503B compounding regulation. fda.gov/drugs
• DailyMed — NLM structured prescribing information. dailymed.nlm.nih.gov
• European Medicines Agency — EU-approved medicines and assessment reports. ema.europa.eu
• World Anti-Doping Agency — Prohibited list and monitored substances. wada-ama.org
• DrugBank — Drug and pharmacokinetic reference database. go.drugbank.com
• PubMed — NLM biomedical literature index. pubmed.ncbi.nlm.nih.gov
• ClinicalTrials.gov — NIH registry of clinical trials. clinicaltrials.gov

H. Per-compound literature references

Every entry in each compound’s reference list, expanded compound by compound. References include peer-reviewed PubMed and PMC citations, NEJM and other primary clinical journals, ClinicalTrials.gov NCT registrations, FDA prescribing information, EMA assessment reports, WADA listings, manufacturer monographs, and named-creator commentary with attribution.

5-Amino-1MQ22 references

1. r/Peptides 5-Amino-1MQ thread aggregation (last 12 months, n=~310) — reddit.com/r/Peptides 5-Amino-1MQ threads
2. r/PeptideStacks + r/longevity + r/biohackers thread aggregation — reddit.com/r/PeptideStacks 5-Amino-1MQ threads
3. FDA April/May 2026 Category 2 list — does not include 5-Amino-1MQ (small molecule, not a peptide) — fda.gov — 503A bulks list April/May 2026 Category 2 update
4. FDA 503A compounding pharmacy regulatory frame — fda.gov — 503A overview
5. WADA 2026 Prohibited List — S0 non-approved-substance catch-all — wada-ama.org — 2026 Prohibited List
6. Neelakantan H et al., ACS Med Chem Lett 2017 — discovery of small-molecule NNMT inhibitors — pubmed.ncbi.nlm.nih.gov/29094925
7. Neelakantan H et al., ACS Med Chem Lett 2018 — 5-Amino-1MQ in diet-induced obese mice — pubmed.ncbi.nlm.nih.gov/29408414
8. Neelakantan H et al., Biochem Pharmacol 2018 — NNMT inhibition mechanism review — pubmed.ncbi.nlm.nih.gov/30312715
9. Kraus D et al., Nature 2014 — NNMT, adipose tissue, obesity — pubmed.ncbi.nlm.nih.gov/24717514
10. Neelakantan — fat mass reduction + lean mass preservation in obese mice — pubmed.ncbi.nlm.nih.gov/30348635
11. NNMT inhibition + lipid metabolism, rodent model — pubmed.ncbi.nlm.nih.gov/32094320
12. Follow-up rodent study on NNMT inhibition + adipocyte energy expenditure — pubmed.ncbi.nlm.nih.gov/33161413
13. ClinicalTrials.gov 5-Amino-1MQ registry — no completed or recruiting human trials as of April 2026 — clinicaltrials.gov — 5-Amino-1MQ search
14. Community dose + administration consensus (oral capsule, AM with food) — r/Peptides — 5-Amino-1MQ dosing megathread
15. Lucas Aoun — Boost Your Biology 5-Amino-1MQ episode — youtube.com/@BoostYourBiology
16. Joe Cohen / SelfHacked — 5-Amino-1MQ overview — selfhacked.com
17. Dr. Kyle Gillett — Gillett Health 5-Amino-1MQ segment — youtube.com/@GillettHealth
18. Andrew Huberman — NAD+/NNMT pathway discussion — hubermanlab.com — NAD+ / longevity discussion
19. r/longevity 8-week cycle outcome threads — reddit.com/r/longevity — 5-Amino-1MQ cycle results threads
20. Whole-blood NAD+ assay validation discussion — pubmed.ncbi.nlm.nih.gov/35064079
21. r/biohackers NNMT-pathway thread aggregation — reddit.com/r/biohackers — NNMT inhibitor discussion
22. NNMT in adipose tissue + metabolic disease review — pubmed.ncbi.nlm.nih.gov/31402260

Anastrozole (Arimidex)25 references

1. r/Testosterone anastrozole / TRT-context thread aggregation (last 12 months) — reddit.com/r/Testosterone — anastrozole threads
2. r/TRT anastrozole thread aggregation — reddit.com/r/TRT — anastrozole threads
3. r/Steroids anastrozole / cycle support thread aggregation — reddit.com/r/Steroids — anastrozole threads
4. FDA Arimidex (anastrozole) prescribing information — 1995 approval, 1mg/day breast cancer dose — accessdata.fda.gov/drugsatfda_docs/label/2010/020541s026lbl.pdf
5. WADA Prohibited List — Section S4 (hormone and metabolic modulators), aromatase inhibitors prohibited at all times — wada-ama.org/en/prohibited-list
6. Plourde PV et al. — anastrozole pharmacology / aromatase inhibition mechanism — pubmed.ncbi.nlm.nih.gov/8634049
7. Buzdar AU et al. J Clin Oncol 2002 — ATAC trial foundation data — pubmed.ncbi.nlm.nih.gov/12351124
8. Anastrozole dose-response in postmenopausal women — >80% E2 suppression at 1mg/day — pubmed.ncbi.nlm.nih.gov/10475055
9. r/PEDs anastrozole + LC/MS sensitive assay community consensus thread — reddit.com/r/PEDs — anastrozole + sensitive E2 megathread
10. Leder BZ et al. JCEM 2004 — E2 suppression effects on bone in men — pubmed.ncbi.nlm.nih.gov/15531497
11. Burnett-Bowie SA et al. JCEM 2009 — anastrozole in men with hypogonadism, bone density outcomes — pubmed.ncbi.nlm.nih.gov/19825816
12. Finkelstein JS et al. NEJM 2013 — E2 and T independent effects on body composition / sexual function in men — pubmed.ncbi.nlm.nih.gov/24024838
13. Mauras N et al. JCEM 2009 — aromatase inhibition in boys with delayed puberty — pubmed.ncbi.nlm.nih.gov/19033366
14. Peter Attia — skeptical-of-routine-AI position on TRT — peterattiamd.com — TRT estradiol AMA
15. Kyle Gillett MD — TRT estradiol management episode — youtube.com/@GillettHealth
16. r/Testosterone aggregation of clinician-walking-back-AI-prescribing discussions — reddit.com/r/Testosterone — clinical consensus shift threads
17. Bhasin S et al. — Endocrine Society 2018 testosterone therapy guideline (does not endorse routine AI use) — academic.oup.com/jcem/article/103/5/1715
18. Aromatase inhibition adverse lipid shift literature — pubmed.ncbi.nlm.nih.gov/14671196
19. More Plates More Dates anastrozole / TRT estradiol management video — youtube.com/@MorePlatesMoreDates
20. Gillett Health podcast — TRT estradiol management — youtube.com/@GillettHealth — TRT estradiol episode
21. Peter Attia — TRT estradiol AMA segment — peterattiamd.com/AMA — TRT estradiol
22. Tony Huge / Enhanced Athlete cycle support content — youtube.com/@EnhancedAthlete
23. Greg Doucette estradiol video — youtube.com/@GregDoucette
24. r/Testosterone wiki — anastrozole crash report aggregation — reddit.com/r/Testosterone/wiki/anastrozole
25. Mauras N — aromatase inhibition long-term safety considerations in male physiology — pubmed.ncbi.nlm.nih.gov/12930931

Andarine (S-4)24 references

1. r/sarmssourcetalk Andarine thread aggregation (last 12 months, n=~520) — reddit.com/r/sarmssourcetalk Andarine threads
2. r/PEDs Andarine / S-4 thread aggregation — reddit.com/r/PEDs S-4 threads
3. FDA SARM consumer warning — fda.gov — public warning on SARMs as research chemicals
4. FDA SARM warning letter archive — fda.gov — warning letters to SARM-marketing supplement companies
5. Gao W, Bohl CE, Dalton JT — Endocrinology 2005, S-4 SARM characterization — pubmed.ncbi.nlm.nih.gov/15860548
6. Yin D, He Y, Perera MA, et al. — J Pharmacol Exp Ther 2003, in vivo S-4 pharmacology — pubmed.ncbi.nlm.nih.gov/12606704
7. Mohler ML, Bohl CE, Jones A, et al. — J Med Chem 2009, SARM medicinal chemistry review — pubmed.ncbi.nlm.nih.gov/19530654
8. Foley TL, et al. — Drug Test Anal 2013, S-4 detection methods — pubmed.ncbi.nlm.nih.gov/23740686
9. S-4 vision side effect — case report (yellow tint, reduced night vision, reversible) — pubmed.ncbi.nlm.nih.gov/27867824
10. Androgen receptor expression in human retina — anatomical basis for retinal SARM binding — pubmed.ncbi.nlm.nih.gov/22001059
11. ClinicalTrials.gov S-4 registry (no completed Phase II/III) — clinicaltrials.gov — S-4 / Andarine search
12. SARM HPG-axis suppression review — pubmed.ncbi.nlm.nih.gov/30681442
13. WADA 2026 Prohibited List — S1.2 includes Andarine — wada-ama.org — 2026 Prohibited List, S1.2 SARMs
14. FDA consumer update on SARMs (research chemicals, not approved) — fda.gov/consumers/consumer-updates/sarms
15. Forum half-life PK and AM/PM split convention discussion — r/sarmssourcetalk — half-life and dosing convention threads
16. SARM-associated drug-induced liver injury case series — pubmed.ncbi.nlm.nih.gov/32616266
17. SARM hepatotoxicity narrative review — pubmed.ncbi.nlm.nih.gov/30403708
18. Selective androgen receptor modulators — clinical development status review — pubmed.ncbi.nlm.nih.gov/21831009
19. More Plates More Dates SARM overview (Derek) — youtube.com/@MorePlatesMoreDates
20. Enhanced Athlete SARM rundown (Tony Huge) — youtube.com/@EnhancedAthlete
21. Vigorous Steve SARM PK breakdown — youtube.com/@VigorousSteve
22. r/sarmssourcetalk pre/post-cycle bloodwork aggregation — reddit.com/r/sarmssourcetalk — bloodwork megathread
23. Community storage and shelf-life consensus for SARM liquids — r/sarmssourcetalk — storage / shelf-life threads
24. Forum discussion of PEG / propylene glycol solvent stability for SARM suspensions — r/sarmssourcetalk — SARM solvent stability threads

AOD-960424 references

1. r/Peptides AOD-9604 thread aggregation (last 12 months, n=~620) — reddit.com/r/Peptides AOD-9604 threads
2. r/PeptideStacks AOD-9604 thread aggregation — reddit.com/r/PeptideStacks AOD-9604 threads
3. r/longevity AOD-9604 discussion threads — reddit.com/r/longevity AOD-9604 threads
4. Stier H et al., Diabetes Obes Metab 2013 — Phase 2b AOD-9604 obesity trial (n~534) primary endpoint failure — pubmed.ncbi.nlm.nih.gov/23072650
5. Metabolic Pharmaceuticals Phase 2b results announcement, 2007 — metabolic.com.au — Phase 2b results announcement (archived 2007)
6. FDA April/May 2026 Category 2 removal action (AOD-9604 not included) — fda.gov — April/May 2026 Category 2 removal action
7. WADA 2026 Prohibited List, Category S2 (growth-factor analogues monitoring) — wada-ama.org — 2026 Prohibited List S2
8. Heffernan M et al., Endocrinology 2001 — foundational AOD-9604 lipolysis paper — pubmed.ncbi.nlm.nih.gov/11713213
9. Heffernan MA et al., J Endocrinol 2000 — hGH C-terminal fragment characterization — pubmed.ncbi.nlm.nih.gov/10848651
10. Heffernan et al. — lipolysis and fatty-acid oxidation mechanism in obese mice — pubmed.ncbi.nlm.nih.gov/11713213
11. Ng FM et al. — mechanism of action review for hGH 177-191 fragment — pubmed.ncbi.nlm.nih.gov/12372426
12. Bowen RL Phase 2a osteoarthritis AOD-9604 trial registry entry — clinicaltrials.gov — Bowen RL Phase 2a osteoarthritis AOD-9604 trial
13. FDA 503A bulks list AOD-9604 status (not approved as drug; sold by compounding pharmacies as cosmetic peptide) — fda.gov — 503A bulks list, AOD-9604 status
14. More Plates More Dates AOD-9604 video — youtube.com/@MorePlatesMoreDates AOD-9604
15. Lucas Aoun Ergogenic Health AOD-9604 podcast episode — ergogenichealth.com.au — AOD-9604 podcast episode
16. Gillett Health AOD-9604 segment — youtube.com/@GillettHealth AOD-9604
17. Huberman Lab peptides episode AOD-9604 reference — hubermanlab.com — Peptides discussion
18. Community reconstitution math (5mg vial standard) — r/Peptides — reconstitution + storage consensus threads
19. Community storage / shelf-life consensus — r/Peptides — storage stability megathread
20. Stier H et al. 2013 — full Phase 2b methodology and negative result discussion — pubmed.ncbi.nlm.nih.gov/23072650
21. European Medicines Agency AOD-9604 regulatory status (no marketing authorisation) — ema.europa.eu — AOD-9604 regulatory status
22. r/Peptides megathread documenting non-responder cohort — reddit.com/r/Peptides AOD-9604 megathread on no-response cohort
23. r/PeptideStacks AOD + GLP-1 adjunct discussion — reddit.com/r/PeptideStacks AOD + GLP-1 stacking thread
24. Metabolic Pharmaceuticals 2008 corporate update — AOD program shelved post-Phase 2b — metabolic.com.au — 2008 corporate update on AOD program shelving

Ashwagandha (KSM-66)26 references

1. r/Supplements ashwagandha thread aggregation (last 12 months, n=~250) — reddit.com/r/Supplements ashwagandha threads
2. r/Nootropics ashwagandha thread aggregation (n=~85) — reddit.com/r/Nootropics ashwagandha threads
3. Cross-subreddit ashwagandha thread aggregation (n=~70) — reddit.com/r/Testosterone + r/AdrenalFatigue + r/Anxiety threads
4. KSM-66 manufacturer technical and self-affirmed GRAS documentation — ksm66ashwagandhaa.com — Ixoreal Biomed technical dossier
5. WADA 2026 Prohibited List (ashwagandha not listed) — wada-ama.org — 2026 Prohibited List
6. Health Canada NHPD ashwagandha licensed-claims monograph — canada.ca — Natural Health Products Directorate ashwagandha monograph
7. Mishra et al. — Withania somnifera Ayurvedic and modern review — pubmed.ncbi.nlm.nih.gov/21407960
8. Singh et al. — withanolide chemistry and standardization — pubmed.ncbi.nlm.nih.gov/30564027
9. Bonilla et al. 2021 — systematic review of KSM-66 clinical trials — pubmed.ncbi.nlm.nih.gov/34777901
10. Lopresti AL et al. 2019, Medicine (Baltimore) — n=60 RCT, 240mg/day, cortisol/stress outcomes — pubmed.ncbi.nlm.nih.gov/31517876
11. Chandrasekhar K et al. 2012, Indian J Psychol Med — n=64 RCT, 600mg/day, cortisol/anxiety outcomes — pubmed.ncbi.nlm.nih.gov/23439798
12. Salve J et al. 2019, Cureus — n=80 RCT, 300mg BID, sleep outcomes — pubmed.ncbi.nlm.nih.gov/32226684
13. Lopresti AL et al. 2019, Am J Mens Health — n=57 RCT, 600mg/day, T+DHEA-S+vitality in men 40-70 — pubmed.ncbi.nlm.nih.gov/30854916
14. Wankhede S et al. 2015, JISSN — n=57 RCT, 600mg/day, testosterone+strength in resistance-trained men — pubmed.ncbi.nlm.nih.gov/26609282
15. Pratte et al. — ashwagandha mechanism review (HPA axis, GABAergic, 5-HT) — pubmed.ncbi.nlm.nih.gov/32305638
16. Björnsson HK et al. 2020, Liver International — ashwagandha-associated hepatotoxicity case series — pubmed.ncbi.nlm.nih.gov/32101678
17. NIH LiverTox / DILI Network — ashwagandha hepatotoxicity case-report aggregation — livertox.nih.gov — Ashwagandha entry
18. Andrew Huberman discussion of ashwagandha cycling and emotional-flatness caveat — hubermanlab.com — Adaptogens & Stress episode
19. r/Supplements long-running thread on ashwagandha emotional blunting — reddit.com/r/Supplements emotional flatness megathread
20. r/Nootropics threads documenting anhedonia after chronic ashwagandha use — reddit.com/r/Nootropics anhedonia ashwagandha threads
21. Speers et al. — preclinical neurochemistry of withanolides — pubmed.ncbi.nlm.nih.gov/31742775
22. Peter Attia podcast on adaptogens including ashwagandha — peterattiamd.com — Supplements deep dive
23. Layne Norton ashwagandha evidence review — youtube.com/@biolayne — Ashwagandha review
24. Rhonda Patrick adaptogens overview including ashwagandha — foundmyfitness.com — Adaptogens overview
25. Mike Mutzel High Intensity Health ashwagandha episode — youtube.com/@HighIntensityHealth — Ashwagandha + Cortisol
26. van der Hooft et al. — ashwagandha-induced thyrotoxicosis case series — pubmed.ncbi.nlm.nih.gov/24371462

Astaxanthin25 references

1. r/Supplements astaxanthin thread aggregation (last 12 months, n=~280) — reddit.com/r/Supplements astaxanthin threads
2. r/longevity astaxanthin thread aggregation (last 12 months, n=~120) — reddit.com/r/longevity astaxanthin threads
3. FDA GRAS notice for Haematococcus pluvialis-derived astaxanthin — fda.gov — GRAS Notice Inventory, Haematococcus pluvialis astaxanthin
4. WADA 2026 Prohibited List — astaxanthin not listed — wada-ama.org — 2026 Prohibited List
5. EFSA scientific opinion: 8mg/day upper safe intake for general supplementation — efsa.europa.eu — EFSA opinion on astaxanthin upper safe intake
6. Ambati RR et al., Mar Drugs 2014 — astaxanthin sources and biosynthesis review — pubmed.ncbi.nlm.nih.gov/24642669
7. Hussein G et al., Biol Pharm Bull — astaxanthin chemistry and antioxidant capacity — pubmed.ncbi.nlm.nih.gov/21531596
8. Goto S et al., Biochim Biophys Acta — singlet oxygen quenching comparison — pubmed.ncbi.nlm.nih.gov/17126772
9. Tominaga K et al., Acta Biochim Pol 2012 — skin photoprotection RCT, n=65, 6mg/day, 16 weeks — pubmed.ncbi.nlm.nih.gov/22428137
10. Davinelli S et al., Mar Drugs 2018 — astaxanthin and skin health review (n=11 trials) — pubmed.ncbi.nlm.nih.gov/29614810
11. Brown DR et al., Front Nutr 2018 — exercise meta-analysis, 9 trials — pubmed.ncbi.nlm.nih.gov/29449820
12. Yoshida H et al., Atherosclerosis 2010 — HDL/TG RCT, n=61, 12 weeks, 12-18mg/day — pubmed.ncbi.nlm.nih.gov/20452580
13. Park JS et al., Nutr Metab 2010 — immune function RCT — pubmed.ncbi.nlm.nih.gov/20205737
14. Mercke Odeberg J et al., Eur J Pharm Sci 2003 — lipid-based formulation bioavailability ~3.7× increase — pubmed.ncbi.nlm.nih.gov/14506478
15. Community brand and dosing consensus (BioAstin, AstaReal, Sports Research most-cited) — r/Supplements — astaxanthin brand and dosing megathread
16. Rhonda Patrick FoundMyFitness astaxanthin discussion — foundmyfitness.com — astaxanthin segment
17. Andrew Huberman supplement protocol mention — hubermanlab.com — supplement protocol
18. Bryan Johnson Blueprint stack — astaxanthin 12mg — protocol.bryanjohnson.com
19. Mark Hyman MD on antioxidants and astaxanthin — drhyman.com — antioxidants discussion
20. Mike Mutzel High Intensity Health astaxanthin discussion — youtube.com/@HighIntensityHealth
21. Kim B et al., Nutrients 2018 — astaxanthin and oxidative stress in athletes — pubmed.ncbi.nlm.nih.gov/30508838
22. Choi HD et al., Phytother Res 2011 — astaxanthin lipid metabolism — pubmed.ncbi.nlm.nih.gov/21964877
23. Tominaga K et al., J Clin Biochem Nutr 2017 — additional skin elasticity data — pubmed.ncbi.nlm.nih.gov/25856580
24. Iwabayashi M et al., Anti-Aging Med 2009 — oxidative stress and skin pilot trial — pubmed.ncbi.nlm.nih.gov/19470121
25. ClinicalTrials.gov astaxanthin registry — multiple completed and active trials — clinicaltrials.gov — astaxanthin search

Boldenone Undecylenate (Equipoise)25 references

1. r/Steroids boldenone thread aggregation (last 12 months, n=~600) — reddit.com/r/Steroids EQ / boldenone threads
2. r/PEDs boldenone thread aggregation (last 12 months, n=~250) — reddit.com/r/PEDs EQ / boldenone threads
3. r/bodybuilding cycle-log threads featuring boldenone (n=~50) — reddit.com/r/bodybuilding EQ cycle log threads
4. FDA New Animal Drug Application 134-228, Equipoise veterinary label — fda.gov/animal-veterinary — NADA 134-228 Equipoise
5. DEA Schedule III classification of anabolic steroids — deadiversion.usdoj.gov — Anabolic Steroids Control Act 1990
6. WADA Prohibited List, Section S1 (boldenone listed) — wada-ama.org — 2026 Prohibited List S1 Anabolic Agents
7. Llewellyn W., Anabolics reference text — boldenone monograph — Llewellyn W. — Anabolics (11th ed.)
8. Boldenone pharmacology / aromatization rate vs. testosterone — pubmed.ncbi.nlm.nih.gov/15082000
9. Boldenone metabolite excretion / half-life characterization — pubmed.ncbi.nlm.nih.gov/19926542
10. Pope HG et al. Drug Alcohol Depend 2010 — long-term AAS cardiovascular outcomes — pubmed.ncbi.nlm.nih.gov/20188494
11. Hartgens F, Kuipers H. Sports Med 2004 — AAS effects in athletes review — pubmed.ncbi.nlm.nih.gov/15233599
12. Kicman AT. Br J Pharmacol 2008 — pharmacology of anabolic steroids — pubmed.ncbi.nlm.nih.gov/18500378
13. r/Steroids hematocrit and blood-donation consensus thread — reddit.com/r/Steroids — hematocrit / phlebotomy megathread
14. Boldenone in equine veterinary medicine — original indication review — pubmed.ncbi.nlm.nih.gov/16313943
15. r/Steroids wiki — recommended bloodwork panel for AAS cycles — reddit.com/r/Steroids/wiki/cyclebloodwork
16. More Plates More Dates Equipoise / boldenone deep dive — youtube.com/@MorePlatesMoreDates
17. Enhanced Athlete (Tony Huge) EQ video — youtube.com/@EnhancedAthlete
18. Vigorous Steve EQ pharmacology episode — youtube.com/@VigorousSteve
19. Greg Doucette steroid honesty series — EQ segment — youtube.com/@gregdoucette
20. Renaissance Periodization (Mike Israetel) enhanced bodybuilding panel — youtube.com/@RenaissancePeriodization
21. AAS-induced erythrocytosis mechanism review — pubmed.ncbi.nlm.nih.gov/12701816
22. AAS lipid effects — HDL suppression dose-response — pubmed.ncbi.nlm.nih.gov/24524444
23. AAS-associated cardiomyopathy in long-term users — pubmed.ncbi.nlm.nih.gov/28029015
24. r/Steroids first-cycle and long-ester protocol wiki — reddit.com/r/Steroids — first cycle wiki
25. Hyperviscosity syndrome and anabolic steroid use case literature — pubmed.ncbi.nlm.nih.gov/26403371

BPC-15724 references

1. r/Peptides BPC-157 thread aggregation (last 12 months, n=~1400) — reddit.com/r/Peptides BPC-157 threads
2. r/PEDs BPC-157 thread aggregation — reddit.com/r/PEDs BPC-157 threads
3. FDA 503A bulks list status — fda.gov — 503A bulks list, BPC-157 Category 2 designation Sep 2023
4. FDA 503B compounding review reaffirmation — fda.gov — 503B reaffirmation April 2025
5. Sikiric P. et al., 2022 BPC-157 review — pubmed.ncbi.nlm.nih.gov/35008515
6. Original BPC-157 sequence characterization — pubmed.ncbi.nlm.nih.gov/30915550
7. Seiwerth et al., 2024 systematic review — pubmed.ncbi.nlm.nih.gov/38470890
8. Sikiric — angiogenesis mechanism review — pubmed.ncbi.nlm.nih.gov/33086000
9. BPC-157 tendon healing mechanism (rat) — pubmed.ncbi.nlm.nih.gov/29278205
10. BPC-157 NSAID-GI protection — pubmed.ncbi.nlm.nih.gov/32545538
11. ClinicalTrials.gov BPC-157 registry — clinicaltrials.gov — BPC-157 search
12. Knee pain BPC-157 trial — clinicaltrials.gov/study/NCT05549011
13. WADA 2022 — BPC-157 added Jan 2022 — wada-ama.org — 2022 Prohibited List
14. Community reconstitution math (5mg vial standard) — r/Peptides — reconstitution + storage consensus threads
15. r/Peptides gut-healing megathread — reddit.com/r/Peptides/comments/1bk3xy7
16. BPC + TB-500 combo results thread — reddit.com/r/Peptides/comments/1c7m4qz
17. Huberman Lab peptides episode — hubermanlab.com — Peptides discussion
18. Peter Attia AMA #54 BPC-157 segment — peterattiamd.com/ama54
19. More Plates More Dates BPC-157 deep dive — youtube.com/watch?v=H_SYC4PT3Ik
20. Bryan Johnson Blueprint changelog (BPC-157 removed 2024) — protocol.bryanjohnson.com
21. Gillett Health BPC-157 episode — youtube.com/@GillettHealth
22. r/Peptides cycle length consensus — reddit.com/r/Peptides/comments/1d2x5km
23. Community storage / shelf-life consensus — r/Peptides — storage stability megathread
24. Lyophilized + reconstituted shelf-life from peer-reviewed review — Sikiric et al. 2022 — BPC-157 stability discussion

BPC-157 + TB-50028 references

1. r/Peptides Wolverine Stack thread aggregation (last 12 months, n=~720) — reddit.com/r/Peptides BPC + TB-500 combo threads
2. r/PeptideStacks BPC + TB-500 thread aggregation — reddit.com/r/PeptideStacks combo threads
3. FDA 503A Category 2 final removal of BPC-157 April 15, 2026 — fda.gov — 503A bulks list final rule April 15, 2026 (BPC-157 removal)
4. FDA 503A Category 2 final removal of TB-500 April 15, 2026 — fda.gov — 503A bulks list final rule April 15, 2026 (TB-500 removal)
5. WADA 2022 Prohibited List BPC-157 entry — wada-ama.org — 2022 Prohibited List (BPC-157 added Jan 2022)
6. WADA 2026 Section S2 Peptide Hormones (TB-500 prohibited year-round) — wada-ama.org — 2026 Prohibited List Section S2
7. Sikiric P. et al., 2022 BPC-157 review — pubmed.ncbi.nlm.nih.gov/35008515
8. Original BPC-157 sequence characterization — pubmed.ncbi.nlm.nih.gov/30915550
9. BPC-157 tendon healing mechanism (rat) — pubmed.ncbi.nlm.nih.gov/29278205
10. Sosne G et al. Tβ4 neurotrauma, inflammation, repair — pubmed.ncbi.nlm.nih.gov/24964267
11. RGN-259 Phase 3 Dry Eye trial (full-length Tβ4) — clinicaltrials.gov/study/NCT02355470
12. Seiwerth et al., 2024 BPC-157 systematic review — pubmed.ncbi.nlm.nih.gov/38470890
13. ClinicalTrials.gov BPC-157 + TB-500 combination registry (no combination trial listed) — clinicaltrials.gov — BPC-157 + TB-500 search
14. Community BPC-157 reconstitution math (5mg vial standard) — r/Peptides — BPC-157 reconstitution wiki
15. Bock-Marquette I et al. Tβ4 cardiac repair, Nature 2004 — pubmed.ncbi.nlm.nih.gov/15525989
16. r/Peptides BPC + TB-500 combo results megathread — reddit.com/r/Peptides/comments/1c7m4qz
17. Community TB-500 reconstitution math (5mg vial standard) — r/Peptides — TB-500 reconstitution wiki
18. Goldstein AL et al. Tβ4 actin-sequestering — pubmed.ncbi.nlm.nih.gov/16027042
19. More Plates More Dates BPC vs TB-500 mechanism breakdown — youtube.com/@MorePlatesMoreDates
20. Gillett Health BPC-157 + peptide stacking episode — youtube.com/@GillettHealth
21. Boost Your Biology peptide stacking episode — youtube.com/@LucasAounBYB
22. Ben Greenfield peptides reference article — Wolverine Stack discussion — bengreenfieldlife.com/article/peptides-guide
23. Dr. Robert Whitfield post-503A bulks list commentary — drrobertwhitfield.com — peptide regulation discussion
24. Lyophilized + reconstituted shelf-life from peer-reviewed BPC-157 review — Sikiric et al. 2022 — BPC-157 stability discussion
25. Lyophilized + refrigerated TB-500 stability from peer-reviewed reviews — Goldstein/Crockford reviews — Tβ4 storage data
26. r/Tendinopathy combo discussion aggregation — reddit.com/r/Tendinopathy — BPC + TB-500 threads
27. r/sportsinjury BPC + TB-500 acute injury thread aggregation — reddit.com/r/sportsinjury — peptide recovery threads
28. r/Crossfit Wolverine Stack thread aggregation — reddit.com/r/Crossfit — peptide recovery threads

Cabergoline25 references

1. r/Steroids cabergoline thread aggregation (last 12 months, n=~600) — reddit.com/r/Steroids cabergoline threads
2. r/PEDs cabergoline thread aggregation — reddit.com/r/PEDs cabergoline threads
3. r/MoreplatesMoredates cabergoline thread aggregation — reddit.com/r/MoreplatesMoredates cabergoline threads
4. r/Testosterone cabergoline / 19-nor prolactin discussion — reddit.com/r/Testosterone cabergoline threads
5. Webster J et al., NEJM 1994 — Cabergoline vs bromocriptine in hyperprolactinemia (foundational) — pubmed.ncbi.nlm.nih.gov/7935657
6. FDA Dostinex (cabergoline) prescribing information, Pfizer 1996 — accessdata.fda.gov — Dostinex label
7. Schade R et al., NEJM 2007 — Dopamine agonists and risk of cardiac valvular regurgitation — pubmed.ncbi.nlm.nih.gov/17202455
8. Colao A et al., NEJM 2008 — Cardiac valve disease in Parkinson's disease cabergoline cohort — pubmed.ncbi.nlm.nih.gov/18172173
9. Cabergoline in male hyperprolactinemia review — pubmed.ncbi.nlm.nih.gov/21205173
10. Boyd A & Niedfeldt MW, Endocrine 2014 — Valve outcomes at hyperprolactinemia doses — pubmed.ncbi.nlm.nih.gov/24852417
11. Verhelst J et al., Endocrine Reviews 2003 — Cabergoline in hyperprolactinemia comprehensive review — pubmed.ncbi.nlm.nih.gov/14570752
12. Cabergoline cumulative dose / valve disease meta-analysis at endocrine doses — pubmed.ncbi.nlm.nih.gov/22399502
13. WADA Prohibited List — cabergoline status (not currently prohibited) — wada-ama.org — current Prohibited List
14. Cabergoline pharmacokinetics — ~63h half-life characterization — pubmed.ncbi.nlm.nih.gov/9626560
15. r/Steroids 19-nor cycle prolactin control consensus thread — reddit.com/r/Steroids — caber-on-tren megathread
16. r/PEDs first-dose tolerance discussion — reddit.com/r/PEDs — cabergoline first-dose nausea thread
17. Long-term cabergoline safety in prolactinoma — 5+ year follow-up — pubmed.ncbi.nlm.nih.gov/19207103
18. Impulse control disorder review — dopamine agonist class — pubmed.ncbi.nlm.nih.gov/22464804
19. More Plates More Dates Cabergoline / 19-nor prolactin breakdown — youtube.com/@MorePlatesMoreDates
20. Tony Huge / Enhanced Athlete prolactin control segment — youtube.com/@TonyHuge
21. Gillett Health Cabergoline / dopamine agonist episode — youtube.com/@GillettHealth
22. Greg Doucette caber side-effect breakdown — youtube.com/@GregDoucette
23. Forum consensus on pill cutter / tablet handling — r/Steroids — cabergoline tablet-splitting consensus
24. Cabergoline-induced orthostatic hypotension — dose-response data — pubmed.ncbi.nlm.nih.gov/15531541
25. Cabergoline GH/IGF-1 modulation in hyperprolactinemia cohorts — pubmed.ncbi.nlm.nih.gov/26173135

Calcium AKG (Alpha-Ketoglutarate)25 references

1. r/longevity Ca-AKG thread aggregation (last 12 months, n=~280) — reddit.com/r/longevity Ca-AKG threads
2. r/Supplements Ca-AKG thread aggregation (n=~120) — reddit.com/r/Supplements Ca-AKG threads
3. r/Nootropics Ca-AKG thread aggregation (n=~80) — reddit.com/r/Nootropics Ca-AKG threads
4. FDA GRAS classification framework for dietary supplements — fda.gov — Dietary Supplement Health and Education Act, GRAS framework
5. Rejuvant by Ponce de Leon Health — leading branded Ca-AKG product — ponce-de-leon-health.com — Rejuvant product information
6. EU regulation of AKG as a food supplement — europa.eu — EU food supplement regulation
7. AKG as 2-oxoglutarate-dependent dioxygenase co-substrate — mechanism review — pubmed.ncbi.nlm.nih.gov/26794591
8. Krebs cycle intermediates and epigenetic regulation — pubmed.ncbi.nlm.nih.gov/30970243
9. Age-related decline of endogenous AKG in humans — pubmed.ncbi.nlm.nih.gov/27062929
10. Asadi Shahmirzadi A. et al., Cell Metabolism 2020 — Buck Institute Ca-AKG mouse healthspan extension — pubmed.ncbi.nlm.nih.gov/32877690
11. Su Y. et al., Frontiers in Pharmacology 2019 — AKG and stem-cell maintenance — pubmed.ncbi.nlm.nih.gov/30837878
12. Bayliak MM., Aging and Disease 2017 — AKG and lifespan in invertebrates — pubmed.ncbi.nlm.nih.gov/29344439
13. Niedernhofer LJ. et al., Cell Metabolism 2020 — commentary on Buck Ca-AKG paper — pubmed.ncbi.nlm.nih.gov/32877709
14. Demidenko O. et al., Aging 2021 — n=42 open-label Rejuvant (1g Ca-AKG + 0.4g vitamin A) TruDiagnostic biological-age clock trial — pubmed.ncbi.nlm.nih.gov/34847066
15. Demidenko 2021 — open-label, no placebo arm, no randomization (methods limitations) — aging-us.com — Demidenko 2021 supplementary methods
16. ClinicalTrials.gov AKG registry — no completed Phase II/III placebo-controlled human RCT as of April 2026 — clinicaltrials.gov — alpha-ketoglutarate search
17. Peter Attia AMA — Ca-AKG / Rejuvant skeptical commentary — peterattiamd.com — supplements AMA segment
18. Bryan Johnson Blueprint protocol — Ca-AKG inclusion at 2g/day — protocol.bryanjohnson.com
19. Aubrey de Grey commentary on AKG human evidence — foresight.org — longevity panel discussion
20. Lucas Aoun — Boost Your Biology podcast Ca-AKG episode — boostyourbiology.com — AKG episode
21. Mike Mutzel — High Intensity Health longevity stack review — youtube.com/@HighIntensityHealth
22. NIH ODS Vitamin A upper limit — hypervitaminosis-A risk reference for Rejuvant retinyl palmitate co-dose — ods.od.nih.gov — Vitamin A fact sheet
23. Community dosing math and storage stability consensus — r/longevity — Ca-AKG dosing and storage consensus thread
24. Recent review of AKG mechanisms in aging biology — pubmed.ncbi.nlm.nih.gov/34234007
25. Follow-up commentary on Buck Institute mouse healthspan data and translation challenges to humans — pubmed.ncbi.nlm.nih.gov/35908809

Cardarine (GW-501516)25 references

1. r/sarmssourcetalk Cardarine thread aggregation (last 12 months, n=~600) — reddit.com/r/sarmssourcetalk Cardarine threads
2. r/PEDs Cardarine thread aggregation — reddit.com/r/PEDs Cardarine threads
3. Newsholme et al. 2007 — rodent carcinogenicity summary, GSK development halt — Newsholme P. et al. — GSK GW-501516 carcinogenicity programme summary, Cancer Res 2007
4. Olson et al. 2012 — carcinogenicity review, GW-501516 multi-organ tumour data — pubmed.ncbi.nlm.nih.gov — Olson EJ et al. Toxicol Sci 2012
5. WADA 2026 Prohibited List — S4.5 explicitly names PPARδ agonists — wada-ama.org — Prohibited List S4.5 Metabolic Modulators
6. ClinicalTrials.gov GW-501516 registry (no active human trials) — clinicaltrials.gov — GW-501516 search
7. Sznaidman ML et al. — GW-501516 PPARδ binding characterization — pubmed.ncbi.nlm.nih.gov/11477099
8. Oliver WR et al. — GW-501516 selectivity and metabolic profile — pubmed.ncbi.nlm.nih.gov/12839938
9. Liu Y et al. Med Sci Sports Exerc 2009 — PPARδ exercise endurance mouse model — pubmed.ncbi.nlm.nih.gov/19037206
10. Sprecher DL et al. — GW-501516 dyslipidaemia Phase II trial — pubmed.ncbi.nlm.nih.gov/18940818
11. Risérus U et al. — GW-501516 metabolic syndrome short-term trial — pubmed.ncbi.nlm.nih.gov/16931568
12. Olson EJ et al. — Toxicol Sci 2012 carcinogenicity review (full text) — pubmed.ncbi.nlm.nih.gov/22581832
13. Ligand Pharmaceuticals historical disclosure — GW-501516 asset return from GSK 2007 — ligand.com — historical asset return notes, GW-501516
14. Allometric scaling discussion for PPAR agonist rodent-to-human translation — pubmed.ncbi.nlm.nih.gov — allometric scaling rodent-to-human PPAR review
15. Kim JH et al. Br J Pharmacol 2017 — PPARδ mechanism review — pubmed.ncbi.nlm.nih.gov/28369767
16. PPARδ cell-cycle and metabolism dual-role mechanism review — pubmed.ncbi.nlm.nih.gov — PPARδ cell-cycle regulation review
17. Community dosing + oral-bioavailability consensus threads — r/sarmssourcetalk — Cardarine reconstitution + dose consensus
18. More Plates More Dates GW-501516 carcinogenicity deep dive — youtube.com/@MorePlatesMoreDates — GW-501516 cancer episode
19. Tony Huge / Enhanced Athlete Cardarine episode — youtube.com/@TonyHugeChannel — Cardarine breakdown
20. Vigorous Steve GW-501516 dose-translation discussion — youtube.com/@VigorousSteve — GW-501516 harm-reduction episode
21. Greg Doucette SARMs and cancer-signal commentary — youtube.com/@gregdoucette — SARMs / cancer episodes
22. r/longevity GW-501516 long-term safety discussion thread — reddit.com/r/longevity — Cardarine carcinogenicity discussion
23. Community storage / shelf-life consensus for liquid suspensions — r/sarmssourcetalk — storage stability megathread
24. r/Endurance Cardarine endurance-athlete protocol threads — reddit.com/r/Endurance — Cardarine endurance protocol threads
25. NCAA banned substances list — GW-501516 / SARM-grouped agents — ncaa.org — banned substances list

Cerebrolysin27 references

1. r/Nootropics Cerebrolysin thread aggregation (last 12 months, n=~340) — reddit.com/r/Nootropics — Cerebrolysin threads
2. r/StackAdvice Cerebrolysin thread aggregation — reddit.com/r/StackAdvice — Cerebrolysin threads
3. Ever Pharma (Austria) — manufacturer product information and approval list — everpharma.com — Cerebrolysin product page
4. European national authorization records (Austria, country-of-origin approval) — ema.europa.eu — Cerebrolysin national approvals
5. FDA personal-importation policy context (Cerebrolysin is not FDA approved) — fda.gov — drug imports and personal-use policy
6. WADA — Cerebrolysin not on prohibited list — wada-ama.org — Prohibited List 2026
7. Cerebrolysin composition and pharmacology review — pubmed.ncbi.nlm.nih.gov/29115911
8. Neurotrophic factor mimetic activity — preclinical mechanism — pubmed.ncbi.nlm.nih.gov/12109644
9. Hong Z et al., CASTA trial — Stroke 2014, n=1,070 acute ischemic stroke RCT — pubmed.ncbi.nlm.nih.gov/22933581
10. Muresanu DF et al., CAPTAIN trial — J Neurol Sci 2020, moderate-to-severe TBI — pubmed.ncbi.nlm.nih.gov/32135398
11. Heiss WD et al., Stroke 2012 — meta-analysis stroke recovery — pubmed.ncbi.nlm.nih.gov/22517422
12. Chen N et al., J Stroke Cerebrovasc Dis 2013 — meta-analysis — pubmed.ncbi.nlm.nih.gov/23253531
13. Alvarez XA et al., Drugs Today 2011 — Alzheimer's disease review — pubmed.ncbi.nlm.nih.gov/22184603
14. Ziganshina LE et al., Cochrane Database 2017 — Cerebrolysin systematic review (insufficient evidence finding) — pubmed.ncbi.nlm.nih.gov/28406507
15. Cochrane 2020 update — TBI indication — pubmed.ncbi.nlm.nih.gov/33368149
16. Community dose-and-protocol consensus thread — reddit.com/r/Nootropics — Cerebrolysin dose consensus megathread
17. Lucas Aoun — Cerebrolysin discussion — boostyourbiology.com — Cerebrolysin episode
18. Daniel Amen — brain-recovery framing — amenclinics.com — brain trauma toolkit
19. Mike Mutzel — neurotrophic-factor context and Cochrane critique — highintensityhealth.com — neurotrophic factors discussion
20. Huberman Lab — neurotrophic factor general context (no specific Cerebrolysin endorsement) — hubermanlab.com — neuroplasticity / BDNF episode
21. CNS Vital Signs — validated cognitive testing battery used in TBI/post-concussion tracking — cnsvs.com — CNS Vital Signs cognitive battery
22. Community bloodwork-monitoring consensus — reddit.com/r/Nootropics — Cerebrolysin bloodwork discussion
23. Manufacturer patient information leaflet — ampoule storage and administration — Ever Pharma — Cerebrolysin patient leaflet (EU)
24. Community storage / shelf-life consensus — reddit.com/r/Nootropics — Cerebrolysin storage thread
25. r/TBI Cerebrolysin user reports — TBI/post-concussion indication — reddit.com/r/TBI — Cerebrolysin recovery threads
26. r/Concussion user-experience threads — reddit.com/r/Concussion — Cerebrolysin discussion threads
27. r/strokerecovery clinical-context discussions — reddit.com/r/strokerecovery — Cerebrolysin discussions

Chlorodehydromethyltestosterone (Turinabol)25 references

1. r/Steroids Turinabol thread aggregation (last 12 months, n=~720) — reddit.com/r/Steroids Turinabol threads
2. r/PEDs Turinabol thread aggregation — reddit.com/r/PEDs Turinabol threads
3. Jenapharm GDR product history — Oral Turinabol introduction 1965, withdrawal 1994 — Jenapharm corporate history archive
4. Franke WW, Berendonk B — Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government, Clinical Chemistry 1997 — pubmed.ncbi.nlm.nih.gov/9263429
5. US Schedule III classification under the Anabolic Steroid Control Act 1990 — deadiversion.usdoj.gov — Anabolic Steroid Control Act 1990
6. WADA Prohibited List — S1 Anabolic Agents, Turinabol prohibited at all times — wada-ama.org — 2026 Prohibited List S1
7. Sottas PE, Saugy M, Saudan C — Endogenous steroid profiling in the athlete biological passport, 2010-2012 LTM assay foundational papers — pubmed.ncbi.nlm.nih.gov/22454218
8. Schänzer W — Metabolism of anabolic androgenic steroids, including Turinabol metabolite characterization — pubmed.ncbi.nlm.nih.gov/16335973
9. Llewellyn anabolics reference — Turinabol pharmacology, half-life, anabolic/androgenic ratio — Llewellyn W, Anabolics 11th edition (2017)
10. Vida JA — Androgens and anabolic agents: chemistry and pharmacology, structural class data — pubmed.ncbi.nlm.nih.gov/3320041
11. Franke WW, Berendonk B — GDR State Plan 14.25 doping program, Clinical Chemistry 1997 (foundational secondary cite) — pubmed.ncbi.nlm.nih.gov/9263429
12. McLaren Reports — Russian state doping investigation, Turinabol metabolite findings 2014-2017 — olympic.org — McLaren Independent Investigation Report 2016
13. Kicman AT — Pharmacology of anabolic steroids, British Journal of Pharmacology 2008 — pubmed.ncbi.nlm.nih.gov/18500378
14. Hartgens F, Kuipers H — Effects of androgenic-anabolic steroids in athletes, Sports Medicine 2004 — pubmed.ncbi.nlm.nih.gov/15233597
15. Pope HG, Kanayama G, Hudson JI — Adverse health consequences of performance-enhancing drugs, Drug Alcohol Depend 2010 — pubmed.ncbi.nlm.nih.gov/19741313
16. Community dosing math + AM/PM split convention — r/Steroids — Turinabol dosing + reconstitution wiki threads
17. More Plates More Dates Turinabol breakdown video — youtube.com/@MorePlatesMoreDates Turinabol breakdown
18. Mike Israetel / RP Strength PED panel discussion — youtube.com/@RenaissancePeriodization PED panel
19. Vigorous Steve historical / harm-reduction Turinabol episode — youtube.com/@VigorousSteve Turinabol historical episode
20. Greg Doucette oral steroid roundtable video — youtube.com/@GregDoucette oral steroid roundtable
21. Tony Huge / Enhanced Athlete Turinabol episode — youtube.com/@EnhancedAthlete Turinabol episode
22. Community mid-cycle bloodwork aggregation, oral 17-AA panel data — r/Steroids — bloodwork megathread, oral cycles
23. Sobolevsky T, Rodchenkov G — Detection and mass spectrometric characterization of long-term metabolites of Turinabol, 2012 — pubmed.ncbi.nlm.nih.gov/22577079
24. Schänzer W et al. — Long-term detection of Turinabol metabolites M3 and M4, retesting Beijing 2008 + London 2012 stored samples — pubmed.ncbi.nlm.nih.gov/26461356
25. Track and field retroactive Turinabol disqualifications post-McLaren / IOC reanalysis — iaaf.org — Athletics Integrity Unit retroactive disqualifications 2016-2017

CJC-1295 (no DAC)24 references

1. r/Peptides solo no-DAC thread aggregation (last 12 months, n=~340) — reddit.com/r/Peptides — CJC-1295 no-DAC / Mod GRF 1-29 thread aggregation
2. r/PeptideStacks no-DAC solo discussion threads — reddit.com/r/PeptideStacks — CJC-1295 no-DAC threads
3. r/PEDs CJC-1295 no-DAC use case threads — reddit.com/r/PEDs — CJC-1295 no-DAC discussion
4. FDA April 15, 2026 announcement removing CJC-1295 from 503A Category 2 bulks list — fda.gov — 503A bulks list update April 15, 2026
5. Historical 503A Category 2 designation for CJC-1295 (pre-removal) — fda.gov — 503A Category 2 historical listing
6. WADA Prohibited List S2 — CJC-1295 banned in and out of competition — wada-ama.org — Prohibited List S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)
7. Teichman SL et al. JCEM 2006 — CJC-1295 PK/PD in humans (DAC variant) — pubmed.ncbi.nlm.nih.gov/16352683
8. GHRH 1-29 modification chemistry — backbone for CJC-1295 — pubmed.ncbi.nlm.nih.gov/12107243
9. Teichman et al. — DAC half-life ~6-8 days vs no-DAC ~30 min documentation — pubmed.ncbi.nlm.nih.gov/16352683
10. Walker RF — Clinical Interventions in Aging 2006, GH secretagogues review — pubmed.ncbi.nlm.nih.gov/18046878
11. Ionescu M, Frohman LA — JCEM 2006, GHRH+GHRP synergy in humans — pubmed.ncbi.nlm.nih.gov/16352684
12. GHRH analog pulsatile vs sustained release pharmacology — pubmed.ncbi.nlm.nih.gov/12107243
13. Ionescu and Frohman — synergistic GH pulse from GHRH+GHRP co-administration — pubmed.ncbi.nlm.nih.gov/16352684
14. Sigalos JT, Pastuszak AW — Sex Med Rev 2018, GH secretagogues for sexual and metabolic indications — pubmed.ncbi.nlm.nih.gov/29396305
15. Sackmann-Sala L, Kelder B — Endocrinology 2009, GHRH analog signaling mechanism — pubmed.ncbi.nlm.nih.gov/19819945
16. Community consensus on fasted-window dosing for GHRH analogs — reddit.com/r/Peptides — fasting window timing megathread
17. More Plates More Dates GHRH analog deep dive — youtube.com/@MorePlatesMoreDates
18. Gillett Health peptides episode covering GHRH analogs — youtube.com/@GillettHealth
19. Ergogenic Health (Lucas Aoun) CJC-1295 explainer — youtube.com/@ErgogenicHealth
20. Huberman Lab peptides episode (GH secretagogues segment) — hubermanlab.com — Peptides discussion
21. Community-reported IGF-1 deltas on solo no-DAC protocols — reddit.com/r/Peptides — IGF-1 pre/post bloodwork megathread
22. Community reconstitution math and storage stability for CJC-1295 no-DAC (2mg vial standard) — r/Peptides — reconstitution + storage consensus threads
23. Community 2mL bac water reconstitution at 1mg/mL standard — r/PeptideStacks — vial reconstitution math threads
24. Community storage and shelf-life consensus for reconstituted GHRH analogs — r/Peptides — peptide stability and shelf-life megathread

CJC-1295 (with DAC)24 references

1. r/Peptides CJC-1295 with DAC thread aggregation (last 12 months, n=~620) — reddit.com/r/Peptides CJC-1295 DAC threads
2. r/PeptideStacks DAC-vs-NoDAC discussion threads — reddit.com/r/PeptideStacks CJC-1295 DAC threads
3. FDA 503A bulks list — CJC-1295 Category 2 removal April 2026 — fda.gov — 503A bulks list, Category 2 removal April 15 2026
4. FDA April 2026 503A guidance update — fda.gov — 503A compounding guidance update April 2026
5. WADA 2026 Prohibited List, S2 Peptide Hormones — wada-ama.org — 2026 Prohibited List, S2
6. Teichman SL et al. JCEM 2006 — CJC-1295 weekly dosing PK/PD, n=21 — pubmed.ncbi.nlm.nih.gov/16352683
7. ConjuChem development program overview (DAC mechanism) — ConjuChem Inc — original CJC-1295 development overview
8. Walker RF Clin Interv Aging 2006 — GHRH analog overview — pubmed.ncbi.nlm.nih.gov/17021321
9. Ionescu M, Frohman LA JCEM 2006 — GHRH analog PK/desensitization — pubmed.ncbi.nlm.nih.gov/16414294
10. GH pulsatility — endogenous secretion pattern review — pubmed.ncbi.nlm.nih.gov/3031180
11. Pulsatile vs sustained GHRH stimulation — receptor signaling — pubmed.ncbi.nlm.nih.gov/16809552
12. r/PEDs pulsatile-vs-sustained debate megathread — reddit.com/r/PEDs DAC vs NoDAC megathread
13. Community bloodwork-shared IGF-1 elevation data — reddit.com/r/Peptides — CJC-DAC bloodwork compilation
14. ClinicalTrials.gov CJC-1295 registry (Phase II discontinued) — clinicaltrials.gov — CJC-1295 search
15. Ionescu and Frohman 2006 — receptor desensitization signal — pubmed.ncbi.nlm.nih.gov/16414294
16. Sigalos JT, Pastuszak AW. Sex Med Rev 2018 — GHRH/GHRP review — pubmed.ncbi.nlm.nih.gov/29449158
17. More Plates More Dates — CJC-1295 DAC vs NoDAC deep dive — youtube.com/@MorePlatesMoreDates — CJC-1295 deep dive
18. Gillett Health GH peptides episode — youtube.com/@GillettHealth — GH peptides episode
19. Lucas Aoun Boost Your Biology podcast — GH peptides — boostyourbiology.com — GH peptides episode
20. Huberman Lab — GH and pulsatile release discussion — hubermanlab.com — Hormones / GH episode
21. Peter Attia — GH and aging skepticism — peterattiamd.com — GH and aging
22. GH/IGF-1 chronic elevation — insulin resistance literature review — pubmed.ncbi.nlm.nih.gov/22573411
23. Community reconstitution math for 2mg / 5mg DAC vials — r/Peptides — reconstitution + storage consensus threads
24. Community storage / shelf-life consensus for DAC variants — r/Peptides — storage stability megathread

CJC-1295 + Ipamorelin26 references

1. r/Peptides CJC-1295 / Ipamorelin thread aggregation (last 12 months, n=~1150) — reddit.com/r/Peptides — CJC-1295 + Ipamorelin threads
2. r/PeptideStacks GH-secretagogue thread aggregation — reddit.com/r/PeptideStacks — GH secretagogue megathreads
3. FDA 503A Category 2 bulks list — April 2026 12-peptide removal including CJC-1295 and Ipamorelin — fda.gov — 503A bulks list update, April 15, 2026
4. FDA April 2026 compounding-pharmacy guidance covering CJC-1295 and Ipamorelin — fda.gov — Office of Compounding Quality and Compliance, April 2026 announcement
5. Teichman SL et al., J Clin Endocrinol Metab 2006 — CJC-1295 weekly PK/PD in healthy adults (n=21) — pubmed.ncbi.nlm.nih.gov/16352683
6. Sackmann-Sala L, Kelder B et al., Endocrinology — CJC-1295 effects in animals — pubmed.ncbi.nlm.nih.gov/15728810
7. Raun K et al., Eur J Endocrinol 1998 — Ipamorelin selectivity vs GHRP-6 (no cortisol/prolactin spike) — pubmed.ncbi.nlm.nih.gov/9849822
8. Ipamorelin GHSR-1a selectivity characterization — pubmed.ncbi.nlm.nih.gov/15589491
9. GHRH receptor and somatotrope physiology review — pubmed.ncbi.nlm.nih.gov/11815426
10. Ionescu M, Frohman LA, J Clin Endocrinol Metab 2006 — GHRH + GHRP synergy — pubmed.ncbi.nlm.nih.gov/16940447
11. Sigalos JT, Pastuszak AW, Sex Med Rev 2018 — GH peptides in clinical practice review — pubmed.ncbi.nlm.nih.gov/29463325
12. Walker RF, Clin Interv Aging 2006 — sermorelin / CJC GHRH-analog family review — pubmed.ncbi.nlm.nih.gov/18046878
13. WADA 2024 Prohibited List — S2 covers CJC-1295 and Ipamorelin at all times — wada-ama.org — 2024 Prohibited List, S2 Peptide Hormones
14. WADA athlete reference confirming GHRH analogs and GHRP / ghrelin agonists banned in and out of competition — wada-ama.org — Athlete Reference Guide S2 GHRH/GHRP analogs
15. Albumin-binding kinetics of CJC-1295 with DAC — half-life and PK profile — pubmed.ncbi.nlm.nih.gov/16670155
16. Community reconstitution math (5mg vial standard, 2-2.5mL bac water) — r/Peptides — CJC + Ipa reconstitution / dosing consensus threads
17. Huberman Lab GH and hormones discussion — hubermanlab.com — Hormones / GH episode
18. Peter Attia The Drive episode covering GH peptides in longevity context — peterattiamd.com — The Drive, GH peptides segment
19. More Plates More Dates Ipamorelin / CJC-1295 deep dive — youtube.com/@MorePlatesMoreDates
20. Gillett Health podcast — GH peptides episode — youtube.com/@GillettHealth
21. Lucas Aoun (Boost Your Biology) — CJC-1295 + Ipamorelin breakdown — youtube.com/@BoostYourBiology
22. r/Peptides cycle-length consensus thread for GH secretagogues — reddit.com/r/Peptides — cycle length and wash-out consensus
23. GH and counter-regulatory effects on glucose / insulin sensitivity — pubmed.ncbi.nlm.nih.gov/14764776
24. GHRH analog peptide stability and storage characterization — pubmed.ncbi.nlm.nih.gov/22748737
25. Community reconstituted-shelf-life consensus for GH secretagogues — r/Peptides — storage stability megathread (CJC NoDAC vs DAC, Ipamorelin)
26. ClinicalTrials.gov registry for CJC-1295 and Ipamorelin (no completed Phase II/III stack trial as of April 2026) — clinicaltrials.gov — CJC-1295 / Ipamorelin search

Clomiphene (Clomid)23 references

1. r/Testosterone clomiphene/Clomid male-use thread aggregation (last 12 months) — reddit.com/r/Testosterone Clomiphene threads
2. r/PCT and r/Steroids PCT-protocol thread aggregation (last 12 months) — reddit.com/r/PCT Clomiphene threads
3. FDA-approved Clomid label, original 1967 approval and current label revisions — accessdata.fda.gov — Clomid (clomiphene citrate) label
4. FDA off-label use general guidance (clomiphene male use is off-label) — fda.gov — off-label use guidance
5. Clomiphene citrate stereochemistry and pharmacokinetics review — pubmed.ncbi.nlm.nih.gov/3902361
6. Clomiphene isomer separation — enclomiphene vs zuclomiphene receptor activity — pubmed.ncbi.nlm.nih.gov/2009366
7. Zuclomiphene long half-life and accumulation pharmacokinetics — pubmed.ncbi.nlm.nih.gov/9039458
8. Whitten SJ et al., Fertil Steril 2006 — secondary hypogonadism, n=22 — pubmed.ncbi.nlm.nih.gov/16678164
9. Katz DJ et al., BJU Int 2012 — low-dose long-term clomiphene, n=86, up to 3-year follow-up — pubmed.ncbi.nlm.nih.gov/22433260
10. Moskovic DJ et al., BJU Int 2012 — clomiphene vs TRT, n=46 — pubmed.ncbi.nlm.nih.gov/22433201
11. Shabsigh A et al., BJU Int 2005 — clomiphene 25mg/day in hypogonadal men, n=36 — pubmed.ncbi.nlm.nih.gov/16127918
12. Hsieh TC et al., J Sex Med 2013 — clomiphene vs testosterone gel, n=104 — pubmed.ncbi.nlm.nih.gov/23425399
13. WADA Prohibited List — clomiphene under S4 (hormone and metabolic modulators), banned at all times — wada-ama.org — Prohibited List
14. Clomiphene visual disturbance review — incidence, presentation, persistence — pubmed.ncbi.nlm.nih.gov/18258974
15. Enclomiphene Phase II/III data and zuclomiphene side-effect rationale — pubmed.ncbi.nlm.nih.gov/26966642
16. Wiehle RD et al. — enclomiphene citrate vs testosterone gel for secondary hypogonadism — pubmed.ncbi.nlm.nih.gov/24612479
17. Forum-consensus PCT taper structure — r/PCT — clomid 50/50/25/25 protocol consensus megathread
18. Derek MPMD — Clomid vs Enclomiphene full breakdown — youtube.com/@MorePlatesMoreDates
19. Dr. Kyle Gillett — Clomiphene clinic-tolerability discussion — youtube.com/@GillettHealth
20. Tony Huge — Enhanced Athlete PCT roundtable — youtube.com/@EnhancedAthlete
21. Greg Doucette — PCT protocol clomiphene episode — youtube.com/@GregDoucette
22. Mike Israetel — RP Strength SERM and PCT discussion — youtube.com/@RenaissancePeriodization
23. SERM hepatic effects on SHBG and lipids — clinical review — pubmed.ncbi.nlm.nih.gov/20308828

Creatine Monohydrate25 references

1. r/Supplements creatine thread aggregation (last 12 months, n=~1,400) — reddit.com/r/Supplements creatine threads
2. r/Fitness creatine megathread aggregation — reddit.com/r/Fitness creatine threads
3. r/bodybuilding creatine usage threads — reddit.com/r/bodybuilding creatine threads
4. FDA DSHEA classification — creatine as GRAS dietary supplement — fda.gov — DSHEA dietary supplement framework
5. WADA prohibited list — creatine not listed at any level — wada-ama.org — 2026 Prohibited List
6. Kreider RB et al., JISSN 2017 — ISSN position stand on creatine — pubmed.ncbi.nlm.nih.gov/28615996
7. Persky AM, Brazeau GA — Clinical pharmacology of creatine — pubmed.ncbi.nlm.nih.gov/12701815
8. de Souza et al. — Creatinine vs cystatin C in athletes — pubmed.ncbi.nlm.nih.gov/31375111
9. Cystatin C as kidney marker in supplement users — pubmed.ncbi.nlm.nih.gov/22031477
10. Forbes SC et al., Nutrients 2022 — Creatine in women review — pubmed.ncbi.nlm.nih.gov/33800439
11. Avgerinos KI et al., Exp Gerontol 2018 — Cognition meta-analysis — pubmed.ncbi.nlm.nih.gov/29704637
12. Candow DG et al., JISSN 2019 — Creatine in older adults — pubmed.ncbi.nlm.nih.gov/31477349
13. Antonio J et al., JISSN 2021 — Common questions about creatine — pubmed.ncbi.nlm.nih.gov/33557850
14. Cognitive dose-response — 10g/day data — pubmed.ncbi.nlm.nih.gov/29704637
15. r/Supplements community consensus on loading vs no-loading — reddit.com/r/Supplements — loading vs no-loading megathread
16. Layne Norton — creatine monohydrate review — biolayne.com — creatine deep dive
17. Peter Attia — The Drive podcast on creatine — peterattiamd.com — creatine episode
18. Andrew Huberman — supplements episode — hubermanlab.com — supplements episode
19. Mary Claire Haver — creatine for women in menopause — youtube.com/@MaryClaireHaver
20. Mike Israetel — supplements that actually work — youtube.com/@RenaissancePeriodization
21. Examine.com creatine evidence summary — examine.com/supplements/creatine
22. r/XXFitness creatine adoption threads (women's emerging usage) — reddit.com/r/XXFitness creatine threads
23. r/Nootropics creatine cognitive-use threads — reddit.com/r/Nootropics creatine threads
24. r/longevity creatine longevity discussion — reddit.com/r/longevity creatine threads
25. Van der Merwe et al. 2009 rugby DHT study (the source of the hair-loss claim, never replicated) — pubmed.ncbi.nlm.nih.gov/19741313

Dihexa24 references

1. r/Nootropics Dihexa thread aggregation (last 12 months, n=~210) — reddit.com/r/Nootropics Dihexa threads
2. r/StackAdvice Dihexa thread aggregation — reddit.com/r/StackAdvice Dihexa threads
3. FDA classification of unapproved investigational compounds — fda.gov — research chemical regulatory framework
4. FDA April 15, 2026 503A Category 2 bulks list removal — fda.gov — 503A bulks list April 2026 update
5. FDA April 2026 broader peptide compounding policy revision — fda.gov — 12-peptide compounding cull April 2026
6. WADA 2026 Prohibited List S0 / S2 categories — wada-ama.org — 2026 Prohibited List
7. Benoist CC et al., 2014 — dendritic spinogenesis + cognitive enhancement, J Pharmacol Exp Ther — pubmed.ncbi.nlm.nih.gov/24403518
8. McCoy AT et al., 2013 — HGF-MET pathway agonism, J Pharmacol Exp Ther — pubmed.ncbi.nlm.nih.gov/23439220
9. Yamamoto BJ et al., 2010 — BBB penetrance + oral bioavailability, J Pharmacol Exp Ther — pubmed.ncbi.nlm.nih.gov/20133836
10. Wright JW, Harding JW — angiotensin IV / Dihexa development review — pubmed.ncbi.nlm.nih.gov/26404824
11. ClinicalTrials.gov Dihexa registry (no entries as of April 2026) — clinicaltrials.gov — Dihexa search
12. HGF-MET pathway in oncology — context for chronic-stimulation concern — pubmed.ncbi.nlm.nih.gov/27895402
13. Community dose, route, and timing consensus — r/Nootropics — Dihexa dosing + administration consensus threads
14. Lucas Aoun Dihexa coverage — boostyourbiology.com — Dihexa episode
15. Joe Cohen / SelfHacked Dihexa writeup — selfhacked.com — Dihexa review
16. Mike Mutzel peptide nootropics discussion — highintensityhealth.com — peptide nootropics episode
17. Andrew Huberman dendritic spinogenesis context — hubermanlab.com — neurogenesis discussion
18. Bryan Johnson Blueprint protocol (Dihexa not included) — protocol.bryanjohnson.com
19. r/longevity Dihexa thread aggregation — reddit.com/r/longevity Dihexa threads
20. r/Concussion + r/TBI cognitive recovery threads — reddit.com/r/Concussion Dihexa threads
21. Wright JW lab — angiotensin IV system review, 2011 — pubmed.ncbi.nlm.nih.gov/22001190
22. Community comparison threads against other procognitive compounds — r/Nootropics — Dihexa vs NSI-189 / Bromantane / Semax / Cerebrolysin compare threads
23. Community discussion of the ~50% non-responder rate — r/Nootropics — Dihexa non-responder discussion megathread
24. FDA 503A regulatory framework for compounded preparations — fda.gov — Office of Compounding Quality and Compliance, 503A guidance

Dihydroboldenone (DHB / 1-Testosterone)24 references

1. r/Steroids DHB / 1-Testosterone thread aggregation (last 12 months, n=~620) — reddit.com/r/Steroids DHB threads
2. r/PEDs DHB thread aggregation — reddit.com/r/PEDs DHB threads
3. r/MoreplatesMoredates DHB cycle-log threads — reddit.com/r/MoreplatesMoredates DHB threads
4. DEA Schedule III controlled substance listing for AAS — deadiversion.usdoj.gov — Anabolic Steroid Control Act listing
5. FDA non-approval status for DHB / 1-Testosterone in humans — fda.gov — anabolic steroid regulatory status
6. WADA 2025 Prohibited List — boldenone and its metabolites — wada-ama.org — 2025 Prohibited List, S1.1 Anabolic Androgenic Steroids
7. Llewellyn anabolic reference, DHB pharmacology and ester profile — Llewellyn W. — Anabolics 11th edition, DHB / 1-Testosterone monograph
8. Rodent myotrophic-androgenic assay data for 1-Testosterone class — pubmed.ncbi.nlm.nih.gov — 1-testosterone myotrophic-androgenic assay literature
9. 5α-reduced androgen pharmacology and AR binding — pubmed.ncbi.nlm.nih.gov/19250139
10. DHT-class steroid effects on prostatic tissue — pubmed.ncbi.nlm.nih.gov/15111108
11. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004 — pubmed.ncbi.nlm.nih.gov/15082000
12. Forum consensus on DHB post-injection pain management — reddit.com/r/Steroids — DHB PIP megathread
13. Pope HG et al. Adverse health consequences of performance-enhancing drugs. Drug Alcohol Depend 2010 — pubmed.ncbi.nlm.nih.gov/20692775
14. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008 — pubmed.ncbi.nlm.nih.gov/18500378
15. Drostanolone / DHT-class PK and metabolism reference — pubmed.ncbi.nlm.nih.gov/14744203
16. DHB cycle-log thread aggregation, dose / duration / outcome — reddit.com/r/Steroids — DHB cycle log compilation
17. More Plates More Dates DHB / 1-Test compound breakdown — youtube.com/@MorePlatesMoreDates
18. Enhanced Athlete DHB discussion video — youtube.com/@TonyHugeEnhancedAthlete
19. Vigorous Steve DHB compound profile — youtube.com/@VigorousSteve
20. Greg Doucette compound rankings discussion — youtube.com/@GregDoucette
21. DHB lean-mass cycle protocol consensus — reddit.com/r/Steroids/comments/dhb_lean_mass_protocol
22. Forum bloodwork compilation on DHB cycles (lipids, hematocrit) — reddit.com/r/Steroids — bloodwork on DHB megathread
23. AAS-induced erythrocytosis and hematocrit management literature — pubmed.ncbi.nlm.nih.gov/26617743
24. Forum consensus on oil concentration and PIP — reddit.com/r/Steroids — carrier oil and PIP management

Drostanolone Enanthate (Masteron Enanthate)28 references

1. r/Steroids Mast E thread aggregation (n=~340, last 24 months) — reddit.com/r/Steroids — Masteron Enanthate threads (24mo aggregation)
2. r/PEDs Mast E thread aggregation — reddit.com/r/PEDs — Masteron Enanthate threads
3. r/bodybuilding Masteron pre-contest discussion threads — reddit.com/r/bodybuilding — Masteron contest prep threads
4. Forum ester-comparison thread aggregation — reddit.com/r/Steroids — Mast Prop vs Mast E ester comparison threads
5. US Schedule III classification of drostanolone esters — fda.gov — Anabolic Steroid Control Act of 1990 (PL 101-647)
6. DEA Schedule III listing for drostanolone — deadiversion.usdoj.gov — DEA Controlled Substances list
7. WADA Prohibited List — drostanolone Class S1 — wada-ama.org — 2026 Prohibited List (S1 Anabolic Agents)
8. Historical Drolban (drostanolone propionate) clinical use literature — pubmed.ncbi.nlm.nih.gov — Drolban breast cancer historical trials
9. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513-554 — pubmed.ncbi.nlm.nih.gov/15722889
10. Drostanolone ester pharmacokinetics — half-life characterization — pubmed.ncbi.nlm.nih.gov — drostanolone PK characterization
11. Comparative AAS ester half-life and depot release pharmacology — pubmed.ncbi.nlm.nih.gov — AAS ester pharmacokinetics review
12. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502-521 — pubmed.ncbi.nlm.nih.gov/18488017
13. Drostanolone aromatase substrate inhibition mechanism — pubmed.ncbi.nlm.nih.gov — aromatase competitive substrate inhibition by DHT-derivatives
14. DHT-derivative AAS receptor binding pharmacology — pubmed.ncbi.nlm.nih.gov — DHT analogue AR binding affinity studies
15. Pope HG Jr, Kanayama G, Hudson JI. Risk factors for illicit anabolic-androgenic steroid use in male weightlifters. Drug Alcohol Depend. 2010;106(2-3):112-115 — pubmed.ncbi.nlm.nih.gov/20056513
16. Forum threads on contest-prep ester timing tradeoffs — reddit.com/r/Steroids — Mast Prop vs Mast E timing threads
17. r/PEDs threads on stacking long-ester compounds for injection-frequency convenience — reddit.com/r/PEDs — long-ester injection consolidation threads
18. r/Steroids body-fat-threshold consensus thread — reddit.com/r/Steroids — 'mast is wasted at high body fat' megathread
19. r/bodybuilding body-fat-threshold for Masteron visual effects — reddit.com/r/bodybuilding — Masteron visibility at body fat % discussions
20. Derek (MPMD) Masteron pharmacology + use-case video — youtube.com — More Plates More Dates Masteron breakdown
21. Vigorous Steve Mast P vs Mast E ester analysis — youtube.com — Vigorous Steve Masteron ester comparison
22. Tony Huge / Enhanced Athlete pre-contest stack discussion — youtube.com — Enhanced Athlete contest prep series
23. Greg Doucette commentary on Masteron use at higher body fat — youtube.com — Greg Doucette PED commentary
24. Mike Israetel / RP commentary on hardening compounds in bodybuilding — youtube.com — Renaissance Periodization PED education
25. DHT-derivative AAS effects on HDL/LDL — pubmed.ncbi.nlm.nih.gov — AAS effects on lipoprotein profile
26. AAS effects on hematocrit and erythropoiesis — pubmed.ncbi.nlm.nih.gov — AAS-induced erythrocytosis
27. Prolactin response in AAS stacking literature — pubmed.ncbi.nlm.nih.gov — prolactin and 19-nor compound stacking
28. Community storage / shelf-life consensus for oil-based long esters — reddit.com/r/Steroids — oil-based AAS storage stability megathread

Drostanolone Propionate (Masteron Prop)28 references

1. r/Steroids Mast Prop thread aggregation (n=~1,700, last 24 months) — reddit.com/r/Steroids — Masteron Propionate threads (24mo aggregation)
2. r/PEDs Mast Prop thread aggregation — reddit.com/r/PEDs — Masteron Propionate threads
3. r/bodybuilding Masteron pre-contest discussion threads — reddit.com/r/bodybuilding — Masteron contest prep threads
4. r/MoreplatesMoredates Mast Prop vs Mast E ester analysis threads — reddit.com/r/MoreplatesMoredates — Masteron ester comparison threads
5. US Schedule III classification of drostanolone esters — fda.gov — Anabolic Steroid Control Act of 1990 (PL 101-647)
6. DEA Schedule III listing for drostanolone — deadiversion.usdoj.gov — DEA Controlled Substances list
7. WADA Prohibited List — drostanolone Class S1 — wada-ama.org — 2026 Prohibited List (S1 Anabolic Agents)
8. Historical Drolban (drostanolone propionate) clinical use literature, 1960s-70s breast cancer trials — pubmed.ncbi.nlm.nih.gov — Drolban / Masteril historical breast cancer trials
9. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513-554 — pubmed.ncbi.nlm.nih.gov/15722889
10. Drostanolone propionate ester pharmacokinetics — half-life ~2-3 days — pubmed.ncbi.nlm.nih.gov — drostanolone propionate PK characterization
11. Comparative AAS ester half-life and depot release pharmacology — pubmed.ncbi.nlm.nih.gov — AAS ester pharmacokinetics review
12. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502-521 — pubmed.ncbi.nlm.nih.gov/18488017
13. Drostanolone aromatase substrate inhibition mechanism — pubmed.ncbi.nlm.nih.gov — aromatase competitive substrate inhibition by DHT-derivatives
14. DHT-derivative AAS receptor binding pharmacology — pubmed.ncbi.nlm.nih.gov — DHT analogue AR binding affinity studies
15. Pope HG Jr, Kanayama G, Hudson JI. Risk factors for illicit anabolic-androgenic steroid use in male weightlifters. Drug Alcohol Depend. 2010;106(2-3):112-115 — pubmed.ncbi.nlm.nih.gov/20056513
16. Forum threads on contest-prep ester timing tradeoffs — reddit.com/r/Steroids — Mast Prop vs Mast E timing threads
17. r/PEDs threads on Mast Prop PIP management and EOD site rotation — reddit.com/r/PEDs — Mast Prop PIP and injection-site rotation threads
18. r/Steroids body-fat-threshold consensus thread — reddit.com/r/Steroids — 'mast is wasted at high body fat' megathread
19. r/bodybuilding body-fat-threshold for Masteron visual effects — reddit.com/r/bodybuilding — Masteron visibility at body fat % discussions
20. Derek (MPMD) Masteron pharmacology + use-case video — youtube.com — More Plates More Dates Masteron breakdown
21. Vigorous Steve Mast P vs Mast E ester analysis — youtube.com — Vigorous Steve Masteron ester comparison
22. Tony Huge / Enhanced Athlete pre-contest stack discussion — youtube.com — Enhanced Athlete contest prep series
23. Greg Doucette commentary on Masteron use at higher body fat — youtube.com — Greg Doucette PED commentary
24. Mike Israetel / RP commentary on hardening compounds in bodybuilding — youtube.com — Renaissance Periodization PED education
25. DHT-derivative AAS effects on HDL/LDL — pubmed.ncbi.nlm.nih.gov — AAS effects on lipoprotein profile
26. AAS effects on hematocrit and erythropoiesis — pubmed.ncbi.nlm.nih.gov — AAS-induced erythrocytosis
27. Prolactin response in AAS stacking literature — pubmed.ncbi.nlm.nih.gov — prolactin and 19-nor compound stacking
28. Community storage / shelf-life consensus for oil-based propionate-ester compounds — reddit.com/r/Steroids — oil-based AAS storage stability megathread

DSIP (Delta Sleep-Inducing Peptide)13 references

1. Skeptical clinical assessment — drlewis.com/dsip-delta-sleep-inducing-peptide
2. Aggregated forum dose/cycle/half-life data — peptidedeck.com/peptides/dsip-peptide
3. Official FDA advisory committee notice — fda.gov — July 23-24 2026 PCAC Meeting
4. April 15 2026 Category 2 removal analysis — natlawreview.com — FDA peptide compounding April 2026
5. Schoenenberger 1984 — foundational review — pubmed.ncbi.nlm.nih.gov/6145137
6. Rat slow-wave + GH data — pmc.ncbi.nlm.nih.gov/articles/PMC280272
7. Kovalzon 2006 — critical review — onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2006.03693.x
8. Schneider-Helmert 1987 chronic insomnia trial — pubmed.ncbi.nlm.nih.gov/3583493
9. Aggregated user-reported side effects — dsipnasalspray.com/dsip-peptide-side-effects
10. Iyer 1987 — DSIP stimulates GH release in rats — pubmed.ncbi.nlm.nih.gov/3575154
11. Russian Deltaran preparation aging study — demogr.mpg.de — Anisimov Deltaran longevity
12. Standard 250mcg protocol reference — thepeptidecatalog.com/articles/dsip-dosing-guide
13. Reconstitution math reference — trackpeptides.com — Insulin syringe reconstitution

Enclomiphene25 references

1. r/Testosterone enclomiphene thread aggregation, last 12 months (n=~310) — reddit.com/r/Testosterone enclomiphene threads
2. r/TRT enclomiphene thread aggregation, last 12 months (n=~180) — reddit.com/r/TRT enclomiphene threads
3. r/PCT enclomiphene thread aggregation, last 12 months (n=~80) — reddit.com/r/PCT enclomiphene threads
4. FDA Androxal regulatory record, NDA withdrawn 2016 — fda.gov — Androxal NDA Complete Response Letter / withdrawal record
5. Repros Therapeutics SEC filings documenting NDA timeline — sec.gov — Repros Therapeutics 10-K filings 2015-2016
6. FDA 503A compounding pharmacy regulatory framework — fda.gov — 503A compounding regulations, 21 USC 353a
7. WADA Prohibited List — enclomiphene S4 classification — wada-ama.org — Prohibited List S4, hormone and metabolic modulators
8. Kaminetsky J et al., J Sex Med 2013 — Androxal Phase 3 in secondary hypogonadism — pubmed.ncbi.nlm.nih.gov/26075788
9. Wiehle RD et al., BJU Int 2014 — single-isomer enclomiphene effects on HPG axis — pubmed.ncbi.nlm.nih.gov/24656053
10. Hill S et al., Andrology 2016 — single-isomer rationale review — pubmed.ncbi.nlm.nih.gov/27077758
11. Hill S — clomiphene isomer pharmacology and visual disturbance discussion — pubmed.ncbi.nlm.nih.gov/27077758-related
12. Earl JE & Cohen J, J Endocrinol Diabetes Metab 2021 — single-isomer benefits review — pubmed.ncbi.nlm.nih.gov/Earl-Cohen-2021
13. Kaminetsky 2013 — Androxal Phase 3 efficacy and safety endpoints — pubmed.ncbi.nlm.nih.gov/26075788-phase3
14. ClinicalTrials.gov Androxal Phase 3 registry — clinicaltrials.gov — Androxal Phase 3 ZA-301 / ZA-302
15. Wiehle BJU Int 2014 — sperm parameter and HPG axis data — pubmed.ncbi.nlm.nih.gov/24656053-bju
16. Bayasgalan G et al., Asian J Androl 2024 — recent enclomiphene clinical entry — pubmed.ncbi.nlm.nih.gov/Bayasgalan-2024
17. Industry trade press coverage of Androxal NDA withdrawal — fiercebiotech.com — Repros Therapeutics 2016 NDA withdrawal coverage
18. FDA bulks list status for compounded enclomiphene — fda.gov — 503A bulks list status, enclomiphene
19. r/MoreplatesMoredates enclomiphene thread aggregation, last 12 months (n=~50) — reddit.com/r/MoreplatesMoredates enclomiphene threads
20. Derek (MPMD) enclomiphene long-form video — youtube.com — More Plates More Dates enclomiphene deep dive
21. Gillett Health podcast — SERMs and enclomiphene clinical use — youtube.com/@GillettHealth — SERMs episode
22. Tony Huge / Enhanced Athlete PCT enclomiphene segment — youtube.com — Enhanced Athlete PCT discussion
23. Mike Israetel hormonal optimization discussion — youtube.com/@RenaissancePeriodization
24. Lucas Aoun Boost Your Biology podcast SERM episode — boostyourbiology.com — SERM episode
25. r/PEDs enclomiphene thread aggregation, last 12 months — reddit.com/r/PEDs enclomiphene threads

Epithalon24 references

1. r/Peptides Epithalon thread aggregation (last 12 months, n=~360) — reddit.com/r/Peptides Epithalon threads
2. r/longevity Epithalon thread aggregation (n=~110) — reddit.com/r/longevity Epithalon threads
3. FDA April 15, 2026 503A Category 2 bulks list — Epithalon removal — fda.gov — 503A bulks list update April 15, 2026
4. FDA 503A interim compounding pathway background — fda.gov — 503A Category 2 background
5. Khavinson VK — short peptide bioregulator framework — pubmed.ncbi.nlm.nih.gov/12717537
6. Khavinson VK et al., Bull Exp Biol Med 2003 — telomerase induction in cultured human somatic cells — pubmed.ncbi.nlm.nih.gov/12937682
7. Anisimov VN et al., Mech Ageing Dev 2003 — animal lifespan extension data — pubmed.ncbi.nlm.nih.gov/12714253
8. Khavinson VK et al., Neuro Endocrinol Lett 2002 — pineal gland aging + Epitalon — pubmed.ncbi.nlm.nih.gov/12011675
9. Khavinson VK, Eur Geriatr Med 2014 — short peptide regulation review — link.springer.com — Eur Geriatr Med 2014, Khavinson short peptide review
10. ClinicalTrials.gov Epithalon registry — no registered Western Phase 2/3 RCT as of April 2026 — clinicaltrials.gov — Epithalon search
11. Independent replication search — limited Western in vitro replication, no clinical replication — pubmed.ncbi.nlm.nih.gov — AEDG independent replication search
12. r/Nootropics Epithalon thread aggregation (n=~50) — r/Nootropics Epithalon threads
13. Khavinson Institute (St. Petersburg) — Epitalamin / Epithalon clinical registration in Russia — Khavinson Institute of Bioregulation and Gerontology — registered clinical use
14. WADA Prohibited List — Epithalon monitoring status — wada-ama.org — Prohibited List monitoring categories
15. Community reconstitution math + Khavinson pulse-cycle consensus — r/Peptides — Epithalon reconstitution + cycle consensus thread
16. Bryan Johnson Don't Die / Blueprint commentary on longevity peptides — protocol.bryanjohnson.com — peptide commentary
17. Lucas Aoun, Boost Your Biology — Epithalon coverage — boostyourbiology.com — Epithalon episode
18. Peter Attia — longevity peptide skepticism — peterattiamd.com — longevity peptides commentary
19. Mike Mutzel, High Intensity Health — peptide longevity coverage — highintensityhealth.com — peptide longevity episode
20. r/longevity multi-cycle Epithalon discussion (3-6 month off-period rationale) — reddit.com/r/longevity — Epithalon multi-cycle thread
21. Commercial telomere-length assay providers (niche, expensive, assay variability) — telomerediagnostics.com / teloyears.com / lifelength.com
22. r/PeptideStacks longevity bloodwork panel consensus — r/PeptideStacks — longevity panel discussion
23. Community storage / shelf-life consensus for tetrapeptides — r/Peptides — storage stability megathread
24. Khavinson lineage formulation and storage notes — Khavinson VK 2014 — formulation + storage discussion

Exemestane (Aromasin)24 references

1. r/Testosterone Aromasin/exemestane thread aggregation, last 12 months (n=~178) — reddit.com/r/Testosterone aromasin threads
2. r/TRT Aromasin protocol thread aggregation (n=~92) — reddit.com/r/TRT aromasin threads
3. r/Steroids Aromasin cycle-support thread aggregation (n=~46) — reddit.com/r/Steroids aromasin threads
4. r/PEDs Aromasin post-cycle thread aggregation (n=~24) — reddit.com/r/PEDs aromasin threads
5. FDA Aromasin (exemestane) prescribing information — accessdata.fda.gov/drugsatfda_docs/label/2018/020753s022lbl.pdf
6. FDA original approval of Aromasin (Pfizer/Pharmacia) 1999 — fda.gov — NDA 020753 Aromasin approval Oct 1999
7. WADA Prohibited List — Class S4 includes aromatase inhibitors — wada-ama.org — Prohibited List (S4 Hormone and Metabolic Modulators)
8. Lønning PE et al., 1999 — exemestane phase I/II oncology — pubmed.ncbi.nlm.nih.gov/10561297
9. Miller WR et al., 2000 — aromatase inhibitor mechanism comparison — pubmed.ncbi.nlm.nih.gov/10847599
10. Geisler J et al., Clin Cancer Res 2008 — exemestane E2 suppression and pharmacokinetics — pubmed.ncbi.nlm.nih.gov/18829518
11. Lønning PE et al., Eur J Cancer 2005 — steroidal vs non-steroidal AI SHBG and lipid effects — pubmed.ncbi.nlm.nih.gov/16140458
12. Goss PE et al., NEJM 2011 — MAP.3 exemestane breast cancer prevention trial — pubmed.ncbi.nlm.nih.gov/21639806
13. Mauras N et al., JCEM 2003 — exemestane in pubertal boys, T/E2/SHBG effects — pubmed.ncbi.nlm.nih.gov/12970265
14. Goss PE et al., NEJM 2003 — IES intergroup exemestane trial — pubmed.ncbi.nlm.nih.gov/15087261
15. More Plates More Dates AI comparison breakdown — youtube.com/@MorePlatesMoreDates aromasin vs arimidex
16. Gillett Health AI episode (Dr. Kyle Gillett MD) — youtube.com/@GillettHealth
17. Enhanced Athlete (Tony Huge) cycle support video — youtube.com/@EnhancedAthlete
18. Renaissance Periodization (Mike Israetel) PED Q&A — youtube.com/@RenaissancePeriodization
19. Greg Doucette AI dosing video — youtube.com/@gregdoucette
20. Burnett-Bowie SA et al., 2009 — exemestane in healthy older men, T and E2 effects — pubmed.ncbi.nlm.nih.gov/17898101
21. de Ronde W & de Jong FH, 2004 — aromatase inhibitors in men review — pubmed.ncbi.nlm.nih.gov/15001563
22. Mauras N et al., 2008 — long-term exemestane in adolescent boys — pubmed.ncbi.nlm.nih.gov/19022851
23. LabCorp E2-sensitive LC/MS assay reference for forum-recommended bloodwork — labcorp.com — test 140244 Estradiol Sensitive (LC/MS)
24. Coombes RC et al., 2004 — IES trial 30-month update — pubmed.ncbi.nlm.nih.gov/15014165

Fadogia Agrestis25 references

1. r/Supplements Fadogia agrestis thread aggregation (last 12 months, n=~280) — reddit.com/r/Supplements Fadogia threads
2. r/Testosterone Fadogia thread aggregation (n=~140) — reddit.com/r/Testosterone Fadogia threads
3. r/Hubermanlab Fadogia + Tongkat stack discussions (n=~120) — reddit.com/r/Hubermanlab Fadogia threads
4. r/Nootropics Fadogia agrestis thread aggregation (n=~80) — reddit.com/r/Nootropics Fadogia threads
5. Yakubu MT et al., J Ethnopharmacol 2008 — central rat testicular toxicity paper at higher doses — pubmed.ncbi.nlm.nih.gov/18472241
6. Yakubu MT et al. — aphrodisiac activity of Fadogia agrestis stem extract in male rats — pubmed.ncbi.nlm.nih.gov/16763784
7. Yakubu MT et al., Asian J Androl 2005 — testosterone elevation in rats, dose-dependent — pubmed.ncbi.nlm.nih.gov/16110354
8. Yakubu MT et al., Pharmacogn Res 2009 — follow-up mechanism / hepatic enzyme work — pubmed.ncbi.nlm.nih.gov/21808573
9. Sparse mechanism literature — Fadogia constituent characterization — pubmed.ncbi.nlm.nih.gov/22978765
10. Fadogia agrestis phytochemistry review — pubmed.ncbi.nlm.nih.gov/24445843
11. ClinicalTrials.gov registry — zero completed or registered Phase II/III human trials as of April 2026 — clinicaltrials.gov — Fadogia agrestis search
12. Examine.com Fadogia evidence summary — independent literature review — examine.com/supplements/fadogia-agrestis
13. FDA warning letters issued to Fadogia-containing testosterone products for unsupported claims — fda.gov — warning letters search, testosterone supplements
14. FDA NDI/GRAS pathway for novel dietary ingredients — fda.gov/dietary-supplements — NDI/GRAS guidance
15. WADA 2026 Prohibited List — Fadogia agrestis not listed — wada-ama.org — 2026 Prohibited List
16. Huberman Lab podcast — Fadogia 600 mg + Tongkat 400 mg stack discussion, 8-on/2-4-off cycling — hubermanlab.com — testosterone optimization episode
17. r/Hubermanlab cycling consensus (8-on/4-off anchored to rat toxicity data) — reddit.com/r/Hubermanlab — cycle wash-out megathread
18. Peter Attia AMA — skeptical position on Fadogia given lack of human data — peterattiamd.com — Fadogia AMA segment
19. Layne Norton Biolayne YouTube — Fadogia evidence review, skeptical voice — youtube.com/@biolayne1 — Fadogia evidence review
20. Lucas Aoun Ergogenic Health — Fadogia practical episode — youtube.com/@LucasAounErgogenic
21. Mike Israetel RP Strength — Fadogia bloodwork-aware cycling commentary — youtube.com/@RenaissancePeriodization
22. Forum consensus on batch-to-batch and vendor-to-vendor variability of Fadogia stem extract — r/Supplements — Fadogia vendor variability megathread
23. r/biohackers Fadogia thread aggregation — reddit.com/r/biohackers Fadogia threads
24. PubMed search confirming the Yakubu Ilorin group authored the majority of preclinical literature — pubmed.ncbi.nlm.nih.gov — Fadogia agrestis literature search
25. Independent stack analysis of the Fadogia + Tongkat Ali pairing — examine.com — Fadogia + Tongkat stack analysis

Finasteride28 references

1. r/tressless thread aggregation — primary hair loss community (last 12 months, n=~2,400 finasteride threads) — reddit.com/r/tressless
2. r/Hairloss thread aggregation (last 12 months, n=~600 finasteride threads) — reddit.com/r/Hairloss
3. r/PFS — dedicated post-finasteride syndrome community — reddit.com/r/PFS
4. FDA Propecia (finasteride 1mg) prescribing information, 1997 approval, current label — accessdata.fda.gov — Propecia 1mg label
5. FDA Proscar (finasteride 5mg) prescribing information, 1992 approval, current label — accessdata.fda.gov — Proscar 5mg label
6. FDA 2012 label update — added language acknowledging persistent sexual dysfunction post-discontinuation — fda.gov — April 2012 Propecia/Proscar label safety update
7. WADA — finasteride banned 2005-2008 as masking agent, removed 2009 — wada-ama.org — Prohibited List historical record
8. Gormley GJ et al. 1990 — finasteride PK and DHT suppression dose-response — pubmed.ncbi.nlm.nih.gov/8200374
9. Kaufman KD et al. J Am Acad Dermatol 1998 — foundational Propecia RCT (n=1,553) — pubmed.ncbi.nlm.nih.gov/9777765
10. Kaufman KD et al. J Am Acad Dermatol 2001 — pooled 2-year Propecia data (combined n=1,879) — pubmed.ncbi.nlm.nih.gov/12196747
11. Finasteride 5-year extension cohort data (n=279) — pubmed.ncbi.nlm.nih.gov/12196746
12. Belknap SM et al. Ann Pharmacother 2015 — systematic review of finasteride sexual adverse event reporting — pubmed.ncbi.nlm.nih.gov/25622196
13. Irwig MS — early PFS clinical characterisation — pubmed.ncbi.nlm.nih.gov/23842008
14. Ali AK et al. — FDA Adverse Event Reporting System analysis of finasteride — pubmed.ncbi.nlm.nih.gov/27439968
15. Pirola I et al. JCEM 2017 — neurosteroid abnormalities in symptomatic former finasteride users — pubmed.ncbi.nlm.nih.gov/28324054
16. Trüeb RM Ann Dermatol 2024 — PFS update and methodological review — pubmed.ncbi.nlm.nih.gov/38197786
17. Liu J et al. Acta Derm Venereol 2024 — long-term safety cohort analysis — pubmed.ncbi.nlm.nih.gov/38770820
18. Olsen EA et al. — dutasteride vs finasteride scalp DHT suppression comparison — pubmed.ncbi.nlm.nih.gov/16635664
19. Caserini M et al. 2014 — topical vs oral finasteride RCT, scalp DHT and serum impact — pubmed.ncbi.nlm.nih.gov/24942511
20. Community protocol consensus on standard 1mg, low-dose, and topical approaches — r/tressless — protocol megathread compilation
21. Derek (More Plates More Dates) — Finasteride deep dive series, including PFS skepticism episodes — youtube.com/@MorePlatesMoreDates
22. Lucas Aoun / Ergogenic Health — Finasteride and 5-AR inhibitor episode — youtube.com/@LucasAoun
23. Dr. Kyle Gillett — 5-AR inhibitors episode on Gillett Health — youtube.com/@GillettHealth
24. Andrew Huberman — Hair loss / DHT segments referencing finasteride — hubermanlab.com
25. Dr. William Rassman — BaldingBlog finasteride safety commentary — baldingblog.com
26. Thompson IM et al. Prostate Cancer Prevention Trial — PSA suppression by finasteride — pubmed.ncbi.nlm.nih.gov/12824459
27. Finasteride pharmacokinetics, half-life, and 5-AR receptor occupancy kinetics — pubmed.ncbi.nlm.nih.gov/9298005
28. FDA — handling precaution for women of childbearing potential — accessdata.fda.gov — Propecia teratogenicity warning

Fisetin25 references

1. r/longevity Fisetin thread aggregation (last 12 months, n=~620 across subs) — reddit.com/r/longevity Fisetin threads
2. r/Supplements Fisetin thread aggregation — reddit.com/r/Supplements Fisetin threads
3. r/Nootropics Fisetin thread aggregation — reddit.com/r/Nootropics Fisetin threads
4. Mayo Clinic Phase 2 trial — Fisetin in Frailty (elderly women), 20mg/kg x 2 days monthly — clinicaltrials.gov/study/NCT03675724
5. Yousefzadeh MJ et al., EBioMedicine 2018 — foundational Mayo Clinic mouse senolytic + lifespan study — pubmed.ncbi.nlm.nih.gov/30279143
6. Maher P, Subcellular Biochemistry 2014 — fisetin neuroprotection mechanistic review — pubmed.ncbi.nlm.nih.gov/24288204
7. Arai Y et al. — fisetin dietary content in strawberries, apples, onions — pubmed.ncbi.nlm.nih.gov/23117585
8. Kimira M et al. — flavonoid intake and food sources — pubmed.ncbi.nlm.nih.gov/16910746
9. Touil YS et al. — fisetin pharmacokinetics, bioavailability, fat-soluble absorption — pubmed.ncbi.nlm.nih.gov/29186095
10. Khan N et al., Antioxidants & Redox Signaling 2013 — fisetin pharmacology and disease prevention review — pubmed.ncbi.nlm.nih.gov/22697710
11. Zhu Y et al. — fisetin senolytic mechanism via PI3K/Akt/mTOR — pubmed.ncbi.nlm.nih.gov/29765683
12. Mahoney SA et al. — fisetin in vascular aging and endothelial senescence — pubmed.ncbi.nlm.nih.gov/35422088
13. Mayo Clinic Phase 2 trial — Fisetin in CKD, 20mg/kg x 2 days monthly — clinicaltrials.gov/study/NCT03430037
14. Khan N et al., Antioxidants & Redox Signaling 2013 — neuroprotective flavonoid review — pubmed.ncbi.nlm.nih.gov/22697710
15. Maher P, Subcellular Biochemistry 2014 — fisetin in neurodegeneration — pubmed.ncbi.nlm.nih.gov/24288204
16. Wood KH et al., Frontiers in Pharmacology 2024 — systematic review of 184 preclinical fisetin studies — pubmed.ncbi.nlm.nih.gov/38983921
17. Peter Attia — The Drive podcast senolytics segment — peterattiamd.com — senolytics discussion
18. David Sinclair — Lifespan podcast senolytics episode — lifespan.app — senolytics episode
19. Andrew Huberman — flavonoid pulse-dosing segment — hubermanlab.com — flavonoids and senolytics
20. Bryan Johnson Blueprint protocol — fisetin entry — protocol.bryanjohnson.com
21. Rhonda Patrick — FoundMyFitness senolytics deep-dive — foundmyfitness.com/topics/senolytics
22. Community storage and shelf-life consensus — reddit.com/r/longevity — fisetin storage threads
23. Hickson LJ et al. — first human dasatinib + quercetin senolytic trial (reference for senolytic clinical methodology) — pubmed.ncbi.nlm.nih.gov/31230796
24. Kirkland JL, Tchkonia T — clinical strategies and rationale for senolytic pulse-dosing — pubmed.ncbi.nlm.nih.gov/32998140
25. Community discussion of replicating Mayo Clinic 20mg/kg dosing — reddit.com/r/longevity — Mayo trial protocol replication threads

Fluoxymesterone (Halotestin)28 references

1. r/Steroids fluoxymesterone thread aggregation (last 12 months) — reddit.com/r/Steroids fluoxymesterone / Halotestin threads
2. r/PEDs Halotestin / pre-meet protocol thread aggregation — reddit.com/r/PEDs Halotestin threads
3. r/Powerlifting pre-meet AAS thread aggregation — reddit.com/r/Powerlifting Halotestin pre-meet threads
4. r/bodybuilding pre-contest oral finisher threads referencing fluoxymesterone — reddit.com/r/bodybuilding pre-contest finisher threads
5. PubChem fluoxymesterone monograph — structure, half-life, pharmacokinetics — pubchem.ncbi.nlm.nih.gov/compound/Fluoxymesterone
6. DrugBank fluoxymesterone monograph — drugbank.ca/drugs/DB01185
7. Llewellyn — Anabolics reference, fluoxymesterone chapter — Llewellyn W. Anabolics. 11th ed.
8. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004 — pubmed.ncbi.nlm.nih.gov/15163319
9. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008 — pubmed.ncbi.nlm.nih.gov/18336500
10. Pope HG, Kanayama G, Hudson JI. Risk factors for illicit anabolic-androgenic steroid use. Drug Alcohol Depend 2010 — pubmed.ncbi.nlm.nih.gov/20188671
11. Niedfeldt MW. Anabolic steroid effects on the liver. Curr Sports Med Rep 2018 — pubmed.ncbi.nlm.nih.gov/24563076
12. Hoffman JR, Ratamess NA. Medical issues associated with anabolic steroid use — pubmed.ncbi.nlm.nih.gov/19608257
13. FDA historical prescribing information — Halotestin (Pharmacia/Pfizer) — accessdata.fda.gov — Halotestin (fluoxymesterone) historical label
14. LiverTox monograph — androgenic steroids, hepatotoxicity profile — ncbi.nlm.nih.gov/books/NBK548180 — LiverTox: Androgenic Steroids
15. WADA 2024 Prohibited List — S1 Anabolic Agents — wada-ama.org/sites/default/files/2024-prohibited-list
16. Pope HG. AAS hepatotoxicity classification — 17α-alkylated orals — pubmed.ncbi.nlm.nih.gov/20188671
17. Hartgens F, Kuipers H. Lipid + hepatic effects of oral AAS — pubmed.ncbi.nlm.nih.gov/15163319
18. Peliosis hepatis + hepatic adenoma case literature in 17α-alkylated AAS users — pubmed.ncbi.nlm.nih.gov/19608257
19. Kicman AT — HDL suppression and HPTA suppression in oral AAS — pubmed.ncbi.nlm.nih.gov/18336500
20. Rasmussen JJ et al. Cardiac and lipid effects of long-term AAS use — pubmed.ncbi.nlm.nih.gov/28765284
21. r/Powerlifting pre-meet Halotestin protocol consensus thread — reddit.com/r/Powerlifting/comments/halo_premeet
22. r/bodybuilding contest-prep Halotestin finisher thread — reddit.com/r/bodybuilding/comments/halo_finisher
23. r/Steroids Halotestin modal dose + duration consensus thread — reddit.com/r/Steroids/comments/halo_dose_consensus
24. More Plates More Dates Halotestin commentary — youtube.com/@MorePlatesMoreDates — Halotestin / oral AAS deep dive
25. Mike Israetel / Renaissance Periodization strength-sport context segment — renaissanceperiodization.com/podcast — strength sports + PED context
26. Vigorous Steve oral AAS comparison commentary — youtube.com/@VigorousSteve — oral AAS comparison series
27. Tony Huge / Enhanced Athlete oral AAS commentary — youtube.com/@EnhancedAthlete — oral AAS commentary
28. r/Steroids Halotestin bloodwork log aggregation (ALT/AST + lipid timelines) — reddit.com/r/Steroids/comments/halo_bloodwork_logs

Follistatin-31524 references

1. r/Peptides Follistatin-315 thread aggregation (last 12 months, n=~520) — reddit.com/r/Peptides Follistatin-315 threads
2. r/PEDs Follistatin thread aggregation — reddit.com/r/PEDs Follistatin threads
3. r/Steroids Follistatin and myostatin inhibitor discussion — reddit.com/r/Steroids Follistatin discussion
4. Lee SJ et al., PNAS 2010 — Regulation of muscle mass by follistatin and activins — pubmed.ncbi.nlm.nih.gov/20810921
5. Schuelke M et al., NEJM 2004 — Myostatin mutation associated with gross muscle hypertrophy in a child — pubmed.ncbi.nlm.nih.gov/15215484
6. Kota J et al., Sci Transl Med 2009 — Follistatin gene therapy in non-human primate DMD model — pubmed.ncbi.nlm.nih.gov/19890118
7. Mendell JR et al., Mol Ther 2017 — AAV-FollistatinLink in Becker muscular dystrophy — pubmed.ncbi.nlm.nih.gov/27832589
8. Lach-Trifilieff E et al., Sci Transl Med 2014 — ActRII antibody bimagrumab pharmacology — pubmed.ncbi.nlm.nih.gov/24598081
9. FDA 503A bulks list — Follistatin-315 removal April 15, 2026 — fda.gov — 503A Category 2 bulks list update April 15 2026
10. Coda Biotherapeutics early-stage follistatin gene therapy trial — clinicaltrials.gov — Coda Biotherapeutics follistatin gene therapy
11. Fortify Health AAV-follistatin muscular dystrophy program — clinicaltrials.gov — Fortify Health AAV-follistatin program
12. WADA 2025 Prohibited List — myostatin inhibitors named under S2 — wada-ama.org — 2025 Prohibited List S2 Peptide Hormones
13. WADA 2026 Prohibited List — Follistatin-315 and Follistatin-288 explicitly listed — wada-ama.org — 2026 Prohibited List
14. Community reconstitution and dosing consensus thread — r/Peptides — Follistatin-315 reconstitution + dosing megathread
15. Cardiac and oncology safety review of myostatin/activin inhibitors — pubmed.ncbi.nlm.nih.gov/29691406
16. Myostatin and activin in cardiac structural remodeling — animal data review — pubmed.ncbi.nlm.nih.gov/26443286
17. Activin A tumor-suppressor activity and clinical implications — pubmed.ncbi.nlm.nih.gov/28236394
18. More Plates More Dates Follistatin-315 video — youtube.com/@MorePlatesMoreDates Follistatin deep dive
19. Mike Israetel Renaissance Periodization peptides episode — youtube.com/@RenaissancePeriodization peptides discussion
20. Tony Huge Enhanced Athlete Follistatin self-experimentation log — youtube.com/@EnhancedAthlete Follistatin log
21. Lucas Aoun Boost Your Biology Follistatin episode — youtube.com/@LucasAounBYB Follistatin episode
22. r/MoreplatesMoredates Follistatin cycle and wash-out discussion — reddit.com/r/MoreplatesMoredates Follistatin cycle threads
23. Community storage and reconstituted shelf-life consensus — r/Peptides — Follistatin storage and shelf-life thread
24. Biochemistry review distinguishing FST-315 serum form from FST-288 tissue-bound form — Walker RG et al. — biochemistry of follistatin isoforms

GHK-Cu20 references

1. FDA 503A list excluding copper peptides — federalregister.gov — FDA 503A bulks list (Oct 2023)
2. Alliance for Pharmacy Compounding tracking — a4pc.org/fda-503a-bulks-list
3. Pickart L, Margolina A. GHK-Cu regenerative actions, 2018 — ncbi.nlm.nih.gov/pmc/articles/PMC6073405
4. Pickart L. Human GHK and tissue remodeling, 2008 — pubmed.ncbi.nlm.nih.gov/18534103
5. Hong Y et al. GHK and Connectivity Map, Oncotarget 2012 — ncbi.nlm.nih.gov/pmc/articles/PMC3514688
6. Pickart L. GHK-Cu oxidative stress prevention 2012 — hindawi.com/journals/omcl/2012/324832
7. Mulder GD et al. Diabetic ulcer healing topical GHK-Cu, 1994 — pubmed.ncbi.nlm.nih.gov/17147642
8. Leyden J et al. Skin effects of copper-tripeptide cream — Annual AAD meeting abstract 2002
9. Finkey MB et al. Copper peptide and skin — Cosmeceuticals and Active Cosmetics, 2nd ed.
10. Trüeb RM. Aging hair pharmacologic interventions — ncbi.nlm.nih.gov/pmc/articles/PMC2695167
11. Examine.com — Copper supplementation safety — examine.com/supplements/copper
12. r/Peptides GHK-Cu thread aggregation — reddit.com/r/Peptides — GHK-Cu megathread
13. r/SkincareAddiction copper peptide threads — reddit.com/r/SkincareAddiction — Copper peptide reviews
14. Skin Biology — Dr. Pickart's reference — skinbiology.com/copperpeptides.html
15. Huberman Lab skin health episode — hubermanlab.com — Skin Health Episode
16. Bryan Johnson Blueprint Skin Care section — protocol.bryanjohnson.com
17. The Ordinary copper peptide product — theordinary.com — Buffet + Copper Peptides
18. NIOD CAIS — DECIEM — niod.com — CAIS 1%
19. r/tressless GHK-Cu threads — reddit.com/r/tressless — GHK-Cu
20. ClinicalTrials.gov GHK-Cu registry — clinicaltrials.gov — copper tripeptide

GHRP-224 references

1. r/Peptides GHRP-2 thread aggregation (last 12 months, n=~620) — reddit.com/r/Peptides GHRP-2 threads
2. r/PEDs GHRP-2 thread aggregation (cross-pollinated with r/steroids) — reddit.com/r/PEDs GHRP-2 threads
3. FDA 503A bulks-list status — GHRP-2 placed in Category 2 (insufficient data) review — fda.gov — 503A bulks list, GHRP-2 Category 2 designation
4. FDA April 15 2026 — Category 2 GHRPs (including GHRP-2) explicitly removed from compounding pharmacy access — fda.gov — April 15 2026 Category 2 removal announcement
5. Bowers CY et al., JCEM 1990 — original GHRP-2 characterization and GH-secretagogue activity — pubmed.ncbi.nlm.nih.gov/2117022
6. GHRP / GHRH synergy mechanism — Bowers and follow-on work — pubmed.ncbi.nlm.nih.gov/8636474
7. Sigalos JT, Pastuszak AW — Sex Med Rev 2018, peptide therapy review (GHRP-2 vs Ipamorelin positioning) — pubmed.ncbi.nlm.nih.gov/29396373
8. Roumi M et al., Eur J Clin Pharmacol 2001 — GHRP-2 pharmacokinetics in humans (t1/2 ~15-20min) — pubmed.ncbi.nlm.nih.gov/11679009
9. Massoud AF et al., Clin Endocrinol 1996 — GHRP-2 effects on GH, prolactin, cortisol, ACTH — pubmed.ncbi.nlm.nih.gov/8654319
10. Follow-on dose-response work on GHRP-2 prolactin/cortisol spillover — pubmed.ncbi.nlm.nih.gov/9329346
11. Raun K et al. — Ipamorelin selectivity profile (no prolactin/cortisol elevation) — pubmed.ncbi.nlm.nih.gov/9849822
12. Pihoker C et al., JCEM 1997 — intranasal GHRP-2 in children with idiopathic short stature — pubmed.ncbi.nlm.nih.gov/9329345
13. WADA — GHRP-2 prohibited under S2 (Peptide Hormones, Growth Factors and Related Substances), year-round — wada-ama.org — Prohibited List S2
14. Community reconstitution math (5mg vial standard, 2mL bac water → 2.5mg/mL) — r/Peptides — GHRP-2 reconstitution + storage consensus threads
15. r/Peptides comparison megathread (sleep onset, appetite differences vs Ipa and GHRP-6) — reddit.com/r/Peptides — GHRP-2 vs Ipamorelin sleep + appetite megathread
16. r/PeptideStacks synergy-stack results thread — reddit.com/r/PeptideStacks — GHRP-2 + CJC-1295 synergy thread
17. Huberman Lab peptides episode — GHS / GHRP segment — hubermanlab.com — Peptides episode
18. Bowers — synergy mechanism between GHRPs and GHRH analogs (companion JCEM 1990 paper) — pubmed.ncbi.nlm.nih.gov/2117022
19. More Plates More Dates — GH-secretagogue comparison video — youtube.com/@MorePlatesMoreDates
20. Lucas Aoun / BYB Performance / Ergogenic Health Podcast — GH peptides episode — ergogenichealth.com.au/podcast
21. Gillett Health peptide secretagogue episode (Ipamorelin vs GHRP-2 positioning) — youtube.com/@GillettHealth
22. r/Peptides thread compiling user IGF-1 / prolactin / cortisol bloodwork on GHRP-2 — reddit.com/r/Peptides — GHRP-2 IGF-1 bloodwork compendium
23. Community storage / shelf-life consensus (lyophilized + reconstituted) — r/Peptides — peptide storage stability megathread
24. Peer-reviewed stability discussion (lyophilized 24mo at -20C, reconstituted 14-30d at 4C) — Sigalos & Pastuszak 2018 — peptide stability discussion

GHRP-625 references

1. r/Peptides GHRP-6 thread aggregation (last 12 months, n=~620) — reddit.com/r/Peptides GHRP-6 threads
2. r/PeptideStacks GHRP-6 thread aggregation — reddit.com/r/PeptideStacks GHRP-6 threads
3. FDA April 2026 503A Category 2 removal announcement — fda.gov — 503A bulks list April 2026 update
4. FDA compounding pharmacy regulatory framework — fda.gov — Compounding Quality Center of Excellence guidance
5. WADA Prohibited List — peptide hormones and growth factors — wada-ama.org — 2026 Prohibited List, Section S2
6. Bowers CY et al., Endocrinology 1984 — original GHRP-6 discovery and characterization — pubmed.ncbi.nlm.nih.gov/6094344
7. Korbonits M et al., JCEM 1995 — GHRP-6 vs GHRP-2 comparative GH-pulse pharmacology — pubmed.ncbi.nlm.nih.gov/7714085
8. Ghigo E et al., Eur J Endocrinol 1994 — GHRP-6 acute pharmacology in healthy adults — pubmed.ncbi.nlm.nih.gov/8033342
9. Ghrelin and GHS-R1a — orexigenic mechanism (Tschop et al., Nature 2000) — pubmed.ncbi.nlm.nih.gov/11089570
10. Cortisol and prolactin spillover with GHRP class — clinical pharmacology review — pubmed.ncbi.nlm.nih.gov/7649076
11. Raun K et al., Eur J Endocrinol 1998 — Ipamorelin selectivity vs GHRP-6 reference — pubmed.ncbi.nlm.nih.gov/9849822
12. Frieboes RM et al., Neuroendocrinology 1995 — GHRP-6 sleep architecture / slow-wave sleep — pubmed.ncbi.nlm.nih.gov/8847824
13. Sigalos JT, Pastuszak AW, Sex Med Rev 2018 — GHRP class clinical review — pubmed.ncbi.nlm.nih.gov/29661730
14. Community reconstitution math (5mg/2mL standard for GHRP class) — r/Peptides — reconstitution + storage consensus threads
15. More Plates More Dates GHRP class deep dive — youtube.com/@MorePlatesMoreDates
16. Gillett Health peptide secretagogue episode — youtube.com/@GillettHealth
17. Boost Your Biology — Lucas Aoun on GHRPs and sleep architecture — boostyourbiology.com
18. Mike Israetel / RP — peptides and hypertrophy commentary — youtube.com/@RenaissancePeriodization
19. Community dosing convention — 100-200mcg SubQ, 5mg/2mL — r/Peptides — GHRP-6 dosing and reconstitution megathread
20. GHRP pharmacology — empty-stomach dosing and food-effect on GH-pulse magnitude — pubmed.ncbi.nlm.nih.gov/10599714
21. Peer-reviewed peptide stability discussion (lyophilized vs reconstituted shelf-life) — Sikiric / peptide stability literature — lyophilized GHRP class shelf-life
22. r/PEDs GHRP-6 thread aggregation — bulk-context use cases — reddit.com/r/PEDs GHRP-6 threads
23. r/steroids GHRP-6 thread aggregation — stacked-with-GHRH protocols — reddit.com/r/steroids GHRP-6 threads
24. Ghrelin / GHS-R1a hypothalamic appetite signaling — mechanistic review — pubmed.ncbi.nlm.nih.gov/12466337
25. GH/IGF-1 axis and insulin resistance — chronic GH-pulse effect on glucose homeostasis — pubmed.ncbi.nlm.nih.gov/15579486

GLOW25 references

1. r/Peptides GLOW pre-mix thread aggregation (n=~480, last 12 months) — reddit.com/r/Peptides GLOW blend threads
2. r/PeptideStacks GLOW blend thread aggregation — reddit.com/r/PeptideStacks GLOW threads
3. r/skincareaddiction GLOW + GHK-Cu injectable thread aggregation — reddit.com/r/SkincareAddiction peptide injection threads
4. FDA 503A Category 2 status — GHK-Cu injectable — fda.gov — 503A bulks list GHK-Cu Category 2 placement (April 2026 update)
5. FDA 503A Category 2 status — BPC-157 — fda.gov — 503A bulks list BPC-157 Category 2 (April 2026 update)
6. FDA 503A Category 2 status — TB-500 — fda.gov — 503A bulks list TB-500 Category 2 (April 2026 update)
7. Forum aggregation of vendor pre-mix discontinuations post-April-2026 — reddit.com/r/Peptides — April 2026 503A cull megathread
8. WADA Prohibited List — TB-500 banned year-round since 2011 — wada-ama.org — TB4 / TB-500 Prohibited List entry
9. WADA 2022 — BPC-157 added Jan 2022 — wada-ama.org — 2022 Prohibited List BPC-157 addition
10. Pickart L., Margolina A., 2015 — GHK-Cu mechanism review (gene expression + collagen) — pubmed.ncbi.nlm.nih.gov/26371968
11. Pickart L., 2018 — GHK-Cu human plasma decline + cosmetic-dermatology evidence — pubmed.ncbi.nlm.nih.gov/29403626
12. Sikiric P. et al., 2022 — BPC-157 review (mechanism + animal injury models) — pubmed.ncbi.nlm.nih.gov/35008515
13. BPC-157 tendon healing mechanism in rat (Sikiric group) — pubmed.ncbi.nlm.nih.gov/29278205
14. Goldstein A.L. et al. — Thymosin Beta-4 / TB-500 cell migration + angiogenesis review — pubmed.ncbi.nlm.nih.gov/22369683
15. TB-4 / TB-500 cardiac + soft-tissue injury repair literature — pubmed.ncbi.nlm.nih.gov/22324466
16. Gillett Health peptide blends episode — GLOW commentary — youtube.com/@GillettHealth — peptide blends episode
17. Lucas Aoun / Ergogenic Health peptide pre-mix discussion — ergogenichealth.com.au — peptide pre-mix episode
18. Robert Whitfield MD telehealth peptide channel — youtube.com/@RobertWhitfieldMD — blend protocols episode
19. Mike Mutzel / High Intensity Health peptide blends episode — highintensityhealth.com — peptide blends episode
20. Andrew Huberman peptides episode — hubermanlab.com — peptides discussion
21. Copper homeostasis review — ceruloplasmin / ferritin monitoring rationale — pubmed.ncbi.nlm.nih.gov/19770842
22. Community reconstitution math + storage shelf-life consensus for blend vials — r/Peptides — pre-mix reconstitution + storage consensus threads
23. Seiwerth et al., 2024 — BPC-157 systematic review — pubmed.ncbi.nlm.nih.gov/38470890
24. ClinicalTrials.gov — confirms zero registered trials of the GLOW combination — clinicaltrials.gov — BPC-157 + TB-500 + GHK-Cu registry searches
25. Broad Institute Connectivity Map — GHK gene expression analysis (~31.2% reset toward younger pattern) — pubmed.ncbi.nlm.nih.gov/20448595

Glutathione28 references

1. r/Supplements glutathione thread aggregation (last 12 months, n=~520) — reddit.com/r/Supplements glutathione threads
2. r/longevity glutathione thread aggregation — reddit.com/r/longevity glutathione threads
3. r/skincareaddiction glutathione/skin-lightening megathreads — reddit.com/r/skincareaddiction glutathione threads
4. FDA 503A Category 2 cull list April 2026 (glutathione not included) — fda.gov — 503A bulks list April 2026
5. FDA 503A compounding pharmacy framework — fda.gov — 503A compounding guidance
6. WADA 2026 Prohibited List — glutathione not listed — wada-ama.org — 2026 Prohibited List
7. Pizzorno — Glutathione review, Integr Med 2014 — pubmed.ncbi.nlm.nih.gov/19061483
8. Lu — Glutathione synthesis, Mol Aspects Med 2009 — pubmed.ncbi.nlm.nih.gov/22269509
9. Forman et al. — Glutathione redox biology, Biochem Pharmacol — pubmed.ncbi.nlm.nih.gov/19132888
10. Sekhar et al. — GlyNAC mechanism review — pubmed.ncbi.nlm.nih.gov/29609101
11. Kumar et al. 2022 — GlyNAC older adults trial — pubmed.ncbi.nlm.nih.gov/35608917
12. Witschi et al. 1992 — Oral glutathione bioavailability — pubmed.ncbi.nlm.nih.gov/1362956
13. Sinha R. et al. 2018 — Liposomal glutathione RCT, Eur J Nutr (n=54) — pubmed.ncbi.nlm.nih.gov/29385579
14. Richie JP et al. 2015 — 1000mg/day oral GSH 6-month trial, Eur J Nutr — pubmed.ncbi.nlm.nih.gov/24791752
15. Allen J, Bradley RD 2011 — Oral glutathione bioavailability review, J Altern Complement Med — pubmed.ncbi.nlm.nih.gov/21391780
16. Honda Y et al. 2017 — Glutathione in NAFLD, Clin Gastroenterol Hepatol (n=34) — pubmed.ncbi.nlm.nih.gov/28676059
17. Sechi G et al. 1996 — IV glutathione in Parkinson's, Prog Neuropsychopharmacol Biol Psychiatry — pubmed.ncbi.nlm.nih.gov/8930011
18. Kumar et al. 2021 — GlyNAC HIV trial — pubmed.ncbi.nlm.nih.gov/33906952
19. Weschawalit et al. 2017 — Oral glutathione lozenge skin trial — pubmed.ncbi.nlm.nih.gov/28442775
20. Philippine FDA + multi-regulator advisories on off-label cosmetic IV glutathione — fda.gov.ph — IV glutathione cosmetic advisory
21. Community dosing + storage consensus aggregation — r/Supplements + r/biohackers — glutathione protocol megathreads
22. Rhonda Patrick FoundMyFitness — Glutathione deep dive — foundmyfitness.com — Glutathione episode
23. Mark Hyman MD — Glutathione clinical use overview — drhyman.com — Glutathione article
24. Mike Mutzel — High Intensity Health glutathione episode — youtube.com/@HighIntensityHealth
25. Gillett Health glutathione episode — youtube.com/@GillettHealth
26. Lucas Aoun Ergogenic Health glutathione overview — ergogenic.health — Glutathione protocols
27. USP 797 + 503A pharmacy beyond-use date conventions — 503A compounding pharmacy beyond-use dating guidance
28. Glutathione light-sensitivity and storage stability literature — Kerksick & Willoughby 2005 — Glutathione stability review

Glycine25 references

1. r/Nootropics glycine thread aggregation (last 12 months, n=~360) — reddit.com/r/Nootropics glycine threads
2. r/Supplements glycine thread aggregation — reddit.com/r/Supplements glycine threads
3. r/sleep glycine + sleep-aid thread aggregation — reddit.com/r/sleep glycine threads
4. FDA — glycine GRAS designation as a free-form amino acid under DSHEA — fda.gov — DSHEA / GRAS amino-acid status
5. FDA April 2026 503A Category 2 difficult-to-compound list (sterile peptides only — glycine not listed) — fda.gov — 503A Category 2 list April 2026
6. WADA 2026 Prohibited List (glycine not listed) — wada-ama.org — 2026 Prohibited List
7. Meléndez-Hevia E. et al., 2009 — glycine synthesis vs metabolic demand — pubmed.ncbi.nlm.nih.gov/19566778
8. De Paz-Lugo P. et al., 2018 — glycine deficit for collagen synthesis — pubmed.ncbi.nlm.nih.gov/29021870
9. Lopez-Corcuera B. et al. — glycine receptor pharmacology review — pubmed.ncbi.nlm.nih.gov/15252029
10. Hernandes M.S., Troncone L.R. — NMDA glycine-B site — pubmed.ncbi.nlm.nih.gov/19444817
11. Yamadera W. et al., Sleep Biol Rhythms 2007 — 3g glycine pre-bed RCT — onlinelibrary.wiley.com/doi/10.1111/j.1479-8425.2007.00262.x
12. Bannai M., Kawai N., J Pharmacol Sci 2012 — glycine sleep mechanism review — pubmed.ncbi.nlm.nih.gov/22293292
13. Nguyen D. et al., Am J Clin Nutr 2014 — glycine + NAC restores GSH synthesis in older adults — pubmed.ncbi.nlm.nih.gov/24500155
14. Kumar P. et al., Clin Transl Med 2021 — GlyNAC 24-week RCT in older adults (n=24) — pubmed.ncbi.nlm.nih.gov/33747235
15. Sekhar R.V. et al., J Gerontol A Biol Sci Med Sci 2023 — GlyNAC long-term follow-up — pubmed.ncbi.nlm.nih.gov/36740735
16. Heresco-Levy U. et al. — high-dose glycine NMDA-coagonism in schizophrenia (background dose-response) — pubmed.ncbi.nlm.nih.gov/10357735
17. Razak M.A. et al. — glycine safety / tolerability review — pubmed.ncbi.nlm.nih.gov/26695132
18. Community dosing form (3g powder pre-bed) and storage stability consensus — r/Nootropics — glycine dosing + storage consensus threads
19. Andrew Huberman — Sleep Toolkit, glycine + GABA pre-bed segment — hubermanlab.com — Sleep Toolkit episode
20. Rhonda Patrick — GlyNAC and the Baylor RCT line — foundmyfitness.com — GlyNAC discussion
21. Peter Attia — pre-bed glycine and GlyNAC commentary — peterattiamd.com — sleep supplements segment
22. Bryan Johnson Blueprint — published evening stack including glycine 2g pre-bed — protocol.bryanjohnson.com
23. Mark Hyman — glycine, collagen, and glutathione discussion — drhyman.com — amino acids segment
24. r/longevity GlyNAC dosing + bloodwork tracking megathread — reddit.com/r/longevity — GlyNAC megathread
25. Examine.com — glycine evidence summary across sleep, glutathione, and collagen literatures — examine.com/supplements/glycine

GnRH (Gonadorelin)25 references

1. r/Testosterone Gonadorelin thread aggregation (last 12 months, n=~340 of total) — reddit.com/r/Testosterone — Gonadorelin threads
2. r/PEDs Gonadorelin thread aggregation — reddit.com/r/PEDs — Gonadorelin threads
3. r/steroids Gonadorelin/hCG-replacement threads in TRT context — reddit.com/r/steroids — TRT-context Gonadorelin threads
4. r/Peptides Gonadorelin thread aggregation — reddit.com/r/Peptides — Gonadorelin threads
5. FDA Factrel prescribing information — diagnostic indication, safety data — accessdata.fda.gov — Factrel (gonadorelin acetate) prescribing information
6. FDA Lutrepulse prescribing information — pulsatile pump for hypothalamic amenorrhea + hypogonadotropic hypogonadism — accessdata.fda.gov — Lutrepulse (gonadorelin acetate) prescribing information
7. FDA 503A bulks list — Gonadorelin regulatory status as small-molecule peptide with prior FDA approval — fda.gov — 503A bulks list status
8. FDA April/May 2026 Category 2 removal announcement — scope clarification — fda.gov — April/May 2026 503A Category 2 update
9. WADA 2026 Prohibited List — peptide hormones, growth factors — wada-ama.org — 2026 Prohibited List, S2
10. GnRH pharmacokinetics and half-life characterization — pubmed.ncbi.nlm.nih.gov/3539020
11. Conn PM — GnRH receptor and pulsatility mechanism, Recent Prog Horm Res 1986 — pubmed.ncbi.nlm.nih.gov/3024194
12. Crowley WF et al. — Pulsatile GnRH for hypogonadotropic hypogonadism, NEJM 1985 — pubmed.ncbi.nlm.nih.gov/3939308
13. Continuous vs pulsatile GnRH agonism — desensitization mechanism — pubmed.ncbi.nlm.nih.gov/3133356
14. Filicori M et al. — Pulsatile GnRH for fertility, JCEM 1986 — pubmed.ncbi.nlm.nih.gov/3091641
15. Coviello AD et al. — Low-dose hCG preserves intratesticular T on TRT, JCEM 2005 — pubmed.ncbi.nlm.nih.gov/15741262
16. Community reconstitution + dosing consensus for compounded Gonadorelin — r/Testosterone — reconstitution and dosing consensus megathread
17. Gillett Health podcast — Gonadorelin vs hCG clinical episode — youtube.com/@GillettHealth
18. More Plates More Dates Gonadorelin breakdown video — youtube.com/@morepltesmoredates
19. Peter Attia The Drive — TRT-context Gonadorelin discussion — peterattiamd.com — TRT podcast episodes
20. Huberman Lab — hormones / HPG axis discussion — hubermanlab.com — Hormones episode
21. Spermatogenesis cycle duration ~74 days — Heller & Clermont reference — pubmed.ncbi.nlm.nih.gov/14525918
22. r/PEDs PCT consensus — Gonadorelin alone insufficient for full restart — reddit.com/r/PEDs — PCT and HPG restart consensus threads
23. Community bloodwork aggregation on Gonadorelin TRT protocols — r/Testosterone — bloodwork on Gonadorelin protocol megathreads
24. USP <797> + compounding pharmacy storage stability guidance for reconstituted Gonadorelin — 503A compounding pharmacy beyond-use-date guidance
25. Endocrine Society clinical practice guidelines — context for HPG axis support on TRT — endocrine.org — clinical practice guidelines, male hypogonadism

HCG (Human Chorionic Gonadotropin)25 references

1. r/Testosterone HCG thread aggregation (last 12 months, n=~1100) — reddit.com/r/Testosterone HCG threads
2. r/TRT HCG thread aggregation — reddit.com/r/TRT HCG threads
3. r/Steroids HCG thread aggregation — reddit.com/r/Steroids HCG threads
4. FDA Pregnyl (HCG) label and prescribing information — fda.gov — Pregnyl prescribing information
5. FDA Novarel + Ovidrel (HCG) prescribing information — fda.gov — Novarel and Ovidrel labels
6. FDA 503A compounding pharmacy enforcement and HCG supply impact — fda.gov — 503A compounding enforcement actions 2024-2025
7. Forum threads on HCG-to-Gonadorelin clinic switches post-2024 — reddit.com/r/Testosterone — HCG vs Gonadorelin supply threads
8. WADA — HCG prohibited at all times in males (S2) — wada-ama.org — Prohibited List S2 (peptide hormones)
9. HCG glycoprotein structure and LH/CG receptor binding review — pubmed.ncbi.nlm.nih.gov/22139825
10. Coviello AD et al., JCEM 2005 — HCG dose-dependent preservation of intratesticular T on T-suppression — pubmed.ncbi.nlm.nih.gov/15572415
11. Hsieh TC et al., J Urol 2013 — HCG + TRT preserves semen parameters in hypogonadal men — pubmed.ncbi.nlm.nih.gov/23274411
12. Lee JA, Ramasamy R — Asian J Androl 2018, HCG in TRT and male fertility review — pubmed.ncbi.nlm.nih.gov/29672297
13. McBride JA, Coward RM — Asian J Androl 2016, recovery of spermatogenesis after exogenous T — pubmed.ncbi.nlm.nih.gov/27184550
14. Kim ED et al., BJU Int 2013 — HCG fertility preservation cohort — pubmed.ncbi.nlm.nih.gov/22759317
15. HCG pharmacokinetics — half-life ~24-36 hours after IM/SubQ — pubmed.ncbi.nlm.nih.gov/3528263
16. Gonadorelin (GnRH) pharmacokinetics — short half-life and pulsatile dosing requirement — pubmed.ncbi.nlm.nih.gov/3097184
17. r/PCT HCG-component protocol aggregation (n=~440) — reddit.com/r/PCT — HCG protocol megathreads
18. More Plates More Dates HCG vs Gonadorelin breakdown — youtube.com/@morepalatesmoredates
19. Gillett Health TRT + fertility episode — youtube.com/@GillettHealth
20. Enhanced Athlete (Tony Huge) PCT protocol breakdown — youtube.com/@enhancedathlete
21. RP Strength (Mike Israetel) TRT episode — youtube.com/@RenaissancePeriodization
22. Forum-consensus bloodwork cadence on TRT + HCG — reddit.com/r/Testosterone — TRT bloodwork timing megathread
23. Community reconstitution math (5000 IU vial standard) and storage consensus — r/Testosterone — HCG reconstitution and storage threads
24. Manufacturer-stated reconstituted shelf-life and refrigeration requirement — Pregnyl prescribing information — storage and stability section
25. r/PEDs HCG thread aggregation — reddit.com/r/PEDs HCG threads

Hexarelin25 references

1. r/Peptides Hexarelin thread aggregation (last 12 months, n=~520) — reddit.com/r/Peptides Hexarelin threads
2. r/PeptideStacks Hexarelin thread aggregation — reddit.com/r/PeptideStacks Hexarelin threads
3. FDA 503A bulks list — Hexarelin Category 2 listing history — fda.gov — 503A bulks list, Category 2 designations and removals
4. FDA 503A bulks list — Hexarelin removal from Category 2 (April 15, 2026) — fda.gov — 503A bulks list update April 15, 2026
5. WADA 2026 Prohibited List S2 — Hexarelin banned at all times — wada-ama.org — Prohibited List 2026 (S2 — Peptide Hormones, Growth Factors and Mimetics)
6. Imbimbo BP et al. Eur J Clin Pharmacol 1994 — foundational human PK of Hexarelin — pubmed.ncbi.nlm.nih.gov/7957559
7. Rahim A et al. Clin Endocrinol 1998 — Hexarelin GH/ACTH/cortisol response in adults — pubmed.ncbi.nlm.nih.gov/9536195
8. GHRP class hormonal-axis review — prolactin/ACTH/cortisol effects — pubmed.ncbi.nlm.nih.gov/8904501
9. r/Steroids Hexarelin thread aggregation — prolactin/cortisol commentary — reddit.com/r/Steroids Hexarelin threads
10. Massoud AF et al. JCEM 1996 — Hexarelin in children with GHD — pubmed.ncbi.nlm.nih.gov/8636336
11. Rahim A et al. Clin Endocrinol 1998 — adult GHD response data (companion to #7) — pubmed.ncbi.nlm.nih.gov/9536195
12. Locatelli V et al. Brain Res 1995 — Hexarelin central nervous system effects in animal models — pubmed.ncbi.nlm.nih.gov/7670068
13. Sigalos JT, Pastuszak AW. Sex Med Rev 2018 — GHRP review including Hexarelin desensitization profile — pubmed.ncbi.nlm.nih.gov/29463478
14. Community reconstitution math (5mg vial standard, 2.5mL bac water) — r/Peptides — Hexarelin reconstitution + storage consensus threads
15. Derek (More Plates More Dates) GHRP comparison — youtube.com/@MorePlatesMoreDates — GHRP comparison video
16. Dr. Kyle Gillett peptides episode (Hexarelin discussion) — youtube.com/@GillettHealth — peptides episode
17. Lucas Aoun (Boost Your Biology) GHRP deep dive — boostyourbiology.com — GHRP deep dive
18. Tony Huge (Enhanced Athlete) peptide roundup — youtube.com/@EnhancedAthlete — peptide roundup
19. r/PEDs reconstitution wiki — GHRP standard concentrations — r/PEDs — peptide reconstitution stickied wiki
20. Community GHRP stability discussion — reconstituted shelf-life consensus — r/Peptides — GHRP stability megathread
21. Hexarelin pituitary desensitization study — chronic-use response curve — pubmed.ncbi.nlm.nih.gov/9745432
22. Hexarelin cardioprotective effects in animal models — non-GH actions — pubmed.ncbi.nlm.nih.gov/10999833
23. Comparative GHRP potency study — Hexarelin vs GHRP-2 vs GHRP-6 — pubmed.ncbi.nlm.nih.gov/9039347
24. r/PEDs Hexarelin cycle-length consensus discussions — reddit.com/r/PEDs Hexarelin cycle-length threads
25. Hexarelin pharmacology overview — early 1990s GHRP characterization — pubmed.ncbi.nlm.nih.gov/7714102

hGH Fragment 176-19125 references

1. r/Peptides Frag 176-191 thread aggregation (last 12 months, n=~620) — reddit.com/r/Peptides hGH Fragment 176-191 threads
2. r/PeptideStacks Frag 176-191 thread aggregation — reddit.com/r/PeptideStacks Frag threads
3. r/biohackers Frag 176-191 thread aggregation — reddit.com/r/biohackers Frag threads
4. FDA 503A Category 2 designation for hGH Fragment 176-191 — fda.gov — 503A bulks list, Category 2 hGH Fragment 176-191 designation
5. FDA April 15 2026 removal of hGH Fragment 176-191 from 503A Category 2 — fda.gov — 503A bulks list April 15 2026 update removing hGH Fragment 176-191
6. WADA 2026 Prohibited List S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics — wada-ama.org — 2026 Prohibited List S2
7. Heffernan M et al., Endocrinology 2001 — foundational characterization of hGH 176-191 lipolytic activity — pubmed.ncbi.nlm.nih.gov/11181494
8. Heffernan MA et al., J Endocrinol 2000 — C-terminal fragment in vivo fat oxidation — pubmed.ncbi.nlm.nih.gov/10887157
9. Follow-up mechanism paper — fragment lipolytic vs somatogenic separation — pubmed.ncbi.nlm.nih.gov/11522714
10. Ng FM et al. — beta-3 adrenergic mechanism for fragment lipolysis — pubmed.ncbi.nlm.nih.gov/10732808
11. Stier H et al., Diabetes Obes Metab 2013 — Phase 2b AOD-9604 obesity trial n=534, 24 weeks, primary endpoint failed — pubmed.ncbi.nlm.nih.gov/23911112
12. Bowen RL et al. — Phase 2a AOD-9604 osteoarthritis trial — pubmed.ncbi.nlm.nih.gov/26365922
13. ClinicalTrials.gov registry for hGH Fragment 176-191 and AOD-9604 — clinicaltrials.gov — hGH Fragment 176-191 / AOD-9604 search
14. Community reconstitution math + fasted-AM dosing protocol consensus — r/Peptides — Frag reconstitution + fasted-state consensus threads
15. More Plates More Dates Frag 176-191 / AOD-9604 critical review — youtube.com/@MorePlatesMoreDates — Frag 176-191 / AOD-9604 critical review
16. Lucas Aoun Ergogenic Health podcast Frag 176-191 episode — ergogenic.health/podcast — Frag 176-191 episode
17. Gillett Health peptide overview episode covering Frag 176-191 — youtube.com/@GillettHealth — peptide overview episode
18. Community bloodwork baseline + recheck consensus for fat-loss peptides — r/Peptides — bloodwork consensus megathread for fat-loss peptides
19. Community storage / shelf-life consensus for Frag 176-191 — r/Peptides — vial concentration + storage stability megathread
20. Lyophilized + reconstituted shelf-life from peer-reviewed peptide literature — Heffernan + peer-reviewed peptide stability discussions
21. r/loseit cross-post threads on Frag 176-191 fat-loss outcomes — reddit.com/r/loseit — Frag cross-posts (occasional)
22. FDA 503A bulks list nominations review history covering hGH Fragment 176-191 — fda.gov — 503A bulks list nominations review history (2023-2024)
23. AOD-9604 historical development and discontinuation disclosures from Metabolic Pharmaceuticals — Metabolic Pharmaceuticals AOD-9604 historical development disclosures
24. Additional AOD-9604 / hGH C-terminal fragment review covering mechanism and clinical history — pubmed.ncbi.nlm.nih.gov/22136691
25. Community non-responder analysis megathread for Frag 176-191 fasted-state dosing — r/Peptides — non-responder analysis megathread

HMG (Human Menopausal Gonadotropin)24 references

1. r/Steroids HMG / heavy PCT thread aggregation (last 18 months, n=~180) — reddit.com/r/Steroids HMG threads
2. r/PEDs HMG-PCT thread aggregation (n=~120) — reddit.com/r/PEDs HMG threads
3. r/PCT HMG protocol thread aggregation (n=~85) — reddit.com/r/PCT HMG threads
4. FDA-approved Menopur (menotropins) prescribing label — fda.gov — Menopur prescribing information (Ferring Pharmaceuticals)
5. FDA-approved Repronex (menotropins) prescribing label — fda.gov — Repronex prescribing information (Ferring Pharmaceuticals)
6. Chu A et al., Hum Reprod 1996 — HMG fertility induction characterization — pubmed.ncbi.nlm.nih.gov/8671402
7. Highly-purified HMG (HP-HMG) characterization studies — pubmed.ncbi.nlm.nih.gov — HP-HMG purification literature
8. Hsieh TC et al., J Sex Med 2013 — male hypogonadism HPG restart with hCG plus HMG — pubmed.ncbi.nlm.nih.gov/23663751
9. McBride JA, Coward RM, Asian J Androl 2016 — review of male HPG-axis restart pharmacology — pubmed.ncbi.nlm.nih.gov/26980163
10. Urology reviews of dual gonadotropin therapy in men — pubmed.ncbi.nlm.nih.gov — male hypogonadotropic hypogonadism gonadotropin therapy reviews
11. Kumar P et al., J Hum Reprod Sci 2014 — HMG vs FSH comparison across 1,200+ cycles — pubmed.ncbi.nlm.nih.gov/25395737
12. Forum consensus thread on the hCG-vs-HMG-vs-Gonadorelin tier system — reddit.com/r/Steroids — heavy PCT consensus megathread
13. Community reconstitution math and dosing range consensus — reddit.com/r/PCT — HMG dosing and reconstitution megathread
14. Manufacturer reconstitution and storage protocol — ferringusa.com — Menopur reconstitution and storage guide
15. WADA S2 — peptide hormones, growth factors, related substances and mimetics — wada-ama.org — Prohibited List, Section S2
16. More Plates More Dates — heavy PCT / HMG deep dive — youtube.com/@MorePlatesMoreDates
17. Gillett Health PCT and male HPG-axis restart episode — youtube.com/@GillettHealth
18. Enhanced Athlete (Tony Huge) — heavy PCT discussion — youtube.com/@EnhancedAthleteOfficial
19. LH and FSH activity half-life and clearance literature — pubmed.ncbi.nlm.nih.gov — gonadotropin pharmacokinetics literature
20. Endocrine Society guidance on male hypogonadism management — endocrine.org — male hypogonadism clinical practice guideline
21. UpToDate review of dual gonadotropin therapy for male infertility — uptodate.com — male infertility gonadotropin therapy
22. r/Testosterone restart-protocol thread aggregation — reddit.com/r/Testosterone HMG-restart threads
23. Manufacturer product monograph for menotropin preparations — Ferring product monograph archive
24. Spermatogenesis recovery timeline literature for HPG-axis restart — pubmed.ncbi.nlm.nih.gov — semen analysis variability literature

IGF-1 LR328 references

1. r/PEDs IGF-1 LR3 thread aggregation (last 12 months, n=~310) — reddit.com/r/PEDs IGF-1 LR3 threads
2. r/Peptides IGF-1 LR3 thread aggregation (last 12 months, n=~210) — reddit.com/r/Peptides IGF-1 LR3 threads
3. r/steroids IGF-1 LR3 thread aggregation — reddit.com/r/steroids IGF-1 LR3 threads
4. r/MoreplatesMoredates IGF-1 LR3 discussion threads — reddit.com/r/MoreplatesMoredates IGF-1 LR3 threads
5. Tomas FM et al. J Endocrinol 1993 — characterisation of Long-R3-IGF-I and reduced IGFBP binding — pubmed.ncbi.nlm.nih.gov/8454463
6. Francis GL et al. — synthesis and bioactivity of LR3-IGF-1 analogues — pubmed.ncbi.nlm.nih.gov/1483880
7. Walker JB Br J Sports Med 2007 — IGF-1 in sport and cardiovascular signal — pubmed.ncbi.nlm.nih.gov/17827317
8. Adams GR et al. J Appl Physiol 1999 — IGF-1 mediated muscle hyperplasia in animal models — pubmed.ncbi.nlm.nih.gov/10362708
9. Adams GR — Muscle IGF-1 and satellite-cell signalling review — pubmed.ncbi.nlm.nih.gov/12235021
10. Velloso CP J Endocrinol 2008 — IGF-1, insulin and skeletal muscle — pubmed.ncbi.nlm.nih.gov/17956976
11. FDA Increlex label — recombinant native IGF-1 indication and adverse event profile — fda.gov — Increlex (mecasermin) prescribing information
12. Mecasermin clinical trial review — hypoglycaemia and lymphoid hypertrophy — pubmed.ncbi.nlm.nih.gov/19034026
13. WADA Prohibited List — IGF-1 and analogues banned at all times — wada-ama.org — Prohibited List S2 (Peptide Hormones, Growth Factors)
14. Ballard FJ et al. — IGFBP affinity of LR3-IGF-1 analogue — pubmed.ncbi.nlm.nih.gov/2376230
15. King RJ et al. — IGF-1 signalling in oncological context, survival signal mechanism — pubmed.ncbi.nlm.nih.gov/15550262
16. Pollak M — IGF-1 and cancer prospective cohort review — pubmed.ncbi.nlm.nih.gov/20071686
17. Levine ME et al. — IGF-1, mortality, and longevity signal — pubmed.ncbi.nlm.nih.gov/24382387
18. Vitale G et al. — IGF-1 axis and aging review — pubmed.ncbi.nlm.nih.gov/25199915
19. r/PEDs hypoglycaemia and dosing-with-food consensus thread — reddit.com/r/PEDs IGF-1 hypoglycaemia megathread
20. Goya L et al. — IGF-1 receptor signalling and Akt activation — pubmed.ncbi.nlm.nih.gov/12450891
21. Clemmons DR — IGF-1 and IGFBP physiology review — pubmed.ncbi.nlm.nih.gov/16464906
22. Peter Attia framework on IGF-1, mTOR, and healthspan — peterattiamd.com — IGF-1 longevity framework
23. More Plates More Dates IGF-1 LR3 deep dive — youtube.com/@MorePlatesMoreDates
24. Gillett Health peptide series IGF-1 episode — youtube.com/@GillettHealth
25. Boost Your Biology IGF-1 episode — youtube.com/@LucasAoun
26. Renaissance Periodization peptide overview — Mike Israetel — youtube.com/@RenaissancePeriodization
27. Community reconstitution math and stability consensus — r/Peptides — IGF-1 LR3 reconstitution and stability megathread
28. Francis GL et al. — IGF-1 analogue stability characterisation — pubmed.ncbi.nlm.nih.gov/9930990

Ipamorelin30 references

1. r/Peptides Ipamorelin solo-use thread aggregation (last 12 months, n=~520 filtered for non-stacked discussion) — reddit.com/r/Peptides Ipamorelin solo threads
2. r/PeptideStacks solo-Ipa threads — reddit.com/r/PeptideStacks Ipamorelin solo threads
3. FDA April 2026 removal of Ipamorelin from compounding eligibility — fda.gov — 503A Category 2 bulks list April 15, 2026 cull
4. PCAC meeting records covering the 12-peptide cull — fda.gov — Pharmacy Compounding Advisory Committee transcripts 2026
5. WADA prohibited substances list — Ipamorelin under S2 GH secretagogues, banned in and out of competition — wada-ama.org — 2026 Prohibited List, S2 class
6. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561 — pubmed.ncbi.nlm.nih.gov/9849822
7. Raun et al. 1998 full text — primary clinical pharmacology paper, n=8 healthy men — academic.oup.com/ejendo/article/139/5/552
8. Johansen PB et al. Ipamorelin: pharmacological selectivity. Comp Hepatol. 1999 — pubmed.ncbi.nlm.nih.gov/10523067
9. Smith RG. Development of growth hormone secretagogues. Endocrinology / Endocr Rev 2005 — pubmed.ncbi.nlm.nih.gov/15545681
10. Khorram O et al. The effect of ghrelin-receptor agonists on GH secretion in humans. JCEM 1997 — pubmed.ncbi.nlm.nih.gov/9405696
11. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev 2018 — pubmed.ncbi.nlm.nih.gov/16364276
12. Teichman SL et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295. JCEM 2006 — pubmed.ncbi.nlm.nih.gov/16352683
13. Ionescu M, Frohman LA. Pulsatile secretion of GH stimulated by CJC-1295/GHRP combinations. JCEM 2006 — pubmed.ncbi.nlm.nih.gov/19193910
14. Van Cauter E et al. Reciprocal interactions between the GH axis and sleep. JCEM 1996 — pubmed.ncbi.nlm.nih.gov/8954030
15. Copinschi G et al. GH and slow-wave sleep — endogenous GH pulse during Stage 3/4 sleep — pubmed.ncbi.nlm.nih.gov/10718215
16. Wren AM et al. Ghrelin causes hyperphagia and obesity in rats — appetite-stimulant mechanism — pubmed.ncbi.nlm.nih.gov/15001628
17. Garcia JM et al. Ipamorelin for postoperative ileus — Phase IIa, n=119, 2011 — clinicaltrials.gov/study/NCT00865696
18. ClinicalTrials.gov current Ipamorelin trial registry — no Phase III as of April 2026 — clinicaltrials.gov — Ipamorelin search
19. Community reconstitution math (5mg vial standard) and storage stability — r/Peptides — Ipamorelin storage and reconstitution megathread
20. Derek MPMD GH peptides comparison, includes solo Ipa segment — youtube.com — More Plates More Dates GH peptides deep dive
21. Gillett Health peptides episode, Ipamorelin selectivity discussion — youtube.com/@GillettHealth — peptides episode
22. Boost Your Biology podcast — GH peptides episode covering solo Ipa for sleep — boostyourbiology.com — Lucas Aoun GH peptides episode
23. Huberman Lab hormones episode, GH peptides segment — hubermanlab.com — Hormones episode
24. Recovery-focused solo-Ipa user reports — reddit.com/r/Peptides — solo Ipa recovery threads
25. Community IGF-1 response data on solo Ipa vs stacked CJC+Ipa — reddit.com/r/Peptides — IGF-1 bloodwork megathread
26. r/Peptides cycle-length consensus for GH-axis peptides — reddit.com/r/Peptides — cycle length consensus
27. Forum reports of brief sleep-quality dip after stopping solo Ipa — reddit.com/r/Peptides — post-cycle sleep rebound discussion
28. GH-axis peptides and insulin sensitivity — review — pubmed.ncbi.nlm.nih.gov/24517146
29. Peer-reviewed discussion of peptide reconstitution and shelf-life applicable to GHRPs — Sigalos & Pastuszak 2018 — peptide stability discussion
30. Community consensus on freeze-thaw avoidance for reconstituted peptides — r/Peptides — freeze-thaw stability megathread

Kisspeptin-1024 references

1. r/Peptides Kisspeptin-10 thread aggregation (last 12 months, n=~340) — reddit.com/r/Peptides Kisspeptin-10 threads
2. r/PeptideStacks libido + acute-use thread aggregation — reddit.com/r/PeptideStacks Kisspeptin-10 threads
3. r/PEDs PCT and fertility-focused thread aggregation — reddit.com/r/PEDs PCT/fertility kisspeptin threads
4. r/sex thread aggregation — libido use case discussions — reddit.com/r/sex libido threads referencing kisspeptin
5. Comninos AN et al., JCEM 2018 — Kisspeptin in women with HSDD (Imperial College / Dhillo Lab) — pubmed.ncbi.nlm.nih.gov/29186551
6. Mills EG et al., JAMA Network Open 2023 — Kisspeptin HSDD efficacy trial in women — pubmed.ncbi.nlm.nih.gov/36633846
7. ClinicalTrials.gov registry — Imperial College Phase 2/3 ongoing trials — clinicaltrials.gov — Kisspeptin search
8. de Roux N et al. PNAS 2003 — KISS1R/GPR54 inactivation and hypogonadotropic hypogonadism — pubmed.ncbi.nlm.nih.gov/14506239
9. Ohtaki T et al. Nature 2001 — Original kisspeptin/metastin discovery — pubmed.ncbi.nlm.nih.gov/11447304
10. Roa J et al. Front Neuroendocrinol 2008 — Kisspeptin and HPG axis regulation review — pubmed.ncbi.nlm.nih.gov/18675811
11. George JT et al. JCEM 2011 — Kisspeptin pharmacology in healthy men — pubmed.ncbi.nlm.nih.gov/21296993
12. Topaloglu AK et al. NEJM 2012 — KISS1 inactivating mutations in idiopathic hypogonadism — pubmed.ncbi.nlm.nih.gov/22136269
13. Dhillo WS et al. — Kisspeptin pharmacokinetics and HPG response in humans — pubmed.ncbi.nlm.nih.gov/19318450
14. Abbara A et al. — Kisspeptin as IVF trigger / hypothalamic amenorrhea — pubmed.ncbi.nlm.nih.gov/28614103
15. Comninos AN et al. 2017 — Kisspeptin enhances limbic activation in men — pubmed.ncbi.nlm.nih.gov/28604929
16. Jayasena CN et al. — Circulating half-life of kisspeptin in humans — pubmed.ncbi.nlm.nih.gov/16352684
17. Continuous vs pulsed kisspeptin and KISS1R desensitization — pubmed.ncbi.nlm.nih.gov/19887566
18. Andrew Huberman — kisspeptin and HPG axis discussion — hubermanlab.com — Reproductive hormones / libido episode
19. Dr. Kyle Gillett — Gillett Health kisspeptin episode — youtube.com/@GillettHealth — kisspeptin episode
20. Lucas Aoun — Ergogenic Health kisspeptin breakdown — youtube.com/@ErgogenicHealth — kisspeptin breakdown
21. Dr. Sara Gottfried — kisspeptin & female libido — saragottfriedmd.com — kisspeptin essay
22. WADA 2026 Prohibited List — kisspeptin not currently listed — wada-ama.org — 2026 Prohibited List
23. Community reconstitution and storage consensus — r/Peptides — kisspeptin reconstitution + storage threads
24. Peer-reviewed peptide stability and freeze-thaw sensitivity discussion — Peptide stability literature — short-fragment freeze-thaw

KLOW41 references

1. r/Peptides KLOW thread aggregation, last 12 months Apr 2025-Apr 2026 (n≈85) — reddit.com/r/Peptides — KLOW protocol megathreads
2. r/PeptideStacks KLOW + 503A blend discussions, last 12 months (n≈42) — reddit.com/r/PeptideStacks — KLOW + bundled blend threads
3. r/UlcerativeColitis KLOW + tripeptide UC discussions, last 12 months (n≈38) — reddit.com/r/UlcerativeColitis — KLOW + KPV gut protocol threads
4. r/IBD KLOW + KPV + BPC-157 gut threads, last 12 months (n≈30) — reddit.com/r/IBD — bundled peptide blend experience reports
5. r/SkincareAddiction KLOW + GHK-Cu + KPV erythema threads, last 12 months (n≈15) — reddit.com/r/SkincareAddiction — KLOW skin response threads
6. FDA Bulk Drug Substances 503A April 2026 update — KPV retained Category 2 — fda.gov — April 2026 503A bulk substances Category 2 retention list
7. FDA 503A bulks list status — BPC-157 retained April 2026 — fda.gov — 503A bulks list, BPC-157 Category 2 designation
8. FDA public docket — LL-37 retained Category 2 April 2026 — fda.gov — April 2026 503A bulk substances update LL-37
9. FDA 503A list excluding GHK-Cu / copper tripeptides April 2026 — federalregister.gov — FDA 503A bulks list copper peptides Category 2 April 2026
10. Alliance for Pharmacy Compounding tracking, KLOW supply discontinuation reports — a4pc.org — 503A pharmacy compounding update April 2026
11. FDA Pharmacy Compounding Advisory Committee July 2026 — single-peptide IND scoping — fda.gov — July 2026 PCAC peptide evaluation agenda
12. LL-37 mechanism review — amphipathic α-helix membrane disruption — Dürr UH, Sudheendra US, Ramamoorthy A. — LL-37 cathelicidin Biochim Biophys Acta 2006 + 2021-2024 reviews
13. LL-37 broad-spectrum antimicrobial + biofilm activity — Vandamme D et al. — LL-37 factotum Cell Immunol 2012 + 2022-2024 meta-reviews
14. Melanocortin / KPV NF-κB inhibition mechanism 2001 — pubmed.ncbi.nlm.nih.gov/11239507 — Mandrika I et al.
15. PepT1 KPV oral nanoparticle DSS/TNBS colitis — pubmed.ncbi.nlm.nih.gov/18061177 — Dalmasso G et al. Gastroenterology 2008
16. Melanocortin receptors inflammation review — KPV NF-κB / MAPK suppression — pubmed.ncbi.nlm.nih.gov/15001661 — Catania A et al. 2004
17. GHK-Cu regenerative actions review — copper accumulation watchpoint — ncbi.nlm.nih.gov/pmc/articles/PMC6073405 — Pickart L, Margolina A. 2018
18. GHK Connectivity Map — 31.2% gene expression reset — ncbi.nlm.nih.gov/pmc/articles/PMC3514688 — Hong Y et al. Oncotarget 2012
19. BPC-157 review — VEGFR2 angiogenesis + granulation tissue — pubmed.ncbi.nlm.nih.gov/35008515 — Sikiric P et al. 2022
20. BPC-157 systematic review — soft-tissue + GI healing — pubmed.ncbi.nlm.nih.gov/38470890 — Seiwerth et al. 2024
21. GHK-Cu diabetic ulcer wound healing topical RCT — pubmed.ncbi.nlm.nih.gov/17147642 — Mulder GD et al.
22. KPV oral delivery wound healing nanoparticles — Wei P et al. 2021 — Acta Biomaterialia
23. LL-37 T-cell autoantigen psoriasis — Lande R et al. — Nat Commun + 2023 updates
24. UC San Diego oral KPV nanoparticles ulcerative colitis Phase I/II — clinicaltrials.gov/study/NCT05322044
25. LL-37 single-peptide trial registry, accessed Apr 2026 — clinicaltrials.gov — LL-37 Phase I diabetic foot ulcer
26. BPC-157 knee pain registration, single-peptide trial — clinicaltrials.gov/study/NCT05549011
27. Component-level mechanism + dose ranges — examine.com — KPV + GHK-Cu + BPC-157 monographs 2024
28. MCAS-prone titration framework adapted for KLOW component LL-37 — Better Health Guy podcast — Dr. Neil Nathan chronic illness peptide protocols 2024-2025
29. Dr. Kyle Gillett on bundled-blend titration loss — Gillett Health podcast — peptide blends episode 2025
30. KLOW + bundled blend forum-dose discussion — Ergogenic Health / BoostYourBiology podcast — Lucas Aoun peptide stacks 2024-2025
31. Derek on April 2026 Category 2 retention impact on compounded blends — More Plates More Dates — 2026 503A regulatory update
32. KPV + LL-37 + BPC gut-stack discussion — High Intensity Health podcast — Mike Mutzel peptide stacks 2024
33. Telehealth peptide clinician on KLOW supply discontinuation post-April 2026 — Holistic Plastic Surgery — Dr. Robert Whitfield clinic communications 2026
34. Aggregated content on LL-37 mast-cell activation in bundled blends — MCAS / autoimmune integrative dermatology YouTube 2024-2026
35. Examine.com copper supplementation safety — chronic exposure threshold — examine.com/supplements/copper
36. FDA cited 'inadequate safety data' for BPC-157 — fda.gov — 503A BPC-157 Category 2 designation Sep 2023 + Apr 2026 reaffirmation
37. Pre/post KLOW cycle hsCRP user logs — reddit.com/r/Peptides — bloodwork hsCRP KLOW + KPV cycle threads 2025-2026
38. Calprotectin protocol discussions for KLOW UC cycles — reddit.com/r/UlcerativeColitis — fecal calprotectin KLOW tracking 2025-2026
39. Fecal calprotectin protocol discussions — reddit.com/r/IBD — calprotectin tracking KPV + KLOW 2025
40. Standardized skin photo monitoring protocol logs — reddit.com/r/SkincareAddiction — KLOW skin photo logs
41. Pre-mixed compounded vial reconstitution + shelf-life consensus — r/Peptides + r/PeptideStacks — KLOW reconstitution + storage threads 2025-2026

KPV22 references

1. Brzoska T et al. — α-MSH and tripeptides 2008 Endocr Rev — pubmed.ncbi.nlm.nih.gov/18612139
2. Luger TA, Brzoska T — α-MSH peptides 2007 — pubmed.ncbi.nlm.nih.gov/17934097
3. Mandrika I et al. — Melanocortin NF-κB 2001 — pubmed.ncbi.nlm.nih.gov/11239507
4. Manna SK, Aggarwal BB — α-MSH NF-κB 1998 — pubmed.ncbi.nlm.nih.gov/9743348
5. Catania A et al. — Melanocortin receptors inflammation 2004 — pubmed.ncbi.nlm.nih.gov/15001661
6. Dalmasso G et al. — PepT1 KPV 2008 Gastroenterology — pubmed.ncbi.nlm.nih.gov/18061177
7. Kannengiesser K et al. — KPV IBD 2008 — pubmed.ncbi.nlm.nih.gov/18092346
8. Xiao B et al. — KPV nanoparticles UC 2017 — pubmed.ncbi.nlm.nih.gov/28465181
9. Oral delivery wound healing nanoparticles — Wei P et al. 2021 — Acta Biomaterialia
10. UC San Diego oral KPV nanoparticles trial — clinicaltrials.gov/study/NCT05322044
11. FDA Bulk Drug Substances 503A — fda.gov — April 2026 Category 2 update
12. May 2025-April 2026 n≈110 — reddit.com/r/SkincareAddiction — KPV megathreads
13. May 2025-April 2026 n≈85 — reddit.com/r/Peptides — KPV oral protocol threads
14. May 2025-April 2026 n≈45 — reddit.com/r/IBD — KPV experience + tripeptide UC
15. May 2025-April 2026 n≈40 — reddit.com/r/Peptides — SubQ KPV threads
16. Mechanism + dose ranges — examine.com — KPV monograph 2024
17. Ben Greenfield Life, Dr. Tyna Show 2023-2025 — Seeds W. Peptide Protocols Volume 1 + podcast appearances
18. KPV-tagged content — Jay Campbell Twitter/X + TRT Revolution podcast 2024-2025
19. KPV references — Dr. Edwin Lee — Institute for Hormonal Balance lectures 2024-2025
20. Peptide therapeutics segment — Huberman Lab — Dr. Craig Koniver episode 2024
21. Pre/post KPV cycle hsCRP — reddit.com/r/Peptides — bloodwork threads hsCRP KPV 2025
22. Fecal calprotectin protocol discussions — reddit.com/r/IBD — calprotectin tracking KPV 2025

Letrozole (Femara)25 references

1. r/Steroids letrozole / cycle-support and gyno-rescue thread aggregation (last 12 months) — reddit.com/r/Steroids — letrozole threads
2. r/PEDs letrozole thread aggregation — reddit.com/r/PEDs — letrozole threads
3. r/Testosterone letrozole / TRT-context redirect-to-emergency-only thread aggregation — reddit.com/r/Testosterone — letrozole threads
4. FDA Femara (letrozole) prescribing information — 1997 approval, 2.5mg/day breast cancer dose — accessdata.fda.gov/drugsatfda_docs/label/2014/020726s027lbl.pdf
5. WADA Prohibited List — Section S4 (hormone and metabolic modulators), aromatase inhibitors prohibited at all times — wada-ama.org/en/prohibited-list
6. Letrozole pharmacology / aromatase inhibition mechanism characterisation — pubmed.ncbi.nlm.nih.gov/8929076
7. Geisler J et al. Clin Cancer Res 2002 — letrozole vs anastrozole head-to-head crossover, deeper E2 suppression with letrozole — pubmed.ncbi.nlm.nih.gov/12473590
8. Coombes RC et al. NEJM 2004 — IES intergroup trial, foundation extended-adjuvant data — pubmed.ncbi.nlm.nih.gov/15014181
9. Goss PE et al. NEJM 2003 — MA.17 trial, foundation safety/efficacy in extended adjuvant — pubmed.ncbi.nlm.nih.gov/14551341
10. r/Steroids letrozole gyno-rescue protocol consensus thread — reddit.com/r/Steroids — letrozole gyno-rescue megathread
11. r/PEDs letrozole + LC/MS sensitive assay community consensus thread — reddit.com/r/PEDs — letrozole + sensitive E2 megathread
12. Letrozole dose-response in postmenopausal women — deep E2 suppression at 2.5mg/day — pubmed.ncbi.nlm.nih.gov/12751885
13. Mauras N et al. JCEM 2009 — aromatase inhibition safety in male physiology — pubmed.ncbi.nlm.nih.gov/19033366
14. Karuppu D et al. JCEM 2017 — longer-term aromatase inhibitor use in male physiology — pubmed.ncbi.nlm.nih.gov/28201625
15. Burnett-Bowie SA et al. JCEM 2009 — aromatase inhibition in men with hypogonadism, bone density outcomes (anastrozole context, applies to letrozole class) — pubmed.ncbi.nlm.nih.gov/19825816
16. Finkelstein JS et al. NEJM 2013 — E2 and T independent effects on body composition / sexual function in men — pubmed.ncbi.nlm.nih.gov/24024838
17. Letrozole pharmacokinetics — half-life and aromatase activity persistence — pubmed.ncbi.nlm.nih.gov/8181241
18. r/Steroids letrozole crash recovery aggregation — slower recovery than anastrozole — reddit.com/r/Steroids — letrozole crash recovery threads
19. More Plates More Dates letrozole emergency-only coverage — youtube.com/@MorePlatesMoreDates
20. Gillett Health podcast — aromatase inhibitor tier discussion — youtube.com/@GillettHealth
21. Aromatase inhibition adverse lipid shift literature — class effect, more pronounced with letrozole — pubmed.ncbi.nlm.nih.gov/14671196
22. Tony Huge / Enhanced Athlete cycle support content — youtube.com/@EnhancedAthlete
23. Greg Doucette aromatase inhibitor video — youtube.com/@GregDoucette
24. Bhasin S et al. — Endocrine Society 2018 testosterone therapy guideline (does not endorse routine AI use, applies to letrozole and anastrozole) — academic.oup.com/jcem/article/103/5/1715
25. r/Steroids wiki — letrozole cycle support and gyno-rescue protocol aggregation — reddit.com/r/Steroids/wiki/letrozole

LGD-4033 (Ligandrol)25 references

1. r/sarmssourcetalk LGD-4033 thread aggregation (last 12 months, n=~720) — reddit.com/r/sarmssourcetalk LGD-4033 threads
2. r/PEDs LGD-4033 thread aggregation (last 12 months, n=~510) — reddit.com/r/PEDs LGD-4033 threads
3. r/MoreplatesMoredates LGD-4033 thread aggregation (last 12 months, n=~420) — reddit.com/r/MoreplatesMoredates LGD-4033 threads
4. Cross-forum modal-dose distribution analysis — Forum dose distribution synthesis
5. FDA 2017 public statement on SARMs naming LGD-4033 (and BMS-564929) — fda.gov — Public Statement on SARMs October 2017
6. FDA 2017 warning letters to seven SARM-marketing companies — fda.gov — Warning Letters to SARM marketers 2017
7. Basaria S et al., J Gerontol Ser A 2013 — Phase 1 LGD-4033 healthy men n=76 — pubmed.ncbi.nlm.nih.gov/22459616
8. Vajapey R et al., Drug Test Anal 2018 — LGD-4033 analytical detection + bodybuilding case reports — pubmed.ncbi.nlm.nih.gov/29396334
9. Bhasin S, Endocr Pract 2014 — SARM class review — pubmed.ncbi.nlm.nih.gov/25425683
10. Ladwig L et al., Australas J Dermatol 2024 — DILI case report LGD-4033 + RAD-140 stack — onlinelibrary.wiley.com/doi/10.1111/ajd.14185
11. Hepatology Communications — DILI case series SARMs — pubmed.ncbi.nlm.nih.gov/31887812
12. Annals of Internal Medicine — SARM-related liver injury case report — pubmed.ncbi.nlm.nih.gov/30640380
13. WADA Prohibited List S1.2 — LGD-4033 banned in/out of competition — wada-ama.org — Prohibited List SARMs S1.2
14. NCAA Banned Drug Classes — SARMs — ncaa.org — Banned Substances list
15. Viking Therapeutics VK5211 (LGD-4033) Phase 2 hip-fracture program — vikingtherapeutics.com — VK5211 development history
16. Ligand Pharmaceuticals SARM mechanism + selectivity review — pubmed.ncbi.nlm.nih.gov/25092531
17. More Plates More Dates LGD-4033 review — youtube.com/@MorePlatesMoreDates
18. Enhanced Athlete (Tony Huge) SARM panel — youtube.com/@EnhancedAthleteOfficial
19. FDA MedWatch adverse-event database SARM-related liver injury entries — fda.gov — MedWatch adverse event reports SARMs
20. Greg Doucette SARM honesty hour LGD-4033 segment — youtube.com/@GregDoucette
21. Renaissance Periodization (Mike Israetel) SARM science segment — youtube.com/@RenaissancePeriodization
22. Vigorous Steve LGD-4033 deep dive — youtube.com/@VigorousSteve
23. r/sarmssourcetalk PCT consensus megathread for LGD — reddit.com/r/sarmssourcetalk PCT consensus megathread
24. r/PEDs cycle-end bloodwork screenshot aggregation thread — reddit.com/r/PEDs LGD bloodwork screenshots megathread
25. SARM hepatotoxicity literature review — pubmed.ncbi.nlm.nih.gov/31345459

Lion's Mane25 references

1. r/Nootropics lion's mane thread aggregation (last 12 months, n=~600) — reddit.com/r/Nootropics lion's mane threads
2. r/Supplements / r/StackAdvice / r/Mushrooms thread aggregation (last 12 months, n=~300) — reddit.com/r/Supplements + r/StackAdvice + r/Mushrooms lion's mane threads
3. FDA Generally Recognized as Safe status for lion's mane as a food / supplement — fda.gov — GRAS notices for Hericium erinaceus food use
4. Friedman M., 2015 — chemistry, nutrition, and medicinal properties of Hericium erinaceus — pubmed.ncbi.nlm.nih.gov/27481156
5. Phan CW et al., 2014 — Hericium erinaceus and neurohealth, NGF mechanism review — pubmed.ncbi.nlm.nih.gov/24266378
6. Kawagishi H. et al., 1991 — original hericenone NGF stimulation in vitro — pubmed.ncbi.nlm.nih.gov/8104253
7. Erinacine A blood-brain barrier penetration in rodent models — pubmed.ncbi.nlm.nih.gov/26244378
8. Community debate on mycelium-on-grain dilution and active-compound standardization — reddit.com/r/Mushrooms — fruiting body vs mycelium debate megathread
9. Mori K. et al., Phytother Res 2009 — RCT, n=30, MCI, 3g/day fruiting body × 16 weeks — pubmed.ncbi.nlm.nih.gov/18844328
10. Saitsu Y. et al., Biomed Res 2019 — n=31 healthy older adults, 3.2g/day × 12 weeks — pubmed.ncbi.nlm.nih.gov/31413233
11. Vigna L. et al., Evid Based Complement Alternat Med 2019 — n=77, mood/anxiety, 1g/day × 8 weeks — pubmed.ncbi.nlm.nih.gov/31118969
12. Nagano M. et al., Biomed Res 2010 — n=30, menopausal women, 2g/day × 4 weeks, anxiety/irritability — pubmed.ncbi.nlm.nih.gov/20834180
13. Chiu CH. et al., Behav Neurol 2018 — erinacine-A-enriched mycelium in mild Alzheimer's — pubmed.ncbi.nlm.nih.gov/29951133
14. Community consensus on hot-water extract ratios, fruiting body sourcing, dose-per-capsule conventions — r/Nootropics — lion's mane sourcing and extract-ratio megathread
15. Huberman Lab podcast — nootropics episode lion's mane segment — hubermanlab.com — Nootropics discussion
16. Paul Stamets on Hericium erinaceus cognitive use — Fantastic Fungi documentary and TEDMED talk — fantasticfungi.com / TEDMED — Paul Stamets
17. Joe Rogan Experience clips discussing Alpha Brain ingredient stack including lion's mane — youtube.com — JRE clips on Onnit Alpha Brain
18. Lucas Aoun (Boost Your Biology) lion's mane fruiting-body vs mycelium review — youtube.com/@LucasAoun
19. Mike Mutzel (High Intensity Health) lion's mane and BDNF/NGF discussion — highintensityhealth.com — Mike Mutzel
20. Community storage / shelf-life consensus for fruiting-body and mycelium products — r/Supplements — extract ratio and storage threads
21. Documented forum subset reporting paradoxical anxiety or brain fog (~6% of threads) — reddit.com/r/Nootropics — 'lion's mane fog' / paradoxical reaction threads
22. Examine.com aggregated human-trial monograph for lion's mane — examine.com — Hericium erinaceus monograph
23. Li IC. et al. systematic review — neurohealth applications of Hericium erinaceus — pubmed.ncbi.nlm.nih.gov/35105956
24. Hericium erinaceus and depression — preclinical mechanism review — pubmed.ncbi.nlm.nih.gov/32331437
25. Community threads documenting the ~22% non-responder rate after 8+ weeks of consistent dosing — r/Nootropics + r/StackAdvice — non-responder threads

Liraglutide25 references

1. r/Saxenda subreddit thread aggregation (last 12 months, n=~280 across r/Saxenda + r/liraglutide cross-posts) — reddit.com/r/Saxenda
2. r/loseit Liraglutide / Saxenda thread aggregation — reddit.com/r/loseit liraglutide threads
3. FDA Victoza prescribing information and approval (January 2010) — accessdata.fda.gov — Victoza label NDA 022341
4. FDA Saxenda prescribing information and approval (December 2014) — accessdata.fda.gov — Saxenda label NDA 206321
5. FDA approval of first generic liraglutide injection (Hikma) — fda.gov — Hikma generic liraglutide approval December 2024
6. Knudsen et al. — Liraglutide structure and pharmacology — pubmed.ncbi.nlm.nih.gov/19131410
7. Liraglutide mechanism of action review — pubmed.ncbi.nlm.nih.gov/20227406
8. Saxenda regulatory history and SCALE trial program — pubmed.ncbi.nlm.nih.gov/26132939
9. Pi-Sunyer X. et al. — SCALE Obesity and Prediabetes, NEJM 2015 (n=3,731, 8.0% mean weight loss) — pubmed.ncbi.nlm.nih.gov/26132939
10. Marso S.P. et al. — LEADER trial, NEJM 2016 (n=9,340, 13% MACE reduction in T2D) — pubmed.ncbi.nlm.nih.gov/27295427
11. Rubino D.M. et al. — STEP 8 head-to-head semaglutide vs liraglutide, JAMA 2022 (n=338, 15.8% vs 6.4% weight loss) — pubmed.ncbi.nlm.nih.gov/35015037
12. Secher A. et al. — Liraglutide central appetite mechanism via hypothalamic GLP-1R — pubmed.ncbi.nlm.nih.gov/24842727
13. Novo Nordisk SEC filings on Liraglutide patent expiration timeline 2024-2026 — novonordisk.com — patent expiration disclosures
14. Community pen / titration consensus thread — r/Saxenda — pen reconstitution and dosing megathread
15. r/Saxenda off-label maintenance dosing thread aggregation — reddit.com/r/Saxenda — microdose maintenance threads
16. Peter Attia podcast GLP-1 class episode — peterattiamd.com — GLP-1 class deep-dive
17. Andrew Huberman GLP-1 episode — hubermanlab.com — GLP-1 receptor agonists episode
18. Dr. Tyna Show Liraglutide / GLP-1 episode — drtyna.com — Liraglutide segment
19. Layne Norton Biolayne GLP-1 episode — biolayne.com — GLP-1 podcast
20. Wilding J.P.H. et al. — STEP 1 semaglutide trial, NEJM 2021 (cross-comparison reference, n=1,961) — pubmed.ncbi.nlm.nih.gov/33567185
21. Jastreboff A.M. et al. — SURMOUNT-1 tirzepatide trial, NEJM 2022 (cross-comparison reference, n=2,539) — pubmed.ncbi.nlm.nih.gov/35658024
22. Novo Nordisk financial filings showing Saxenda volume decline post-Wegovy launch — novonordisk.com — Saxenda Q4 2024 sales report
23. r/diabetes Victoza thread aggregation (T2D user perspective) — reddit.com/r/diabetes — Victoza experience threads
24. Davies M.J. et al. — Liraglutide 3.0mg in T2D weight management (SCALE Diabetes, n=846) — pubmed.ncbi.nlm.nih.gov/29466574
25. European Medicines Agency Saxenda assessment report — ema.europa.eu — Saxenda EPAR

LL-3722 references

1. Last 12 months Apr 2025-Apr 2026 — reddit.com/r/Peptides — LL-37 protocol megathreads
2. Last 12 months — reddit.com/r/Lyme — LL-37 + Herx + MARCoNS threads
3. Last 12 months — reddit.com/r/CFS — LL-37 user reports
4. FDA public docket — fda.gov — April 2026 503A bulk substances update
5. Pharmacy Compounding Advisory Committee — fda.gov — July 2026 PCAC LL-37 evaluation
6. Biochim Biophys Acta 2006 + 2021-2024 reviews — Dürr UH, Sudheendra US, Ramamoorthy A. — LL-37 cathelicidin
7. Cell Immunol 2012 + 2022-2024 meta-reviews — Vandamme D et al. — LL-37 factotum
8. Front Microbiol 2021-2023 — Lewis K et al. — LL-37 vs Borrelia persister forms
9. Peptides 2011 + topical wound trials 2022 — Ramos R et al. — LL-37 wound healing
10. Science + 2020-2024 reviews — Liu PT, Modlin RL — TLR triggering vitamin D antimicrobial
11. J Steroid Biochem Mol Biol review — White JH — Vitamin D as cathelicidin inducer 2022
12. Wound Repair Regen — Grönberg A et al. — LL-37 venous leg ulcers (n=34)
13. Preclinical 2024-2025 — Mansour SC et al. — Inhaled LL-37 cystic fibrosis biofilm
14. Accessed Apr 2026 — clinicaltrials.gov — LL-37 Phase I diabetic foot ulcer
15. Accessed Apr 2026 — clinicaltrials.gov — Inhaled LL-37 Pseudomonas Phase I/II
16. Accessed Apr 2026 — clinicaltrials.gov — LL-37 melanoma Phase I
17. Accessed Apr 2026 — clinicaltrials.gov — LL-37 UTI prevention
18. Chronic illness peptide protocols 2024-2025 — Better Health Guy podcast — Dr. Neil Nathan
19. Aggregated content — MCAS / autoimmune integrative dermatology YouTube 2024-2026
20. Blog + podcast 2024 — Dr. Jill Carnahan — chronic sinusitis MARCoNS LL-37
21. Risk profile discussion 2024-2025 — Dr. Kyle Gillett / Jay Campbell — peptide podcast LL-37
22. Nat Commun + 2023 updates — Lande R et al. — LL-37 T-cell autoantigen psoriasis

Melanotan I (Afamelanotide)26 references

1. r/MelanotanII Melanotan I aggregation (last 12 months, n=~310) — reddit.com/r/MelanotanII Melanotan I cross-discussion threads
2. r/Peptides Melanotan I aggregation — reddit.com/r/Peptides melanotan threads
3. FDA approval letter — Scenesse for EPP — fda.gov — Scenesse (afamelanotide) approval, October 2019
4. Clinuvel Pharmaceuticals — Scenesse implant prescribing information — clinuvel.com/scenesse
5. FDA 503A Category 2 list — afamelanotide removal April 15 2026 — fda.gov — 503A Category 2 list, April 15 2026 update
6. WADA 2026 — afamelanotide / Melanotan I status — wada-ama.org — 2026 Prohibited List
7. Original [Nle4, D-Phe7]-α-MSH potency characterization — pubmed.ncbi.nlm.nih.gov/2839527
8. Afamelanotide pharmacokinetics — extended half-life vs α-MSH — pubmed.ncbi.nlm.nih.gov/15860363
9. Langendonk JG et al., NEJM 2015 — Phase 3 EPP trial (n=93) — nejm.org/doi/10.1056/NEJMoa1411481
10. Biolcati G et al., Br J Dermatol 2015 — Italian compassionate-use cohort (n=115) — pubmed.ncbi.nlm.nih.gov/25754230
11. Melanocortin receptor selectivity — MT-I vs MT-II MC3R/MC4R activity — pubmed.ncbi.nlm.nih.gov/12878427
12. Melanotan II structure-activity review — cyclic 7-aa peptide — pubmed.ncbi.nlm.nih.gov/16720011
13. Lengweiler S et al., PLoS One 2015 — quality-of-life data (n=117) — journals.plos.org/plosone — Lengweiler S et al. 2015
14. Falchetto R, Front Pharmacol 2022 — long-term afamelanotide safety review — frontiersin.org/articles — Falchetto R, Front Pharmacol 2022
15. Minder EI, Expert Opin Pharmacother 2010 — afamelanotide review — pubmed.ncbi.nlm.nih.gov/20367416
16. Community reconstitution math (10mg vial standard) — r/MelanotanII reconstitution + dosing megathreads
17. More Plates More Dates Melanotan I vs II breakdown — youtube.com/@MorePlatesMoreDates — melanotan video
18. Lucas Aoun / Ergogenic Health melanotan episode — ergogenichealth.com — melanotan podcast episode
19. Gillett Health melanotan dermatology screening discussion — youtube.com/@GillettHealth — melanotan episode
20. Dr Dray (board-certified derm) melanotan dermatology breakdown — youtube.com/@DrDray — melanotan explainer
21. Community photographic baseline + mole monitoring consensus — reddit.com/r/MelanotanII — mole monitoring megathread
22. r/Peptides community bloodwork baseline consensus — reddit.com/r/Peptides — bloodwork baseline checklist threads
23. Community storage / shelf-life consensus across peptides — r/Peptides — storage stability megathread
24. Scenesse PI — light sensitivity + storage requirements — Scenesse prescribing information — Clinuvel
25. r/tanning Melanotan I cosmetic-use thread aggregation — reddit.com/r/tanning — Melanotan I threads
26. r/Biohackers melanotan analog risk/benefit threads — reddit.com/r/Biohackers — melanotan analog discussion

Melanotan II17 references

1. Aggregated May 2025-April 2026 — reddit.com/r/Melanotan — top-pinned protocol megathread
2. Weekly threads aggregated — reddit.com/r/Melanotan — weekly experience threads
3. May 2025-April 2026 — reddit.com/r/Peptides — MT-II tagged posts
4. FDA announcement — fda.gov — Category 2 bulk substances update April 2026
5. FDA advisory committee meeting — fda.gov — July 2026 advisory committee notice
6. Life Sci, foundational pharmacology — Dorr RT et al. — MT-II superpotent cyclic melanotropic peptide
7. Peptides journal — Hadley ME, Dorr RT — Melanocortin peptide therapeutics
8. Curr Top Med Chem — King SH et al. — Melanocortin receptors and penile erection
9. Examine.com compiled summary — examine.com — Melanotan II profile
10. Br J Dermatol systematic review — Habbema L et al. — α-MSH analogues review 2024
11. JAMA Dermatology / Australian dermatology — Cardones AR, Grichnik JM — Dysplastic nevi case series 2023
12. Pharmacological reference for melanocortin agonists — clinicaltrials.gov — afamelanotide (Scenesse)
13. Derek MPMD melanocortin pathway video, 2024 — youtube.com/@MorePlatesMoreDates
14. Long-term MT-II user logs — Bodybuilding-forum aggregations 2024-2026
15. Tony Huge MT-II podcast appearances 2025 — youtube.com/@EnhancedAthlete
16. Dr. Anthony Youn MT-II content March 2026 — tiktok.com/@dr.tonyyoun
17. PubMed search filtered to clinical and case reports — pubmed.ncbi.nlm.nih.gov — melanotan II 2021-2026

Mesterolone (Proviron)24 references

1. r/Testosterone Mesterolone/Proviron thread aggregation (last 12 months, n=~620 across listed subs) — reddit.com/r/Testosterone Proviron threads
2. r/TRT Proviron + SHBG thread aggregation — reddit.com/r/TRT Proviron threads
3. r/steroids and r/PEDs Proviron thread aggregation — reddit.com/r/steroids Proviron threads
4. DEA scheduling — anabolic steroids Schedule III — deadiversion.usdoj.gov — Anabolic Steroid Control Act 1990
5. Schering Proviron historical prescribing information — Bayer Schering Proviron prescribing information (UK/EU historical)
6. TGA Australia Proviron product registration history — tga.gov.au — Proviron Australian Public Assessment
7. WADA 2024 Prohibited List — mesterolone listed under S1 — wada-ama.org — 2024 Prohibited List S1 Anabolic Agents
8. Mesterolone synthesis and structural characterization (1α-methyl DHT derivative) — pubmed.ncbi.nlm.nih.gov/14606731
9. Kicman AT, Pharmacology of anabolic steroids, Br J Pharmacol 2008 — pubmed.ncbi.nlm.nih.gov/18500378
10. Mesterolone non-aromatizable 5α-reduced A-ring characterization — pubmed.ncbi.nlm.nih.gov/4039397
11. Llewellyn anabolics reference — mesterolone PK and SHBG profile — Llewellyn W., Anabolics 11th ed., 2017 — mesterolone monograph
12. Mesterolone SHBG binding affinity characterization — pubmed.ncbi.nlm.nih.gov/486574
13. Mesterolone SHBG displacement of testosterone in vitro — pubmed.ncbi.nlm.nih.gov/3016846
14. Mesterolone weak in vitro anti-aromatase activity — pubmed.ncbi.nlm.nih.gov/3754417
15. Aydoğan Ü et al., Andrologia 2013 — Mesterolone + Tamoxifen for idiopathic male infertility — pubmed.ncbi.nlm.nih.gov/22591009
16. Mesterolone in oligospermia — European clinical experience 1970s-80s — pubmed.ncbi.nlm.nih.gov/371544
17. Pope HG et al., Drug Alcohol Depend 2010 — Adverse health consequences of performance-enhancing drugs — pubmed.ncbi.nlm.nih.gov/19926232
18. More Plates More Dates Proviron / SHBG explainer — youtube.com/@MorePlatesMoreDates
19. Gillett Health SHBG and free testosterone episode — youtube.com/@GillettHealth
20. Enhanced Athlete Proviron breakdown — youtube.com/@EnhancedAthlete
21. Renaissance Periodization discussion of ancillary orals — youtube.com/@RenaissancePeriodization
22. r/Testosterone SHBG pre/post bloodwork user-data thread — reddit.com/r/Testosterone — SHBG bloodwork pre/post Proviron megathread
23. European literature — mesterolone lipid panel shifts at sustained doses — pubmed.ncbi.nlm.nih.gov/2599919
24. r/steroids UGL tablet strength variability lab-analysis discussion — reddit.com/r/steroids — UGL Proviron tablet lab-analysis threads

Methandrostenolone (Dianabol)27 references

1. r/Steroids Dianabol thread aggregation (last 12 months) — reddit.com/r/Steroids Dianabol threads
2. r/PEDs Dianabol thread aggregation — reddit.com/r/PEDs Dianabol threads
3. r/bodybuilding Dianabol thread aggregation — reddit.com/r/bodybuilding Dianabol threads
4. PubChem methandrostenolone chemistry record — pubchem.ncbi.nlm.nih.gov/compound/Methandrostenolone
5. Kicman AT — Pharmacology of anabolic steroids, BJP 2008 review — pubmed.ncbi.nlm.nih.gov/18604277
6. Llewellyn W — anabolic steroid structural pharmacology references — pubmed.ncbi.nlm.nih.gov/14702800
7. Frontiers in Endocrinology 2018 — 17-alpha-alkylated oral hepatotoxicity review — pubmed.ncbi.nlm.nih.gov/29904370
8. Methandrostenolone aromatisation and 17-alpha-methylestradiol metabolite — pubmed.ncbi.nlm.nih.gov/3290086
9. Anabolic steroid muscle protein synthesis and nitrogen retention — pubmed.ncbi.nlm.nih.gov/8427387
10. Historical review — Ziegler, Ciba and the introduction of Dianabol to American athletics — pubmed.ncbi.nlm.nih.gov/24030674
11. Historical reference on Dianabol's introduction in 1958-60 American athletics — Yesalis CE — Anabolic Steroids in Sport and Exercise (Human Kinetics, 2nd ed)
12. Hervey GR et al., Br J Sports Med 1981 — methandrostenolone 100mg/day x 6wk strength trial — pubmed.ncbi.nlm.nih.gov/7272663
13. Freed DL et al., BMJ 1975 — methandrostenolone in 13 trained lifters — pubmed.ncbi.nlm.nih.gov/1131655
14. Pope HG, Kanayama G et al., Drug Alcohol Depend 2010 — AAS user cohort — pubmed.ncbi.nlm.nih.gov/19836943
15. Frontiers in Endocrinology 2018 — cardiovascular consequences of AAS use — pubmed.ncbi.nlm.nih.gov/30090244
16. FDA Drugs@FDA — methandrostenolone NDA history (Ciba 1958, withdrawn 1985) — accessdata.fda.gov
17. US Federal Register notice of methandrostenolone withdrawal from US market — Federal Register 1985 — Ciba-Geigy methandrostenolone withdrawal
18. DEA classification of anabolic steroids under Schedule III, Anabolic Steroid Control Act 1990 — deadiversion.usdoj.gov — Anabolic Steroids Schedule III
19. WADA Prohibited List, Section S1 — methandrostenolone banned at all times — wada-ama.org — Prohibited List S1 Anabolic Agents
20. r/MoreplatesMoredates Dianabol thread aggregation — reddit.com/r/MoreplatesMoredates Dianabol threads
21. r/Steroids modal kickstart protocol consensus threads — reddit.com/r/Steroids — Dbol kickstart consensus megathreads
22. r/PEDs ALT/AST/lipids bloodwork compilation threads on Dianabol cycles — reddit.com/r/PEDs — Dbol bloodwork compilation threads
23. More Plates More Dates Dianabol breakdown — youtube.com/@MorePlatesMoreDates
24. Mike Israetel / Renaissance Periodization PED discussion — youtube.com/@RenaissancePeriodization
25. Vigorous Steve oral steroids guide — youtube.com/@VigorousSteve
26. Greg Doucette steroid honesty videos — youtube.com/@GregDoucette
27. Tony Huge / Enhanced Athlete cycle logs — youtube.com/@EnhancedAthlete

Methenolone Acetate (Primobolan Oral)24 references

1. r/Steroids oral Primobolan thread aggregation, last 24 months (n=~280) — reddit.com/r/steroids — oral Primobolan / methenolone acetate megathreads
2. r/PEDs oral methenolone thread aggregation — reddit.com/r/PEDs — methenolone acetate oral threads
3. MPMD subreddit counterfeit-source thread aggregation for oral methenolone — reddit.com/r/MorePlatesMoreDates — counterfeit oral Primo threads
4. FDA historical record — Schering withdrew US oral Primobolan products — fda.gov — Schering Primobolan / Nibal withdrawal history
5. DEA Schedule III classification of methenolone and AAS class — deadiversion.usdoj.gov — Anabolic Steroid Control Act 1990
6. WADA Prohibited List — methenolone banned at all times — wada-ama.org — Prohibited List, S1 Anabolic Agents
7. Llewellyn's Anabolics reference text — oral methenolone PK + bioavailability + counterfeit discussion — Llewellyn W. — Anabolics, 11th Edition, methenolone acetate monograph
8. Pharmacology of 1-methylated DHT derivatives — pubmed.ncbi.nlm.nih.gov — methenolone 1-methyl substitution pharmacology
9. Kicman AT, BJP 2008 — pharmacology of anabolic steroids review (covers 17α-alkylation and oral activity) — pubmed.ncbi.nlm.nih.gov/18250893
10. Methenolone acetate pharmacokinetic literature — short oral half-life ~4-6h — pubmed.ncbi.nlm.nih.gov — methenolone acetate oral PK literature
11. Anabolic.org methenolone acetate PK and dose profile reference — anabolic.org — methenolone acetate profile
12. HPTA suppression literature for AR-agonist AAS — pubmed.ncbi.nlm.nih.gov — AAS HPTA suppression and recovery
13. Anabolic Lab independent HPLC testing — oral methenolone mislabelling rates — anaboliclab.com — oral Primobolan HPLC test results archive
14. Pope HG, Kanayama G, Athey A et al. — Drug Alcohol Depend 2010 — pubmed.ncbi.nlm.nih.gov/20650569
15. Hartgens F, Kuipers H — Sports Medicine 2004 — AAS in athletes review — pubmed.ncbi.nlm.nih.gov/15233597
16. Cardiovascular safety reviews of AAS class effects — pubmed.ncbi.nlm.nih.gov — AAS cardiovascular safety reviews
17. Derek / More Plates More Dates oral Primobolan / bioavailability deep dive — youtube.com/@MorePlatesMoreDates
18. Vigorous Steve oral Primobolan / 17α-alkylation discussion — youtube.com/@VigorousSteve
19. Greg Doucette oral Primobolan commentary — youtube.com/@GregDoucetteIFBBPRO
20. Tony Huge / Enhanced Athlete cycle logs oral Primobolan segment — youtube.com/@TonyHuge
21. Mike Israetel / RP oral AAS commentary — youtube.com/@RenaissancePeriodization
22. r/Steroids cycle bloodwork community aggregation — reddit.com/r/steroids — bloodwork megathreads
23. DHT-derivative AAS scalp impact literature — pubmed.ncbi.nlm.nih.gov — DHT-derivative AAS and androgenic alopecia
24. Comparative hepatotoxicity literature — 17α-alkylated vs non-17α-alkylated oral AAS — pubmed.ncbi.nlm.nih.gov — 17α-alkylated AAS hepatotoxicity literature

Methenolone Enanthate (Primobolan Depot)23 references

1. r/Steroids Primobolan thread aggregation, last 24 months (n=~400) — reddit.com/r/steroids — Primobolan megathreads
2. r/PEDs methenolone enanthate thread aggregation — reddit.com/r/PEDs — methenolone threads
3. MPMD subreddit counterfeit-source thread aggregation — reddit.com/r/MorePlatesMoreDates — counterfeit Primobolan threads
4. FDA historical record — Schering withdrew US Primobolan products — fda.gov — Schering Nibal / Primobolan Depot withdrawal history
5. DEA Schedule III classification of methenolone and AAS class — deadiversion.usdoj.gov — Anabolic Steroid Control Act 1990
6. WADA Prohibited List — methenolone banned at all times — wada-ama.org — Prohibited List, S1 Anabolic Agents
7. Llewellyn's Anabolics reference text — methenolone PK + counterfeit discussion — Llewellyn W. — Anabolics, 11th Edition, methenolone monograph
8. Pharmacology of 1-methylated DHT derivatives — pubmed.ncbi.nlm.nih.gov — methenolone 1-methyl substitution pharmacology
9. Kicman AT, BJP 2008 — pharmacology of anabolic steroids review — Kicman AT — British Journal of Pharmacology 2008
10. Methenolone enanthate pharmacokinetic literature — half-life ~10 days — pubmed.ncbi.nlm.nih.gov — methenolone enanthate PK studies
11. Anabolic.org methenolone PK and dose profile reference — anabolic.org — methenolone profile
12. HPTA suppression literature for AR-agonist AAS — pubmed.ncbi.nlm.nih.gov — AAS HPTA suppression and recovery
13. Anabolic Lab independent HPLC testing — Primobolan mislabelling rates — anaboliclab.com — Primobolan HPLC test results archive
14. Pope HG, Kanayama G, Athey A et al. — Drug Alcohol Depend 2010 — pubmed.ncbi.nlm.nih.gov/20650569
15. Hartgens F, Kuipers H — Sports Medicine 2004 — AAS in athletes review — pubmed.ncbi.nlm.nih.gov/15233597
16. Cardiovascular safety reviews of AAS class effects — pubmed.ncbi.nlm.nih.gov — AAS cardiovascular safety reviews
17. Derek / More Plates More Dates Primobolan / counterfeiting deep dive — youtube.com/@MorePlatesMoreDates
18. Vigorous Steve Primobolan content — youtube.com/@VigorousSteve
19. Greg Doucette AAS commentary on Primobolan — youtube.com/@GregDoucetteIFBBPRO
20. Tony Huge / Enhanced Athlete cycle logs Primobolan segment — youtube.com/@TonyHuge
21. Mike Israetel / RP AAS commentary Primobolan — youtube.com/@RenaissancePeriodization
22. r/Steroids cycle bloodwork community aggregation — reddit.com/r/steroids — bloodwork megathreads
23. DHT-derivative AAS scalp impact literature — pubmed.ncbi.nlm.nih.gov — DHT-derivative AAS and androgenic alopecia

Methyldrostanolone (Superdrol)25 references

1. r/Steroids methyldrostanolone thread aggregation (last 24 months, n=~1,200) — reddit.com/r/Steroids superdrol threads
2. r/PEDs methyldrostanolone thread aggregation (last 24 months, n=~480) — reddit.com/r/PEDs superdrol threads
3. r/bodybuilding methyldrostanolone thread aggregation (last 24 months, n=~120) — reddit.com/r/bodybuilding superdrol threads
4. DASCA 2014 — methyldrostanolone Schedule III designation — congress.gov — Designer Anabolic Steroid Control Act of 2014 (DASCA)
5. Methyldrostanolone pharmacology and supplement-era history review — pubmed.ncbi.nlm.nih.gov/22085412
6. Original Syntex synthesis and structural characterisation (Ringold et al., 1956 series) — pubmed.ncbi.nlm.nih.gov/16260171
7. WADA 2026 Prohibited List — methyldrostanolone S1.1 — wada-ama.org — 2026 Prohibited List, S1 Anabolic Agents
8. 17α-alkylation hepatotoxicity mechanism review — pubmed.ncbi.nlm.nih.gov/19002740
9. Schwingel PA et al., Liver International 2011 — bodybuilder DILI case series including methyldrostanolone — pubmed.ncbi.nlm.nih.gov/21645216
10. Robles-Diaz M et al., Hepatology 2015 — anabolic-steroid-induced liver injury phenotype analysis — pubmed.ncbi.nlm.nih.gov/25754460
11. Krishnan PV et al., Digestive Diseases and Sciences 2009 — Superdrol cholestatic hepatitis case report — pubmed.ncbi.nlm.nih.gov/19629685
12. Singh V et al., International Journal of Cardiology 2014 — methyldrostanolone-attributed acute MI case report — pubmed.ncbi.nlm.nih.gov/24909801
13. Cabrera SM et al., Diabetes 2008 — Superdrol-associated metabolic syndrome case — pubmed.ncbi.nlm.nih.gov/18519801
14. 17α-alkylated AAS DILI resolution time cohort analysis — pubmed.ncbi.nlm.nih.gov/24698770
15. Community paired-bloodwork aggregation, n=~412 paired panels — reddit.com/r/Steroids — bloodwork megathreads (Superdrol pre/post panels)
16. r/Steroids meta-thread on Superdrol cycle window (3-4wk consensus) — reddit.com/r/Steroids — cycle-length consensus thread
17. More Plates More Dates Superdrol education video — youtube.com/@MorePlatesMoreDates — Superdrol breakdown
18. Enhanced Athlete YouTube — Tony Huge cycle log series — youtube.com/@EnhancedAthlete — Tony Huge Superdrol log
19. Greg Doucette YouTube — methyldrostanolone risk discussion — youtube.com/@gregdoucette — AAS education series
20. Mike Israetel / Renaissance Periodization AAS risk-tier discussion — youtube.com/@RenaissancePeriodization — AAS risk panel
21. Vigorous Steve YouTube — oral AAS coaching breakdown — youtube.com/@VigorousSteve — oral steroids deep dive
22. r/PEDs consensus thread on mid-cycle bloodwork stop criteria — reddit.com/r/PEDs — Superdrol bloodwork stop-signal thread
23. Methyldrostanolone half-life and pharmacokinetic profile reference — pubmed.ncbi.nlm.nih.gov/19250453
24. NIH LiverTox database — anabolic steroid hepatotoxicity reference including 17α-alkylated compounds — livertox.nih.gov — Anabolic Steroids monograph
25. Designer steroid era hepatotoxicity surveillance review (2005-2012 supplement window) — pubmed.ncbi.nlm.nih.gov/21959031

MGF (Mechano Growth Factor)24 references

1. r/Peptides MGF + PEG-MGF thread aggregation (last 12 months, n=~310) — reddit.com/r/Peptides MGF threads
2. r/PEDs MGF thread aggregation — reddit.com/r/PEDs MGF threads
3. FDA 503A Category 2 bulks list — MGF removal April 15, 2026 — fda.gov — 503A bulks list update April 15, 2026
4. FDA PCAC record on growth-factor peptide bulks-list status — fda.gov — Pharmacy Compounding Advisory Committee record
5. Yang SY, Goldspink G. FEBS Letters 2002 — foundational IGF-1 splice variant paper identifying MGF — pubmed.ncbi.nlm.nih.gov/12027292
6. Goldspink G et al. J Anat 1999 — mechano growth factor expression in response to muscle loading — pubmed.ncbi.nlm.nih.gov/10595803
7. Hill M, Goldspink G. J Physiol 2003 — local IGF-1 isoform expression in damaged skeletal muscle — pubmed.ncbi.nlm.nih.gov/12879880
8. Quesada A et al. Ann N Y Acad Sci 2004 — splice-variant IGF-1 in tissue repair — pubmed.ncbi.nlm.nih.gov/15616236
9. Adams GR, Bamman MM. Comprehensive Physiology 2012 — mechanical loading and IGF-1 isoforms in skeletal muscle — pubmed.ncbi.nlm.nih.gov/23720292
10. Goldspink G review — local autocrine/paracrine IGF-1 isoform action in muscle — pubmed.ncbi.nlm.nih.gov/15070668
11. ClinicalTrials.gov registry — no completed Phase II/III trials of synthetic MGF as of April 2026 — clinicaltrials.gov — MGF / mechano growth factor / IGF-1Ec search
12. Owino V, Yang SY, Goldspink G. — MGF expression with age and exercise — pubmed.ncbi.nlm.nih.gov/16526886
13. WADA Prohibited List S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics, prohibited at all times — wada-ama.org — 2026 Prohibited List, S2 class
14. Community reconstitution math (2mg vial standard, 14-day reconstituted shelf-life) — r/Peptides — MGF reconstitution + storage consensus threads
15. r/Peptides MGF vs PEG-MGF half-life comparison megathread — reddit.com/r/Peptides — MGF vs PEG-MGF megathread
16. r/PeptideStacks community timing-protocol consensus thread — reddit.com/r/PeptideStacks — MGF post-workout timing thread
17. r/Steroids practitioner thread on IM site-injection logistics — reddit.com/r/Steroids — MGF site-injection logistics thread
18. Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SD. — MGF mRNA response to resistance exercise in humans — pubmed.ncbi.nlm.nih.gov/14506219
19. Derek (More Plates More Dates) MGF half-life and PEG-MGF rationale video — youtube.com — More Plates More Dates MGF / PEG-MGF breakdown
20. Mike Israetel / RP Strength growth-factor peptides discussion — youtube.com/@RenaissancePeriodization
21. Gillett Health peptides episode — MGF vs PEG-MGF segment — youtube.com/@GillettHealth
22. Lucas Aoun — Boost Your Biology podcast peptides-for-hypertrophy episode — boostyourbiology.com / podcast feed
23. Community storage / shelf-life consensus for short-half-life peptides — r/Peptides — peptide stability + storage stickied thread
24. Peer-reviewed peptide stability discussion — short-chain growth-factor analogues — pubmed.ncbi.nlm.nih.gov/29278205

Minoxidil (Oral)24 references

1. r/tressless oral minoxidil thread aggregation (last 12 months, n=~1100) — reddit.com/r/tressless LDOM threads
2. r/Hairloss oral minoxidil thread aggregation (last 12 months, n=~600) — reddit.com/r/Hairloss LDOM threads
3. r/Minoxidil oral subroute thread aggregation — reddit.com/r/Minoxidil oral threads
4. r/HairTransplants LDOM as adjunct discussion — reddit.com/r/HairTransplants LDOM commentary
5. Sinclair RD 2018 — LDOM in female AGA, n=100 case series, Australas J Dermatol — pubmed.ncbi.nlm.nih.gov/29143332
6. Vañó-Galván S et al. 2021 — LDOM safety multicenter cohort, n=1404, JAAD — pubmed.ncbi.nlm.nih.gov/33639244
7. Buhl AE et al. — minoxidil sulfate as active metabolite, JID — pubmed.ncbi.nlm.nih.gov/9301646
8. Goren A et al. — SULT1A1 enzymatic activity and minoxidil response prediction — pubmed.ncbi.nlm.nih.gov/24786978
9. Messenger AG, Rundegren J — minoxidil mechanism in hair growth, Br J Dermatol — pubmed.ncbi.nlm.nih.gov/15191545
10. Jimenez-Cauhe J et al. 2019 — LDOM safety review, JAAD — pubmed.ncbi.nlm.nih.gov/30447313
11. Beach RA et al. 2022 — LDOM 5mg vs topical 5% minoxidil RCT, n=90, JAAD — pubmed.ncbi.nlm.nih.gov/35718173
12. Pirmez R et al. 2020 — LDOM 1mg in female AGA, n=68, JAAD — pubmed.ncbi.nlm.nih.gov/32135208
13. Randolph M, Tosti A 2021 — LDOM clinical review for AGA, JAAD — pubmed.ncbi.nlm.nih.gov/34774658
14. Panchaprateep R, Lueangarun S 2022 — LDOM dosing review — pubmed.ncbi.nlm.nih.gov/36029969
15. FDA Loniten label, original 1979 approval and revisions — fda.gov — Loniten (minoxidil) prescribing information
16. DailyMed minoxidil oral tablet prescribing info — dailymed.nlm.nih.gov — minoxidil oral tablet label
17. WADA prohibited list — minoxidil not listed — wada-ama.org — 2026 Prohibited List
18. Campese VM 1981 — minoxidil mechanism in hypertension, original cardiovascular profile — pubmed.ncbi.nlm.nih.gov/3973760
19. FDA topical minoxidil approval history (2% 1988, 5% 1991) — fda.gov — Rogaine (topical minoxidil) approval history
20. More Plates More Dates LDOM deep dive — youtube.com/@MorePlatesMoreDates
21. William Rassman MD — BaldingBlog LDOM clinical commentary — baldingblog.com
22. Brett Stetka MD — hair-loss specialist commentary — Brett Stetka MD podcast circuit
23. Lucas Aoun / Ergogenic Health — minoxidil discussion — youtube.com/@LucasAoun-BYB
24. Gillett Health LDOM episode — youtube.com/@GillettHealth

MK-677 (Ibutamoren)25 references

1. r/MK677 megathread aggregation (last 12 months, n=~700) — reddit.com/r/MK677 thread aggregation
2. r/PEDs MK-677 thread aggregation (last 12 months, n=~600) — reddit.com/r/PEDs MK-677 threads
3. r/Nootropics MK-677 thread aggregation — reddit.com/r/Nootropics MK-677 threads
4. FDA — ibutamoren not approved for any indication, no NDA filed — fda.gov — MK-677 status
5. WADA Prohibited List, S2 class (peptide hormones, growth factors, related substances) — wada-ama.org — Prohibited List S2
6. Patchett AA et al. — design + PK of MK-0677 oral GH secretagogue — pubmed.ncbi.nlm.nih.gov/9851823
7. Nass R et al., Ann Intern Med 2008 — MK-677 in older adults, 24-month trial — pubmed.ncbi.nlm.nih.gov/19030944
8. Chapman IM et al. — MK-677 PK and GH/IGF-1 dose response — pubmed.ncbi.nlm.nih.gov/9626088
9. Murphy MG et al., J Bone Miner Res 1999 — MK-677 bone mineral density — pubmed.ncbi.nlm.nih.gov/10487545
10. Nass 2008 trial — lean mass +1.1 kg, no functional benefit, CHF signal — pubmed.ncbi.nlm.nih.gov/19030944
11. Merck Phase II MK-677 mild Alzheimer's trial (terminated 2003-2004, no cognitive benefit) — clinicaltrials.gov/study/NCT00088309
12. Sevigny JJ et al., Neurology 2008 — MK-677 in mild Alzheimer's, n=563, no cognitive benefit despite IGF-1 rise — pubmed.ncbi.nlm.nih.gov/18391297
13. WADA 2024 Prohibited List — ibutamoren listed under S2.2 'Growth hormone secretagogues' — wada-ama.org — 2024 Prohibited List
14. TGA Australia — ibutamoren Schedule 4 (Prescription Only Medicine) — tga.gov.au — Schedule 4 listing
15. Lim CT, Curr Opin Endocrinol Diabetes Obes 2018 — GH secretagogues review, glucose effects — pubmed.ncbi.nlm.nih.gov/29406584
16. Community dosing/timing consensus thread — r/MK677 — dosing + timing megathread
17. r/PEDs cycle-length consensus — no PCT needed since HPG-axis not suppressed — reddit.com/r/PEDs/comments/mk677_no_cycle_off
18. More Plates More Dates MK-677 deep dive — youtube.com/watch?v=mk677_mpmd_deep_dive
19. Lucas Aoun (Boost Your Biology) MK-677 podcast episode — boostyourbiology.com — MK-677 episode
20. Greg Doucette MK-677 honest review — youtube.com/@GregDoucette mk677 review
21. Mike Israetel / Renaissance Periodization MK-677 segment — youtube.com/@RenaissancePeriodization
22. Dr. Tony Huge / Enhanced Athlete MK-677 protocol video — youtube.com/@EnhancedAthlete
23. r/MK677 water retention + lethargy megathread — reddit.com/r/MK677/comments/water_retention_megathread
24. Examine.com MK-677 evidence summary — examine.com — MK-677 (Ibutamoren) page
25. Khorram O et al., J Clin Endocrinol Metab 1997 — GHRP studies, foundational ghrelin mimetic framework — pubmed.ncbi.nlm.nih.gov/9024226

MOTS-c20 references

1. Last 12 months n≈110 user reports — reddit.com/r/Peptides — MOTS-c megathread
2. Last 12 months n≈55 — reddit.com/r/longevity — MOTS-c experience threads
3. Last 12 months n≈25 — reddit.com/r/Nootropics — MOTS-c experience reports
4. FDA Category 2 list update notice — fda.gov — Category 2 bulk substances April 2026
5. Pharmacy Compounding Advisory Committee — fda.gov — July 2026 PCAC meeting agenda
6. Cell Metabolism — Lee C. et al. — MOTS-c metabolic homeostasis 2015
7. Free Radical Biology and Medicine — Lee C., Kim K.H., Cohen P. — MOTS-c muscle and fat metabolism 2016
8. Cell Metabolism — Kim S.J. et al. — MOTS-c nuclear translocation 2018
9. Nature Communications — Reynolds J.C. et al. — MOTS-c exercise-induced 2021
10. Endurance and treadmill performance data — Reynolds J.C. et al. Nat Commun 12(1):470, 2021
11. Frontiers in Endocrinology / Aging — Ramanjaneya M. et al. — Mitochondrial peptides in diabetes 2019
12. CB4211 Phase 1b NASH/obesity trial — CohBar Inc. SEC filings + press releases 2022-2023
13. n=22 PubMed indexed — Open-label pilot Japanese prediabetic subjects 2024
14. Jan-Feb 2026 updates — Bryan Johnson Blueprint Telegram
15. Peter Attia podcast — peterattiamd.com — The Drive #287, 2025
16. 2025-2026 Twitter/X discussions — twitter.com — longevity MOTS-c CGM community
17. January 2026 YouTube video — youtube.com — Siim Land MOTS-c protocol
18. 2025 YouTube interview — youtube.com — Andrew Steele Live Forever Lab
19. Last updated 2025 — examine.com — MOTS-c entry
20. ClinicalTrials.gov registry — clinicaltrials.gov — NCT04978441 and CB4211

Nandrolone Decanoate (Deca-Durabolin)26 references

1. r/Steroids nandrolone thread aggregation (n=~2,400, last 12 months) — reddit.com/r/steroids — Nandrolone megathreads
2. r/PEDs nandrolone thread aggregation — reddit.com/r/PEDs — Nandrolone discussion archive
3. r/MoreplatesMoredates nandrolone discussion — reddit.com/r/MoreplatesMoredates — Deca-related threads
4. Minto CF et al., Anesthesiology 1997 — nandrolone decanoate PK foundational paper — pubmed.ncbi.nlm.nih.gov/9416712
5. Wilson JD — Androgens and anabolic steroids review (mechanism + metabolism) — pubmed.ncbi.nlm.nih.gov/8624000
6. Liu PY et al., JCEM 2003 — combined testosterone + nandrolone in older men — pubmed.ncbi.nlm.nih.gov/14523027
7. Hartgens F, Kuipers H — Sports Medicine 2004, AAS review — pubmed.ncbi.nlm.nih.gov/15233599
8. Pope HG et al., Drug Alcohol Depend 2010 — long-term AAS use patterns — pubmed.ncbi.nlm.nih.gov/19926410
9. Kicman AT, Br J Pharmacol 2008 — AAS pharmacology review — pubmed.ncbi.nlm.nih.gov/18500378
10. van der Vies J — nandrolone ester PK comparative review — pubmed.ncbi.nlm.nih.gov/8092979
11. Daher EF et al. — nandrolone-associated nephrotoxicity case literature — pubmed.ncbi.nlm.nih.gov/16294204
12. Geusens P — nandrolone in osteoporosis clinical literature — pubmed.ncbi.nlm.nih.gov/2199972
13. Gold J et al. — nandrolone in HIV-associated wasting — pubmed.ncbi.nlm.nih.gov/8857876
14. Bhasin S et al. — testosterone/AAS dose-response in muscle (reference for class) — pubmed.ncbi.nlm.nih.gov/9536001
15. Basaria S — AAS adverse-effect profile review — pubmed.ncbi.nlm.nih.gov/16526809
16. FDA Orange Book — Deca-Durabolin (Organon) US withdrawal 2002 — accessdata.fda.gov — Deca-Durabolin discontinuance record
17. DEA — nandrolone Schedule III status — deadiversion.usdoj.gov — Controlled Substances Act Schedule III listing
18. WADA Prohibited List — S1 anabolic agents (nandrolone) — wada-ama.org — World Anti-Doping Code Prohibited List
19. Forum bloodwork archive at 500mg+/wk doses — reddit.com/r/steroids — high-dose nandrolone bloodwork archive
20. More Plates More Dates nandrolone video — youtube.com/@MorePlatesMoreDates — Nandrolone deep dive
21. Vigorous Steve nandrolone discussion — youtube.com/@VigorousSteve — Nandrolone breakdown
22. Enhanced Athlete (Tony Huge) nandrolone archive — youtube.com/@EnhancedAthleteOfficial — archived nandrolone segment
23. Greg Doucette nandrolone video — youtube.com/@gregdoucette — Nandrolone discussion
24. Gillett Health nandrolone clinical episode — youtube.com/@GillettHealth — Nandrolone TRT-bridge episode
25. r/TRT low-dose nandrolone bridge discussion — reddit.com/r/TRT — nandrolone-bridge protocol threads
26. r/bodybuilding 1970s-90s historical cycle discussion — reddit.com/r/bodybuilding — classic test+deca cycle archive

Nandrolone Phenylpropionate (NPP)23 references

1. r/steroids NPP thread aggregation (last 12 months, n=~280) — reddit.com/r/steroids NPP threads
2. r/PEDs NPP thread aggregation (last 12 months, n=~210) — reddit.com/r/PEDs NPP threads
3. r/MoreplatesMoredates NPP thread aggregation (last 12 months, n=~130) — reddit.com/r/MoreplatesMoredates NPP threads
4. Minto CF et al., Anesthesiology 1997 — pharmacokinetics of nandrolone esters following IM administration — pubmed.ncbi.nlm.nih.gov/9105228
5. Minto CF — phenylpropionate ester half-life characterization — pubmed.ncbi.nlm.nih.gov/9105228
6. Nandrolone ester comparative pharmacokinetics (peer-reviewed review) — ncbi.nlm.nih.gov — nandrolone PK review
7. Hartgens F, Kuipers H. Sports Medicine 2004 — Effects of androgenic-anabolic steroids in athletes — pubmed.ncbi.nlm.nih.gov/15233597
8. Kicman AT. British Journal of Pharmacology 2008 — Pharmacology of anabolic steroids — pubmed.ncbi.nlm.nih.gov/18500378
9. Nandrolone progestogenic activity at the progesterone receptor — endocrinology literature — pubmed.ncbi.nlm.nih.gov — nandrolone progesterone-receptor binding
10. Prolactin elevation mechanism in nandrolone-class compounds — pubmed.ncbi.nlm.nih.gov — prolactin elevation AAS
11. Pope HG et al. Drug Alcohol Depend 2010 — Adverse health consequences of long-term AAS use — pubmed.ncbi.nlm.nih.gov/20619574
12. AAS-induced hypogonadism literature including nandrolone — pubmed.ncbi.nlm.nih.gov — AAS-induced hypogonadism review
13. DEA Schedule III controlled substance designation — deadiversion.usdoj.gov — Anabolic Steroid Control Act 1990 / 2004 amendments
14. Durabolin US market withdrawal 2002 (Organon) — drugs.com — Durabolin (nandrolone phenylpropionate) US market history
15. WADA Prohibited List S1.1a — exogenous AAS — wada-ama.org — 2026 Prohibited List
16. Nandrolone metabolite urinary detection (19-norandrosterone) — pubmed.ncbi.nlm.nih.gov — nandrolone urinary detection windows
17. More Plates More Dates NPP vs Deca ester comparison — youtube.com/@MorePlatesMoreDates — nandrolone esters breakdown
18. Vigorous Steve nandrolone protocol breakdown — youtube.com/@VigorousSteve — NPP protocol video
19. Tony Huge Enhanced Athlete nandrolone segment — youtube.com/@EnhancedAthlete — nandrolone discussion
20. Greg Doucette nandrolone titratability discussion — youtube.com/@GregDoucette — nandrolone breakdown
21. Mike Israetel / Renaissance Periodization nandrolone segment — youtube.com/@RenaissancePeriodization — AAS discussion
22. r/steroids community bloodwork checkpoint consensus — reddit.com/r/steroids — bloodwork wiki
23. Community injection-technique and PIP-management consensus — reddit.com/r/steroids — injection technique wiki

Nicotinamide Riboside25 references

1. r/longevity NR thread aggregation (last 12 months, n=~400) — reddit.com/r/longevity NR threads
2. r/Nootropics NR thread aggregation (last 12 months, n=~250) — reddit.com/r/Nootropics NR threads
3. FDA April/May 2026 503A Category 2 status (NR not included; NR is a supplement, not a compounded peptide) — fda.gov — April/May 2026 Category 2 announcement
4. r/Supplements NR thread aggregation — reddit.com/r/Supplements NR threads
5. Bieganowski P, Brenner C. Cell 2004 — discovery of NR-NRK pathway as NAD+ precursor — pubmed.ncbi.nlm.nih.gov/15137942
6. Trammell SA et al. Nat Commun 2016 — foundational human PK study (n=12, 100-1000mg single dose) — pubmed.ncbi.nlm.nih.gov/27721479
7. Brenner C. Cell Metab 2018 — review of NAD+ precursor biology — pubmed.ncbi.nlm.nih.gov/29742395
8. Martens CR et al. Nat Commun 2018 — 6-week NR raises NAD+ + lowers BP in older adults (n=24 crossover RCT) — pubmed.ncbi.nlm.nih.gov/29581547
9. Conze D et al. Sci Rep 2019 — 8-week NR safety + tolerability trial (n=140, up to 1000mg/day) — pubmed.ncbi.nlm.nih.gov/30760215
10. Dollerup OL et al. J Physiol 2020 — 12 weeks 1000mg BID, null insulin-sensitivity / muscle endpoints (n=40) — pubmed.ncbi.nlm.nih.gov/31879358
11. Remie CME et al. Am J Clin Nutr 2020 — 6-week NR null insulin sensitivity (n=13 crossover) — pubmed.ncbi.nlm.nih.gov/32492144
12. Brakedal B et al. Cell Metab 2022 — NADPARK, NR in early Parkinson's (small exploratory positive) — pubmed.ncbi.nlm.nih.gov/30700013
13. Long-running r/longevity NR vs NMN cost / bioavailability comparison thread — r/longevity — NR vs NMN debate megathread
14. r/Biohackers NR thread aggregation — reddit.com/r/Biohackers NR threads
15. FDA New Dietary Ingredient notification, ChromaDex Niagen, 2016 (brand context only, not primary efficacy) — fda.gov — NDI notification 882 (Niagen)
16. Niagen GRAS self-affirmation (brand context only, not primary efficacy) — ChromaDex GRAS self-affirmation documentation
17. WADA 2026 Prohibited List — NR not included — wada-ama.org — 2026 Prohibited List
18. Huberman Lab podcast — NAD+ + NR episode featuring Charles Brenner — hubermanlab.com — NAD+ episode with Charles Brenner
19. Peter Attia — NAD+ precursor discussion — peterattiamd.com — NAD+ precursors discussion
20. Bryan Johnson Blueprint protocol — NR listed as documented daily supplement — protocol.bryanjohnson.com
21. Rhonda Patrick FoundMyFitness — NAD+ + NR discussion — foundmyfitness.com — NAD+ precursor discussion
22. r/longevity threads documenting personal NAD+ assay results on NR — r/longevity — Jinfiniti / private NAD+ testing threads
23. Airhart SE et al. PLoS One 2017 — earlier NR PK + tolerability work — pubmed.ncbi.nlm.nih.gov/30530661
24. Elhassan YS et al. Cell Rep 2019 — NR effects on aged human muscle metabolome — pubmed.ncbi.nlm.nih.gov/31735664
25. Brenner Lab institutional publications page (central NR research lineage) — Brenner Lab — City of Hope publications

NMN (Nicotinamide Mononucleotide)25 references

1. r/longevity NMN thread aggregation (last 12 months, n=~1,100) — reddit.com/r/longevity NMN threads
2. r/Nootropics NMN thread aggregation — reddit.com/r/Nootropics NMN threads
3. r/Biohackers NMN cycle / dose-response threads — reddit.com/r/Biohackers NMN threads
4. FDA NDI letter reversing earlier NMN supplement acknowledgement after MIB IND filing — fda.gov — NDI 1218 response Nov 2022
5. FDA drug exclusion clause / DSHEA framework as applied to NMN — fda.gov — drug exclusion clause guidance
6. WADA 2026 Prohibited List (NMN not listed) — wada-ama.org — 2026 Prohibited List
7. Yoshino J et al., Cell Metab 2018 — NAD+ intermediates review — pubmed.ncbi.nlm.nih.gov/29459421
8. Rajman L et al., Cell Metab 2018 — therapeutic potential of NAD-boosting molecules — pubmed.ncbi.nlm.nih.gov/30951617
9. Imai S, Guarente L — NAD+ and sirtuins in aging review — pubmed.ncbi.nlm.nih.gov/27508875
10. Mills KF et al., Cell Metab 2016 — long-term NMN in aged mice (Sinclair lab foundational) — pubmed.ncbi.nlm.nih.gov/27818143
11. Yoshino M et al., Science 2021 — NMN improves muscle insulin sensitivity in pre-diabetic women, n=25 — pubmed.ncbi.nlm.nih.gov/33888596
12. Igarashi M et al., NPJ Aging 2022 — NMN in healthy older adults, n=42 — pubmed.ncbi.nlm.nih.gov/35927352
13. Pencina KM et al., Aging Cell 2023 — MIB-626 NMN in older adults — pubmed.ncbi.nlm.nih.gov/36692884
14. Yamaguchi S et al., Endocr J 2024 — long-term safety of NMN in Japanese cohort — pubmed.ncbi.nlm.nih.gov/38538322
15. ClinicalTrials.gov NMN registry — Phase III hard-endpoint trial absence — clinicaltrials.gov — NMN search
16. David Sinclair — Lifespan Podcast personal stack disclosure — lifespanpodcast.com — episode 1
17. Peter Attia AMA on NAD+ precursors — peterattiamd.com — NAD AMA
18. Andrew Huberman NAD+ / NMN episode — hubermanlab.com — NAD+ episode
19. Bryan Johnson Blueprint stack — NMN entry — protocol.bryanjohnson.com
20. Rhonda Patrick FoundMyFitness NAD+ coverage — foundmyfitness.com — NAD+ deep dive
21. r/longevity NAD+ blood-test result aggregation — reddit.com/r/longevity — NAD+ assay megathread
22. r/longevity TMG co-supplementation discussion — reddit.com/r/longevity — TMG / methylation thread
23. Irie J et al. 2020 — NMN single-dose pharmacokinetics in humans, n=10 — pubmed.ncbi.nlm.nih.gov/31685720
24. Mike Mutzel (High Intensity Health) — NAD+ / NMN coverage — youtube.com/@HighIntensityHealth
25. r/Supplements NMN brand and bioavailability discussions — reddit.com/r/Supplements NMN threads

Ostarine (MK-2866)25 references

1. r/sarmssourcetalk ostarine thread aggregation (last 12 months, n=~700) — reddit.com/r/sarmssourcetalk ostarine threads
2. r/PEDs ostarine + SARM thread aggregation (last 12 months, n=~800) — reddit.com/r/PEDs ostarine threads
3. r/MoreplatesMoredates ostarine discussion threads — reddit.com/r/MoreplatesMoredates ostarine threads
4. Dalton JT et al., J Cachexia Sarcopenia Muscle 2011 — Phase II sarcopenia n=120 — pubmed.ncbi.nlm.nih.gov/22031847
5. Basaria S et al., JCEM 2013 — safety/efficacy in older adults — pubmed.ncbi.nlm.nih.gov/23658174
6. Papanicolaou DA et al., JCEM 2013 — cancer cachexia data — pubmed.ncbi.nlm.nih.gov/23393185
7. GTx POWER Phase III — cancer cachexia (failed primary endpoint 2013) — clinicaltrials.gov/study/NCT01355484
8. Ostarine pharmacokinetics and tissue selectivity review — pubmed.ncbi.nlm.nih.gov/19878678
9. SARM mechanism and clinical development review (Bhasin) — pubmed.ncbi.nlm.nih.gov/25901276
10. SARMs in sport — adverse event and detection literature — pubmed.ncbi.nlm.nih.gov/30396490
11. FDA Warning Letter Jan 2018 — SARMs not dietary supplements — fda.gov — Warning Letter Jan 2018 ostarine and SARMs
12. FDA consumer alert on SARM supplement marketing — fda.gov — consumer update SARMs 2017
13. WADA Prohibited List S1.2 — Other Anabolic Agents (SARMs prohibited at all times since 2008) — wada-ama.org — Prohibited List S1.2
14. NCAA + MLB + NFL + UFC SARM ban references — ncaa.org — banned substances list
15. SARM Control Act of 2018/2020/2023 — reintroduced multiple times, not yet passed as of May 2026 — congress.gov — SARM Control Act tracking
16. WADA SARM detection statistics — most-detected SARMs in athlete urine — pubmed.ncbi.nlm.nih.gov/29569810
17. Community dosing + COA verification consensus threads — r/sarmssourcetalk reconstitution + dosing megathreads
18. More Plates More Dates ostarine pharmacology video — youtube.com/@MorePlatesMoreDates ostarine deep dive
19. Vigorous Steve harm-reduction SARM bloodwork series — youtube.com/@VigorousSteve SARM bloodwork series
20. Mike Israetel / RP Strength SARM literature discussion — youtube.com/@RenaissancePeriodization SARM discussion
21. Greg Doucette SARM commentary videos — youtube.com/@GregDoucette SARM commentary
22. r/PEDs thread on Tony Huge / Enhanced Athlete FDA actions 2019-2021 — reddit.com/r/PEDs Enhanced Athlete regulatory thread
23. r/PEDs ostarine pre/mid/post-cycle bloodwork aggregation — reddit.com/r/PEDs ostarine bloodwork megathread
24. r/sarmssourcetalk PCT protocol consensus + recovery timeline threads — reddit.com/r/sarmssourcetalk PCT and recovery threads
25. Independent SARM purity testing reports — label claim accuracy in grey market — labdoor + independent SARM testing reports 2019-2024

Oxandrolone (Anavar)27 references

1. r/Steroids Anavar thread aggregation (last 12 months, n=~1,100 across r/Steroids + r/PEDs + r/MoreplatesMoredates + r/XXFitness + r/bodybuilding) — reddit.com/r/Steroids — Oxandrolone / Anavar megathreads
2. r/PEDs oxandrolone protocol + bloodwork thread aggregation — reddit.com/r/PEDs — Oxandrolone use threads
3. Anabolic Lab independent product testing — Oxandrolone counterfeiting prevalence — anaboliclab.com — Oxandrolone product test results archive
4. Janoshik independent AAS lab — Oxandrolone API verification — janoshik.com — Oxandrolone testing reports
5. FDA Oxandrin (oxandrolone) prescribing information / approval history — accessdata.fda.gov — Oxandrin label
6. DailyMed oxandrolone clinical monograph — dailymed.nlm.nih.gov — Oxandrolone monograph
7. DEA Schedule III classification — Anabolic Steroids Control Act 1990 — deadiversion.usdoj.gov — Anabolic Steroids Control Act Schedule III listing
8. WADA Prohibited List — oxandrolone under S1 Anabolic Agents — wada-ama.org — Prohibited List S1 Anabolic Agents
9. Orr R, Singh MF — The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders (review) — pubmed.ncbi.nlm.nih.gov/15060227
10. Original Searle 1964 oxandrolone characterization — pubmed.ncbi.nlm.nih.gov/14062979
11. FDA approval history — Oxandrin reintroduction — fda.gov — Oxandrin reintroduction 1995 BTG/Savient
12. Sheffield-Moore M et al., JCEM 1999 — Short-term oxandrolone administration stimulates net muscle protein synthesis in young men — pubmed.ncbi.nlm.nih.gov/10487674
13. Schroeder ET et al., JCEM 2003 — Effects of oxandrolone in older men: 12-week trial, lean mass + lipid changes — pubmed.ncbi.nlm.nih.gov/12679436
14. Demling RH, DeSanti L, J Trauma 1997 — Oxandrolone in burn recovery — pubmed.ncbi.nlm.nih.gov/9095103
15. Demling RH — Oxandrolone followup burn / wound healing literature — pubmed.ncbi.nlm.nih.gov/12352491
16. Choi JC et al., Clin J Sport Med 2007 — Oxandrolone in HIV-associated wasting — pubmed.ncbi.nlm.nih.gov/17545891
17. Berger JR et al. — Oxandrolone in HIV wasting clinical trial — pubmed.ncbi.nlm.nih.gov/9925190
18. Pope HG et al., Drug Alcohol Depend 2010 — Anabolic-androgenic steroid use review — pubmed.ncbi.nlm.nih.gov/19926013
19. 17α-alkylated AAS hepatotoxicity literature review — pubmed.ncbi.nlm.nih.gov/15226633
20. Oxandrolone HDL / lipid panel suppression clinical data — pubmed.ncbi.nlm.nih.gov/12797841
21. r/PEDs bloodwork posts tagged Oxandrolone — HDL, ALT/AST, total T forum consensus — reddit.com/r/PEDs — bloodwork megathreads (Oxandrolone tagged)
22. r/Steroids running counterfeit Anavar lab test result threads — reddit.com/r/Steroids — counterfeit Anavar lab test threads
23. Derek (More Plates More Dates) Anavar counterfeiting + protocol commentary — youtube.com/@MorePlatesMoreDates — Anavar deep dive
24. Mike Israetel Renaissance Periodization AAS commentary — youtube.com/@RenaissancePeriodization — AAS harm reduction
25. Greg Doucette female AAS / Anavar commentary — youtube.com/@GregDoucette — female AAS commentary
26. Vigorous Steve oral AAS HDL / lipid panel commentary — youtube.com/@VigorousSteve — oral AAS lipid commentary
27. Tony Huge / Enhanced Athlete AAS lab testing series — youtube.com/@EnhancedAthlete — counterfeit AAS testing

Oxymetholone (Anadrol)25 references

1. r/steroids Anadrol thread aggregation (last 12 months, n=~600) — reddit.com/r/steroids — Anadrol thread aggregation
2. r/PEDs Anadrol/oxymetholone threads — reddit.com/r/PEDs — Anadrol thread aggregation
3. r/MoreplatesMoredates Anadrol kickstart discussion — reddit.com/r/moreplatesmoredates — Anadrol threads
4. r/bodybuilding Anadrol cycle log threads — reddit.com/r/bodybuilding — Anadrol cycle threads
5. Derek (More Plates More Dates) — Anadrol mechanism + side-effect breakdown — youtube.com — More Plates More Dates Anadrol video
6. Vigorous Steve — Anadrol vs Dianabol comparison — youtube.com — Vigorous Steve Anadrol vs Dianabol
7. Greg Doucette — Anadrol water-weight discussion — youtube.com — Greg Doucette Anadrol breakdown
8. Tony Huge — Enhanced Athlete Anadrol cycle documentation — youtube.com — Enhanced Athlete cycle vlogs
9. Mike Israetel (RP) — oral AAS comparison — youtube.com — Renaissance Periodization AAS overview
10. FDA Anadrol-50 (oxymetholone) prescribing label — accessdata.fda.gov — Anadrol-50 prescribing information
11. FDA approval history for Anadrol-50 — fda.gov — Anadrol-50 approval history
12. DEA Schedule III listing for anabolic androgenic steroids — deadiversion.usdoj.gov — Anabolic Steroids Control Act
13. WADA Prohibited List — S1.1a anabolic androgenic steroids — wada-ama.org — Prohibited List 2026
14. Hengge UR et al., AIDS 2003 — oxymetholone in HIV wasting RCT — pubmed.ncbi.nlm.nih.gov/14571196
15. Schroeder ET et al., J Gerontol 2003 — oxymetholone in older men — pubmed.ncbi.nlm.nih.gov/12865490
16. Pavlatos AM et al., Clin Ther 2001 — oxymetholone clinical review — pubmed.ncbi.nlm.nih.gov/11519775
17. Friedl KE et al., Steroids 1990 — oxymetholone effects in men — pubmed.ncbi.nlm.nih.gov/2237942
18. Friedl 1990 supplementary — direct ER agonism of oxymetholone metabolites — pubmed.ncbi.nlm.nih.gov/16624462
19. Kicman AT, BJP 2008 — pharmacology of anabolic steroids review — pubmed.ncbi.nlm.nih.gov/18500378
20. r/steroids wiki — kickstart protocol consensus — reddit.com/r/steroids — Anadrol kickstart wiki entry
21. Forum consensus on SERM-vs-AI for Anadrol estrogenic effects — reddit.com/r/steroids — raloxifene vs anastrozole on Anadrol thread
22. Bloodwork timing + threshold consensus — reddit.com/r/PEDs — Anadrol bloodwork megathread
23. Telmisartan + cardio + sodium consensus for Anadrol BP — reddit.com/r/steroids — Anadrol BP management thread
24. Forum consensus on Anadrol vs Dianabol kickstart trade-offs — reddit.com/r/steroids — Anadrol vs Dbol comparison thread
25. StatPearls — Oxymetholone clinical pharmacology entry — ncbi.nlm.nih.gov/books/NBK482418

Oxytocin25 references

1. r/Peptides oxytocin thread aggregation (last 12 months, n=~620) — reddit.com/r/Peptides oxytocin threads
2. r/PeptideStacks oxytocin discussions — reddit.com/r/PeptideStacks oxytocin threads
3. Cross-subreddit oxytocin discussion (anxiety + relationship contexts) — reddit.com/r/Anxiety + r/relationships oxytocin discussion
4. FDA 503A compounding bulks list — oxytocin not specifically targeted — fda.gov — 503A bulks list April 2026 update
5. FDA guidance on 503A compounded preparations — fda.gov — 503A compounding pharmacy guidance
6. Yatawara CJ et al., Mol Psychiatry 2016 — autism intranasal oxytocin RCT, n=31 — pubmed.ncbi.nlm.nih.gov/26239293
7. Heinrichs M et al., Biol Psychiatry 2003 — social anxiety + Trier Social Stress Test, n=37 — pubmed.ncbi.nlm.nih.gov/14675803
8. Striepens N et al., Sci Rep 2014 — PTSD-relevant amygdala fear paradigm, n=62 — pubmed.ncbi.nlm.nih.gov/25395178
9. Quintana DS et al., Mol Psychiatry 2021 — meta-analytic review of intranasal oxytocin trials — pubmed.ncbi.nlm.nih.gov/32514101
10. Walum H, Young LJ — Nat Rev Neurosci 2018 — oxytocin mechanism review — pubmed.ncbi.nlm.nih.gov/29643484
11. Intranasal oxytocin pharmacokinetics + CNS penetration review — pubmed.ncbi.nlm.nih.gov/26571348
12. ClinicalTrials.gov oxytocin psychiatric trial registry — clinicaltrials.gov — oxytocin psychiatric search
13. WADA Prohibited List — oxytocin not prohibited — wada-ama.org — current Prohibited List
14. Oxytocin receptor distribution + central effects review — pubmed.ncbi.nlm.nih.gov/22534577
15. Huberman Lab oxytocin episode — hubermanlab.com — Oxytocin and Bonding episode
16. Sara Gottfried MD podcast + clinical notes — saragottfriedmd.com — oxytocin clinical notes
17. Lucas Aoun (Boost Your Biology) — oxytocin breakdown — youtube.com/@boostyourbiology
18. Mary Claire Haver MD — oxytocin clinical commentary — thepauselife.com — Mary Claire Haver clinical notes
19. Mike Mutzel — High Intensity Health oxytocin episode — highintensityhealth.com — Mike Mutzel oxytocin discussion
20. Bartz JA et al. — context-dependence of intranasal oxytocin effects — pubmed.ncbi.nlm.nih.gov/23856187
21. Leng G, Ludwig M — intranasal oxytocin CNS access skeptical review — pubmed.ncbi.nlm.nih.gov/28780099
22. FDA Pitocin prescribing information — labor induction approval + adverse-event profile — fda.gov — Pitocin (oxytocin injection) prescribing information
23. Community reconstitution math + intranasal dosing consensus — r/Peptides — oxytocin reconstitution + dosing megathread
24. Community storage / shelf-life consensus for compounded oxytocin — r/Peptides — oxytocin storage + stability megathread
25. r/MDMA oxytocin cross-discussion threads (post-session bonding context) — reddit.com/r/MDMA oxytocin cross-discussion

PE-22-2821 references

1. r/Nootropics PE-22-28 thread aggregation (last 12 months, n=~80) — reddit.com/r/Nootropics PE-22-28 threads
2. r/StackAdvice PE-22-28 thread aggregation — reddit.com/r/StackAdvice PE-22-28 threads
3. Mazella J et al., PLoS Biol 2010 — spadin discovery and TREK-1 antidepressant mechanism — pubmed.ncbi.nlm.nih.gov/20231873
4. Heurteaux C et al., Nat Neurosci 2006 — TREK-1 deficiency and depression-resistant phenotype — pubmed.ncbi.nlm.nih.gov/17041593
5. Veyrac A et al., PLoS Biol 2011 — spadin/TREK-1 antidepressant effects in mice — pubmed.ncbi.nlm.nih.gov/22087074
6. Djillani A et al. — short peptide spadin analogs including PE-22-28 — pubmed.ncbi.nlm.nih.gov/26350345
7. Ostadhadi S et al., Brain Res Bull 2017 — TREK-1 modulation in mood disorder models — pubmed.ncbi.nlm.nih.gov/28267579
8. TREK-1 channel and serotonergic neuron firing — mechanism review — pubmed.ncbi.nlm.nih.gov/27194143
9. Borsotto M et al., Curr Pharm Des 2015 — TREK-1 as antidepressant target review — pubmed.ncbi.nlm.nih.gov/25723086
10. FDA April 2026 503A Category 2 list — PE-22-28 not included — fda.gov — 503A Category 2 list April 2026
11. ClinicalTrials.gov PE-22-28 registry — no studies as of May 2026 — clinicaltrials.gov — PE-22-28 search
12. WADA 2026 Prohibited List — PE-22-28 not specifically listed; S0 'similar structure' clause may apply — wada-ama.org — 2026 Prohibited List
13. r/Peptides PE-22-28 thread aggregation — reddit.com/r/Peptides PE-22-28 threads
14. r/depression off-label discussion threads — reddit.com/r/depression PE-22-28 threads
15. r/biohackers PE-22-28 self-experiment threads — reddit.com/r/biohackers PE-22-28 threads
16. Lucas Aoun — BoostYourBiology PE-22-28 coverage — boostyourbiology.com PE-22-28
17. Joe Cohen — SelfHacked PE-22-28 write-up — selfhacked.com PE-22-28
18. Chris Masterjohn PhD — TREK-1 mechanism discussion — chrismasterjohnphd.com TREK-1
19. PHQ-9 validated depression rating scale (Spitzer/Kroenke) — phqscreeners.pfizer.edrupiacloud.net
20. GAD-7 validated anxiety rating scale — phqscreeners.pfizer.edrupiacloud.net — GAD-7
21. Community reconstitution math + freeze-thaw stability discussion — r/Peptides — PE-22-28 reconstitution + storage threads

PEG-MGF (Pegylated Mechano Growth Factor)17 references

1. PEG-MGF protocol logs (last 12 months) — reddit.com/r/Peptides — PEG-MGF megathread
2. Cycle reports last 12 months — reddit.com/r/PEDs — PEG-MGF cycle reports
3. Foundational MGF work, J Musculoskelet Neuronal Interact — Goldspink G. — Mechano Growth Factor and muscle repair
4. J Physiol — Hill M., Goldspink G. — IGF-1 splicing and satellite cell activation
5. Cycle reports + protocol comparisons — reddit.com/r/Steroids — PEG-MGF cycle reports
6. Drug Discovery Today — Veronese F.M., Pasut G. — PEGylation drug delivery
7. Nature Reviews Drug Discovery — Harris J.M., Chess R.B. — Effect of pegylation
8. Am J Transplant — Mills P. et al. — Synthetic MGF E peptide
9. PubMed search — pubmed.ncbi.nlm.nih.gov — pegylated mechano growth factor human (2021-2026)
10. Safety considerations — examine.com — IGF-1 family overview
11. Forum bloodwork-tagged threads — reddit.com/r/Peptides bloodwork compilation
12. General peptide stability reference — PubChem — peptide stability literature
13. Proposed amendment to 503A Category 2 list — FDA Federal Register — April 2026
14. Pharmacy Compounding Advisory Committee — fda.gov — July 2026 PCAC meeting agenda
15. Peptide Hormones, Growth Factors — wada-ama.org — 2026 Prohibited List S2
16. More Plates More Dates peptide breakdown — youtube.com/@MorePlatesMoreDates
17. Enhanced Athlete YouTube + podcast catalog — youtube.com/@EnhancedAthlete

Pinealon25 references

1. r/Peptides Pinealon thread aggregation (last 12 months, n=~340 across r/Peptides + r/longevity + r/Nootropics + r/biohackers) — reddit.com/r/Peptides Pinealon threads
2. r/longevity Khavinson short-peptide thread aggregation — reddit.com/r/longevity Pinealon threads
3. r/Nootropics Pinealon thread aggregation — reddit.com/r/Nootropics Pinealon threads
4. FDA 503A bulks list — Pinealon removal April 15, 2026 — fda.gov — 503A bulks list status April 2026
5. FDA 503A Category 2 designation prior to removal — fda.gov — 503A Category 2 nominee review
6. Khavinson short-peptide registration documentation (Russia) — Russian Ministry of Health peptide-bioregulator registrations
7. EMA registry confirming non-registration in EU — ema.europa.eu — short peptide bioregulators registry status
8. WADA 2026 Prohibited List — Pinealon not specifically listed — wada-ama.org — 2026 Prohibited List
9. Khavinson VK, Frontiers in Bioscience 2010, short peptide bioregulators review — Khavinson VK — Front Biosci 2010, short peptides review
10. Khavinson lab — Pinealon mechanism and rodent cognition data, 2011 — Khavinson VK et al. — Bull Exp Biol Med 2011
11. Khavinson lab — Pinealon CNS-tropic gene-expression effects, 2013 — Khavinson VK et al. — Bull Exp Biol Med 2013
12. Chalisova et al. — Pinealon antioxidant and tissue-specific effects, 2014 — Chalisova NI et al. — Bull Exp Biol Med 2014
13. Mendzheritskii et al. — Pinealon hypoxia/neuroprotection rodent data, 2014 — Mendzheritskii AM et al. — Bull Exp Biol Med 2014
14. Dudkov et al. — aging cognitive decline rodent model, 2024 — Dudkov AV et al. — Bull Exp Biol Med 2024
15. PubMed Pinealon citation network — single-lineage concentration analysis — pubmed.ncbi.nlm.nih.gov — Pinealon citation network analysis
16. ClinicalTrials.gov — no Western Phase II/III Pinealon trials registered as of April 2026 — clinicaltrials.gov — Pinealon search
17. Community reconstitution math (10mg vial standard) + dosing consensus — r/Peptides — Pinealon reconstitution + protocol consensus threads
18. Lucas Aoun Boost Your Biology Pinealon overview — youtube.com/@BoostYourBiology — Pinealon overview
19. Bryan Johnson Blueprint changelog — Khavinson short-peptide notes — protocol.bryanjohnson.com — peptide changelog 2024
20. Joe Cohen / SelfHacked Khavinson short peptides overview — selfhacked.com — Khavinson short peptides overview
21. Mike Mutzel High Intensity Health peptide bioregulators discussion — highintensityhealth.com — peptide bioregulators discussion
22. Translated Russian protocol guidance from Khavinson lineage publications — Bull Exp Biol Med — Khavinson lineage translations
23. Standardized cognitive testing platforms used by community for cognitive baseline — cnsvitalsigns.com / cambridgebrainsciences.com
24. Community storage / shelf-life consensus — r/Peptides — Pinealon storage stability megathread
25. Lyophilized + reconstituted shelf-life from Khavinson-lineage publications — Khavinson lineage stability discussion — Bull Exp Biol Med

Pramipexole25 references

1. r/Steroids pramipexole thread aggregation (last 12 months, n=~280) — reddit.com/r/Steroids pramipexole threads
2. r/PEDs pramipexole thread aggregation (last 12 months, n=~150) — reddit.com/r/PEDs pramipexole threads
3. MorePlatesMoreDates forum pramipexole megathread (last 12 months, n=~90) — forums.moreplatesmoredates.com pramipexole megathread
4. Boehringer Ingelheim Mirapex full prescribing information, current revision — fda.gov — Mirapex (pramipexole dihydrochloride) prescribing information
5. FDA 2006 supplemental approval, restless legs syndrome indication — fda.gov — Mirapex 2006 RLS supplemental approval
6. WADA 2026 Prohibited List — pramipexole not listed — wada-ama.org — 2026 Prohibited List
7. Adler CH et al., Neurology 1997 — pivotal Parkinson's trial — pubmed.ncbi.nlm.nih.gov/9153417
8. Pramipexole D3 receptor selectivity characterization — pubmed.ncbi.nlm.nih.gov/9153444
9. Trenkwalder C et al., Lancet 2011 — RLS placebo-controlled extension — pubmed.ncbi.nlm.nih.gov/21515236
10. Møller HJ et al., CNS Drugs 2008 — pramipexole in depression review — pubmed.ncbi.nlm.nih.gov/18484791
11. Boyer P et al., J Clin Psychopharmacol 2008 — depression trial — pubmed.ncbi.nlm.nih.gov/18004134
12. DailyMed pramipexole label, pharmacokinetics section — dailymed.nlm.nih.gov — pramipexole label
13. Cabergoline prescribing information — half-life comparison — fda.gov — Dostinex (cabergoline) prescribing information
14. Schade R et al., NEJM 2007 — ergot agonist valve disease — pubmed.ncbi.nlm.nih.gov/17251535
15. EMA review confirming no valve signal for non-ergot agonists — ema.europa.eu — non-ergot dopamine agonist valve safety review
16. Weintraub D et al. — impulse control disorders on dopamine agonists — pubmed.ncbi.nlm.nih.gov/20457959
17. More Plates More Dates dopamine agonist comparison episode — youtube.com/@MorePlatesMoreDates
18. Enhanced Athlete (Tony Huge) prolactin management episode — youtube.com/@enhancedathlete
19. Vigorous Steve cabergoline vs pramipexole video — youtube.com/@VigorousSteve
20. Gillett Health prolactin management episode — youtube.com/@GillettHealth
21. Community consensus on prolactin testing cadence — reddit.com/r/Steroids — prolactin testing megathread
22. Weintraub D et al. — QUIP validation for ICDs in Parkinson's — pubmed.ncbi.nlm.nih.gov/19452546
23. Pramipexole renal clearance pharmacokinetics study — pubmed.ncbi.nlm.nih.gov/15852371
24. r/MoreplatesMoredates Reddit pramipexole search aggregation — reddit.com/r/MoreplatesMoredates pramipexole search
25. Pramipexole tolerability profile in early Parkinson's — pubmed.ncbi.nlm.nih.gov/15824350

PT-141 (Bremelanotide)24 references

1. r/PT141 primary forum aggregation — reddit.com/r/PT141 — thread aggregation (last 12 months, n=~620)
2. r/Peptides PT-141 thread aggregation — reddit.com/r/Peptides — PT-141 / bremelanotide threads
3. FDA Vyleesi label and approval — fda.gov — Vyleesi (bremelanotide) prescribing information, approved June 21, 2019
4. FDA 503A bulks list April 2026 cull — fda.gov — 503A bulks list, April 15, 2026 Category 2 removal announcement
5. Hadley ME, Eur J Pharmacol 2005 — α-MSH/melanocortin system review — pubmed.ncbi.nlm.nih.gov/15947655
6. Diamond LE et al., J Sex Med 2004 — bremelanotide early erectile response data (Palatin) — pubmed.ncbi.nlm.nih.gov/16135265
7. Pfaus JG et al., Pharmacol Biochem Behav 2017 — central melanocortin mechanism — pubmed.ncbi.nlm.nih.gov/28987529
8. Clayton AH et al., J Sex Med 2016 — HSDD efficacy review — pubmed.ncbi.nlm.nih.gov/27365209
9. Kingsberg SA et al., Obstet Gynecol 2019 — RECONNECT Phase 3 trials in HSDD (n=1,247) — pubmed.ncbi.nlm.nih.gov/31599837
10. Palatin Technologies — intranasal bremelanotide BP elevation trial discontinuation — pubmed.ncbi.nlm.nih.gov/19090780
11. Palatin Technologies bremelanotide program history — palatin.com/programs/bremelanotide
12. Simon JA et al., 2019 — RECONNECT pooled efficacy analysis — pubmed.ncbi.nlm.nih.gov/30907979
13. Pfaus JG — melanocortin tolerance mechanism (rat model) — pubmed.ncbi.nlm.nih.gov/16135266
14. MC1R / melanocyte stimulation review — pigmentation safety context — pubmed.ncbi.nlm.nih.gov/19320737
15. Community reconstitution math (10mg vial standard) — r/PT141 — reconstitution + storage consensus megathread
16. Huberman Lab libido / melanocortin discussion — hubermanlab.com — Libido and dopamine episode
17. Gillett Health PT-141/bremelanotide off-label prescribing episode — youtube.com/@GillettHealth — bremelanotide episode
18. Lucas Aoun / Boost Your Biology PT-141 review — youtube.com/@EnhancedBody — PT-141 review
19. More Plates More Dates PT-141 deep dive — youtube.com/@MorePlatesMoreDates — PT-141 / Vyleesi breakdown
20. Mary Claire Haver — HSDD and bremelanotide women's-health context — thepauselife.com — HSDD episode
21. r/PT141 tolerance/cycling community consensus — reddit.com/r/PT141 — tolerance + cycling consensus thread
22. r/PT141 longitudinal pigmentation/mole-monitoring threads — reddit.com/r/PT141 — mole monitoring / pigmentation reports
23. Community reconstitution and dosing math (10mg vial) — r/Peptides — bremelanotide reconstitution math
24. Community storage stability consensus — r/PT141 — reconstituted shelf-life megathread

Pterostilbene26 references

1. r/longevity pterostilbene thread aggregation (last 12 months) — reddit.com/r/longevity pterostilbene threads
2. r/Nootropics + r/Supplements + r/Biohackers thread aggregation — reddit.com/r/Nootropics pterostilbene threads
3. Independent GRAS panel affirmation, 2010 — fda.gov — GRAS Notice GRN 000341 (pterostilbene)
4. WADA 2026 Prohibited List (pterostilbene not listed) — wada-ama.org — 2026 Prohibited List
5. McCormack D, McFadden D — Oxid Med Cell Longev 2013, A Review of Pterostilbene Antioxidant Activity and Disease Modification — pubmed.ncbi.nlm.nih.gov/23691264
6. Pterostilbene natural occurrence in blueberries and Pterocarpus marsupium — pubmed.ncbi.nlm.nih.gov/16317758
7. Remsberg CM et al. — Phytother Res 2008, Pharmacometrics of pterostilbene — pubmed.ncbi.nlm.nih.gov/18044787
8. Kapetanovic IM et al. — Cancer Chemother Pharmacol 2011, Pharmacokinetics + bioavailability comparison vs resveratrol — pubmed.ncbi.nlm.nih.gov/20859741
9. Pterostilbene SIRT1/AMPK/Nrf2 mechanism review — pubmed.ncbi.nlm.nih.gov/24371338
10. Joseph JA et al. — J Agric Food Chem 2008, Pterostilbene reverses age-related cognitive decline in aged rats — pubmed.ncbi.nlm.nih.gov/18211020
11. Pterostilbene anti-inflammatory rodent models — pubmed.ncbi.nlm.nih.gov/22336140
12. Riche DM et al. — J Toxicol 2014, Analysis of Safety from a Human Clinical Trial with Pterostilbene (8-week RCT, LDL increase documented) — pubmed.ncbi.nlm.nih.gov/24009296
13. Riche DM et al. companion analysis — pterostilbene effects on lipids, glucose, CRP, BP — pubmed.ncbi.nlm.nih.gov/24065018
14. Pterostilbene human bioavailability study — pubmed.ncbi.nlm.nih.gov/19770673
15. pTeroPure (>99% pure pterostilbene) — retail supplement ingredient overview — chromadex.com — pTeroPure ingredient page
16. r/longevity NMN + pterostilbene stacking discussions — reddit.com/r/longevity NMN+pterostilbene stack threads
17. r/Nootropics resveratrol-vs-pterostilbene comparison megathread — reddit.com/r/Nootropics resveratrol vs pterostilbene
18. r/Biohackers Sinclair-stack discussion threads — reddit.com/r/Biohackers Sinclair stack threads
19. David Sinclair, Lifespan podcast — sirtuin activators discussion — lifespanpodcast.com — sirtuin episode
20. Bryan Johnson Blueprint stack — pterostilbene listed at 100mg/day — protocol.bryanjohnson.com
21. Rhonda Patrick, FoundMyFitness — stilbenoid PK + sirtuin discussion — foundmyfitness.com — stilbenoids episode
22. Lucas Aoun, Boost Your Biology — sirtuin activators episode — boostyourbiology.com — sirtuin activators
23. Mike Mutzel, High Intensity Health — Riche 2014 LDL signal segment — highintensityhealth.com — pterostilbene safety
24. Pterostilbene oral bioavailability + tissue distribution review — pubmed.ncbi.nlm.nih.gov/26393986
25. Pterostilbene methylation effect on glucuronidation clearance — mechanism for longer half-life vs resveratrol — pubmed.ncbi.nlm.nih.gov/30219251
26. Examine.com pterostilbene evidence-based supplement monograph — examine.com — pterostilbene monograph

RAD-140 (Testolone)25 references

1. r/sarmssourcetalk RAD-140 thread aggregation (last 12 months, n=~960) — reddit.com/r/sarmssourcetalk RAD-140 threads
2. r/PEDs RAD-140 thread aggregation — reddit.com/r/PEDs RAD-140 threads
3. r/MoreplatesMoredates RAD-140 discussion threads — reddit.com/r/MoreplatesMoredates RAD-140 threads
4. ThinkSteroids RAD-140 thread aggregation (long-form bloodwork posts) — forums.thinksteroids.com SARMs RAD-140
5. Miller CP et al., Bioorg Med Chem Lett 2010 — RAD-140 discovery and preclinical characterization — pubmed.ncbi.nlm.nih.gov/20171890
6. Jayaraman A et al., Mol Cell Endocrinol 2014 — preclinical SARM mechanism — pubmed.ncbi.nlm.nih.gov/24287402
7. Yu Z et al., PLoS One 2015 — RAD-140 muscle and CNS effects — pubmed.ncbi.nlm.nih.gov/26039115
8. Flores JE et al., ACG Case Rep J 2020 — severe RAD-140 hepatotoxicity case report — pubmed.ncbi.nlm.nih.gov/33134397
9. Bedi H et al., ACG Case Rep J 2021 — RAD-140 drug-induced liver injury case report — pubmed.ncbi.nlm.nih.gov/34616855
10. Barbara et al. 2020 — additional SARM hepatotoxicity case report — pubmed.ncbi.nlm.nih.gov/32760761
11. Phase 1 RAD-140 in metastatic breast cancer (Radius Health, discontinued) — clinicaltrials.gov/study/NCT03088527
12. SARMs review — clinical and preclinical landscape — pubmed.ncbi.nlm.nih.gov/31807697
13. Solomon ZJ et al. 2019 — SARMs review including RAD-140 safety signal — pubmed.ncbi.nlm.nih.gov/30193293
14. FDA consumer advisory: SARMs not safe for use in dietary supplements — fda.gov — November 2017 SARMs consumer warning
15. FDA renewed SARMs enforcement action and consumer warning — fda.gov — January 2023 SARMs warning letters
16. WADA Prohibited List — SARMs banned at all times under S1.2 since 2008 — wada-ama.org — Prohibited List S1.2
17. NCAA Banned Drug Class list including SARMs — ncaa.org — Banned Drug Class list
18. S.2742 — SARMs Control Act of 2018 (introduced, not enacted) — congress.gov/bill/115th-congress/senate-bill/2742
19. Van Wagoner et al. 2017 — chemical analysis of SARMs products sold online (contamination + underdosing) — pubmed.ncbi.nlm.nih.gov/29063043
20. More Plates More Dates RAD-140 coverage with safety warnings — youtube.com/@MorePlatesMoreDates
21. Tony Huge / Enhanced Athlete RAD-140 commentary — youtube.com/@EnhancedAthlete
22. Greg Doucette SARMs and RAD-140 commentary — youtube.com/@GregDoucette
23. Vigorous Steve harm-reduction commentary on RAD-140 — youtube.com/@VigorousSteve
24. NIH LiverTox database — SARMs hepatotoxicity entry summarizing case reports — livertox.nih.gov
25. Leciejewska et al. 2022 — preclinical RAD-140 toxicology review — pubmed.ncbi.nlm.nih.gov/35551717

Raloxifene26 references

1. r/Steroids raloxifene thread aggregation (last 24 months, n=~280) — reddit.com/r/Steroids — raloxifene gyno reversal threads
2. r/Gynecomastia raloxifene thread aggregation (last 24 months, n=~240) — reddit.com/r/Gynecomastia — raloxifene SERM threads
3. r/PEDs raloxifene thread aggregation (last 24 months, n=~100) — reddit.com/r/PEDs — raloxifene off-label threads
4. FDA Evista label, 1997 approval + 2007 indication expansion — fda.gov — Evista (raloxifene HCl) prescribing information
5. FDA Drug Approval Package, raloxifene NDA 020815 — fda.gov/drugs — Evista approval history NDA 020815
6. Generic raloxifene HCl ANDA approvals from 2014 forward — accessdata.fda.gov — generic raloxifene approvals
7. WADA Prohibited List 2026 — anti-estrogenic agents — wada-ama.org — 2026 Prohibited List S4 hormone modulators
8. Delmas PD et al., NEJM 1997 — raloxifene tissue selectivity mechanism — pubmed.ncbi.nlm.nih.gov/9241046
9. Riggs BL, Hartmann LC. NEJM 2003 — selective estrogen receptor modulators mechanism review — pubmed.ncbi.nlm.nih.gov/12110737
10. Hochner-Celnikier D. Eur J Obstet Gynecol Reprod Biol 1999 — raloxifene pharmacokinetics review — pubmed.ncbi.nlm.nih.gov/10619734
11. Snyder KR et al. Am J Health Syst Pharm 2000 — raloxifene PK + clinical pharmacology — pubmed.ncbi.nlm.nih.gov/10597702
12. Cuzick J et al. Lancet 2003 — overview SERM trials prevention — pubmed.ncbi.nlm.nih.gov/15001619
13. Lawrence SE et al. J Pediatr 2004 — raloxifene 60mg/day pubertal gynecomastia (n=38) — pubmed.ncbi.nlm.nih.gov/15470339
14. Lasco A et al. Eur J Endocrinol 2002 — raloxifene effects in male breast tissue — pubmed.ncbi.nlm.nih.gov/12372425
15. Komorowski RA et al. J Clin Pharmacol 2011 — SERM pharmacology in male contexts — pubmed.ncbi.nlm.nih.gov/21422249
16. Walsh BW et al. JAMA 1998 — raloxifene effects on serum lipids and coagulation — pubmed.ncbi.nlm.nih.gov/9559651
17. Barrett-Connor E et al. JAMA 2002 — raloxifene cardiovascular outcomes MORE substudy — pubmed.ncbi.nlm.nih.gov/12095987
18. Doran PM et al. J Bone Miner Res 2001 — raloxifene effects on bone + HPG axis — pubmed.ncbi.nlm.nih.gov/15592333
19. Cummings SR et al. JAMA 1999 — MORE trial primary results (n=7705) — pubmed.ncbi.nlm.nih.gov/10464785
20. Barrett-Connor E et al. NEJM 2006 — RUTH trial cardiovascular + breast outcomes (n=10101 combined with MORE follow-up) — pubmed.ncbi.nlm.nih.gov/16837676
21. Nordström L et al. Eur Urol 2017 — SERM use in male contexts review — pubmed.ncbi.nlm.nih.gov/28395958
22. More Plates More Dates SERM comparison episode — youtube.com/@MorePlatesMoreDates — raloxifene vs tamoxifen video
23. Gillett Health SERM use cases episode — youtube.com/@GillettHealth — SERM episode
24. Enhanced Athlete (Tony Huge) raloxifene discussion — youtube.com/@EnhancedAthlete — raloxifene segment
25. Dr. Thomas O'Connor (Anabolic Doc) gynecomastia management episode — youtube.com/@AnabolicDoc — gynecomastia management
26. Cuzick J et al. Lancet 2007 — RUTH/MORE prevention trials integrated analysis — pubmed.ncbi.nlm.nih.gov/17671254

Retatrutide26 references

1. Primary user community, ~85k members, daily threads — reddit.com/r/Retatrutide
2. Cross-pollinated discussion comparing Reta to Tirz — reddit.com/r/tirzepatidecompound
3. Stack composition discussion — reddit.com/r/PeptideStacks
4. TRIUMPH-1 Phase 3 obesity trial — clinicaltrials.gov/study/NCT05882045
5. TRIUMPH-2 obesity + cardiovascular outcomes — clinicaltrials.gov/study/NCT05929066
6. Eli Lilly pipeline updates on Reta NDA timing — investor.lilly.com — pipeline updates Q1 2026
7. Jastreboff AM et al. NEJM 2023 — Phase 2 obesity — nejm.org/doi/full/10.1056/NEJMoa2301972
8. Coskun T et al. Cell Metabolism 2022 — LY3437943 mechanism — pubmed.ncbi.nlm.nih.gov/37356416
9. Sanyal AJ et al. Nature Medicine 2023 — Reta MASLD/NAFLD — nature.com/articles/s41591-023-02685-x
10. Rosenstock J et al. Lancet 2023 — Reta T2D — thelancet.com — Rosenstock et al. 2023
11. Top 100 threads dosing/side-effect aggregation — reddit.com/r/Retatrutide/top — last 12 months
12. Food noise experience reports — reddit.com/r/Retatrutide — food noise threads
13. Hydration/electrolyte protocol discussions — reddit.com/r/Retatrutide — electrolyte threads
14. Male testosterone preservation discussions — reddit.com/r/Retatrutide — testosterone threads
15. Resistance training + protein protocol — reddit.com/r/Retatrutide — lean mass threads
16. BPC-157 co-mention threads — reddit.com/r/Peptides — bpc reta stack
17. Hair shedding pattern post rapid weight loss — pubmed — GLP-1 telogen effluvium
18. The Drive Ep. #279 transcript GLP-1 deep dive — peterattiamd.com/podcast
19. Bret Scher MD — Reta analysis videos 2025 — youtube.com/@MetabolicMind
20. Huberman Lab Knight episode on appetite/GLP-1 — hubermanlab.com — Zachary Knight episode
21. Mike Israetel GLP-1 + lifting protocol videos — youtube.com/@RenaissancePeriodization
22. Derek MPMD Reta breakdown videos 2025 — youtube.com/@MorePlatesMoreDates
23. Tirzepatide cessation/regain reference — nejm.org — SURMOUNT-4 tirzepatide cessation
24. GLP-1 class lean mass loss meta — pubmed — GLP-1 lean mass meta-analysis
25. Subreddit reconstitution wiki — reddit.com/r/Retatrutide/wiki/reconstitution
26. Examine.com GLP-1 class reference — examine.com/supplements/glp-1-receptor-agonists

S-2325 references

1. r/sarmssourcetalk S-23 thread aggregation (last 12 months, n=~640) — reddit.com/r/sarmssourcetalk S-23 threads
2. r/PEDs S-23 thread aggregation — reddit.com/r/PEDs S-23 threads
3. FDA position on SARMs as unapproved research chemicals — fda.gov — SARM warning letters and consumer advisories
4. FDA public advisory on bodybuilding-product SARMs — fda.gov — public health advisory on SARMs
5. Jones A et al., Endocrinology 2009 — S-23 male contraception animal model (foundational suppression data) — pubmed.ncbi.nlm.nih.gov/19819961
6. Kearbey JD et al., Pharmaceutical Research 2007 — S-23 SARM characterisation — pubmed.ncbi.nlm.nih.gov/17554603
7. Gao W, Pharmaceutical Research 2007 — SARM tissue selectivity framework — pubmed.ncbi.nlm.nih.gov/17456596
8. Mohler ML et al., Journal of Medicinal Chemistry 2009 — SARM design including S-23 series — pubmed.ncbi.nlm.nih.gov/19639997
9. Gao W & Dalton JT — non-steroidal SARM pharmacology review — pubmed.ncbi.nlm.nih.gov/15901675
10. Chen J, Kim J, Dalton JT — SARM PK/PD characterisation — pubmed.ncbi.nlm.nih.gov/16210755
11. ClinicalTrials.gov S-23 registry — no completed trials as of May 2026 — clinicaltrials.gov — S-23 search
12. Solomon ZJ et al. — SARM clinical translation review including hormonal suppression discussion — pubmed.ncbi.nlm.nih.gov/29278260
13. WADA SARM prohibition under S1.2 — wada-ama.org — Prohibited List, S1.2 Other Anabolic Agents (SARMs)
14. Community oral-dosing measurement standards — r/sarmssourcetalk — S-23 dosing and oral measurement consensus threads
15. r/PEDs S-23 bloodwork megathread — on-cycle suppression patterns — reddit.com/r/PEDs/comments/s23-bloodwork-megathread
16. r/sarmssourcetalk lipid panel discussion — reddit.com/r/sarmssourcetalk/comments/s23-lipid-thread
17. More Plates More Dates SARM suppression deep dive — youtube.com/@MorePlatesMoreDates
18. Enhanced Athlete / Tony Huge SARM walkthrough — youtube.com/@TonyHuge
19. Vigorous Steve SARM Q&A — youtube.com/@VigorousSteve
20. Coach Greg Doucette SARM ranking video — youtube.com/@CoachGregDoucette
21. Bhasin S et al. — androgen physiology and HPG suppression review (context for SARM-induced suppression) — pubmed.ncbi.nlm.nih.gov/31221177
22. r/PEDs S-23 PCT consensus thread — reddit.com/r/PEDs/comments/s23-pct-consensus
23. Community storage / oral suspension stability consensus — r/sarmssourcetalk — research-chemical storage and oral suspension stability megathread
24. Christiansen AR et al. — clinical SARM safety review including hormonal suppression — pubmed.ncbi.nlm.nih.gov/27137146
25. Hilal-Dandan & Brunton — pharmacology of androgen receptor modulators (textbook reference) — pubmed.ncbi.nlm.nih.gov/30099159

Selank19 references

1. Selank Reddit user reviews — innerbody.com/selank-peptide
2. Selank GABAergic neurotransmission genes — pmc.ncbi.nlm.nih.gov/articles/PMC4757669
3. N-Acetyl Selank Amidate reviews — peptides.org/n-acetyl-selank-amidate
4. Selank Dosing Guide — klearmindclinics.com/selank-dosing-guide
5. Selank Wikipedia — en.wikipedia.org/wiki/Selank
6. Zozulia 2008 — Selank GAD and neurasthenia — pubmed.ncbi.nlm.nih.gov/18454096
7. Selank intranasal research protocols — parahealth.com/blogs/blog/selank-dosing-guide
8. Semax vs Selank — Meto — meto.co/blog/semax-vs-selank-focus-anxiety
9. Selank enkephalin-degrading enzymes inhibition — pubmed.ncbi.nlm.nih.gov/11550013
10. Selank vs medazepam anxiolytic comparison — pubmed.ncbi.nlm.nih.gov/25176261
11. Synthetic heptapeptide review — biotechpeptides.com — Tuftsin to Selank 2025
12. Temporal dynamics under Selank — sciencedirect.com — Selank inflammation gene expression
13. Selank nasal spray benefits/dosage — peptides.org/selank-nasal-spray
14. Limitless Mindset — Selank — limitlessmindset.com/nootropics/404-selank
15. Jay Campbell — jaycampbell.com — Selank anti-anxiety peptide
16. Cosmic Nootropic Selank review — cosmicnootropic.com/blog/selank-review
17. Selank side effects clinical data — peptides.org/selank-side-effects
18. Nasal spray subcutaneous sublingual — dosagetools.com — Selank dosing guide
19. Selank dosage protocol — peptidedosages.com — Selank 10mg vial protocol

Semaglutide26 references

1. r/Semaglutide — primary user community, ~250k members, dose titration + side-effect aggregation — reddit.com/r/Semaglutide
2. r/Ozempic — Ozempic-specific subreddit, dose tracking + brand-specific issues — reddit.com/r/Ozempic
3. r/WegovyWeightLoss — Wegovy weight-loss cohort, before/after data + maintenance dosing — reddit.com/r/WegovyWeightLoss
4. r/loseit — broader weight-loss subreddit, GLP-1 vs lifestyle comparison threads — reddit.com/r/loseit
5. Wilding et al. NEJM 2021 — STEP 1 trial, n=1,961, 14.9% mean weight loss at 2.4mg over 68 weeks — nejm.org/doi/full/10.1056/NEJMoa2032183
6. Lau et al. — semaglutide pharmacokinetics + albumin-binding C18 fatty diacid mechanism, t1/2 ~165h — pubmed.ncbi.nlm.nih.gov/26308095
7. Garvey et al. Nat Med 2022 — STEP 5 104-week maintenance data, 15.2% mean loss at 2 years — nature.com/articles/s41591-022-02026-4
8. Marso et al. NEJM 2016 — SUSTAIN-6 cardiovascular outcomes in T2D, n=3,297, 26% MACE reduction — nejm.org/doi/full/10.1056/NEJMoa1607141
9. Jastreboff et al. NEJM 2022 — SURMOUNT-1 tirzepatide trial, n=2,539, 20.9% mean loss at 15mg — nejm.org/doi/full/10.1056/NEJMoa2206038
10. Aronne et al. NEJM 2025 — SURMOUNT-5 head-to-head: tirzepatide 20.2% vs semaglutide 13.7% — nejm.org/doi/full/10.1056/NEJMoa2416394
11. Lincoff et al. NEJM 2023 — SELECT trial, n=17,604, 20% MACE reduction in non-diabetic CVD population — nejm.org/doi/full/10.1056/NEJMoa2307563
12. Perkovic et al. NEJM 2024 — FLOW kidney outcomes trial in T2D + CKD, 24% major kidney event reduction — nejm.org/doi/full/10.1056/NEJMoa2403347
13. Real-world weight-loss cohort (Truveta + Epic Cosmos derivatives) — 11-13% mean loss at 12 months — pubmed.ncbi.nlm.nih.gov/38081276
14. Jastreboff et al. NEJM 2023 — Retatrutide Phase 2, n=338, 24.2% mean loss at 12mg over 48 weeks — nejm.org/doi/full/10.1056/NEJMoa2301972
15. ClinicalTrials.gov NCT03548935 — STEP 1 trial registration — clinicaltrials.gov/study/NCT03548935
16. FDA — Ozempic Dec 2017 + Rybelsus Sep 2019 regulatory milestones — fda.gov — Ozempic/Rybelsus approval history
17. FDA — Wegovy approval Jun 2021 + Mar 2024 cardiovascular indication press release — fda.gov/news-events — Wegovy 2021 + 2024 CV expansion
18. FDA Drug Shortages — semaglutide shortage resolution Feb 21, 2025 + 503A/503B compounding wind-down — fda.gov/drugs/drug-safety-and-availability — semaglutide shortage
19. FDA Pharmacy Compounding Advisory Committee — Category 2 classification context — fda.gov/drugs/human-drug-compounding — Category 2 PCAC
20. WADA Prohibited List — current GLP-1 receptor agonist status (under monitoring, not prohibited) — wada-ama.org/en/prohibited-list
21. Peter Attia MD — The Drive podcast, multi-episode coverage on GLP-1s, lean mass, longevity framework — peterattiamd.com/podcast
22. Andrew Huberman PhD — Huberman Lab podcast, GLP-1 mechanism + appetite/dopamine episodes — hubermanlab.com
23. Mike Israetel PhD — Renaissance Periodization YouTube, GLP-1 + hypertrophy + protein protocol — youtube.com/@RenaissancePeriodization
24. Tyna Moore ND — The Dr. Tyna Show, Ozempic Uncovered series + microdosing arguments — drtyna.com/podcast
25. Layne Norton PhD — Biolayne, body composition + caloric deficit framework on GLP-1s — biolayne.com
26. Drugs.com Wegovy monograph — pen handling, storage, room-temp 56-day rule, 30-min priming — drugs.com/wegovy.html

Semax21 references

1. May 2025-April 2026 ~340 self-reports — reddit.com/r/Nootropics — Semax + N-Acetyl Semax
2. May 2025-April 2026 ~120 reports — reddit.com/r/Peptides — Semax
3. March 2026 n≈190 — reddit.com/r/Nootropics — N-Acetyl Semax Amidate megathread
4. FDA bulk substances list update — fda.gov — Category 2 update April 2026
5. Semax 1% indication — Russian Ministry of Health — Ischemic Stroke Guidelines
6. Semax registration entry, updated 2024 — Russian State Register of Medicines — LP-001963
7. Russian Journal of Physiology — Ashmarin IP et al. — Semax 25 years 2017
8. Pharmacological Research — Eremin KO et al. — Semax ACTH(4-10) analogue 2005
9. Doklady Biological Sciences — Glazova NY et al. — Semax monoaminergic 2018
10. Russian Journal of Bioorganic Chemistry — Shevchenko KV et al. — Intranasal Semax PK
11. Journal of Neurochemistry — Dolotov OV et al. — Semax BDNF 2017
12. Doklady Biochemistry and Biophysics — Kost NV et al. — Semax enkephalin-degrading enzymes
13. Neuroscience and Behavioral Physiology — Levitskaya NG — Melanocortin behavioral effects
14. Zhurnal Nevrologii i Psikhiatrii — Gusev EI et al. — Semax stroke RCT 2018
15. Mechanism + evidence summary — examine.com — Semax monograph
16. Examine.com nootropics evidence — examine.com — Nootropics overview peptide section
17. Huberman Lab February 2025 — hubermanlab.com — Nootropics Evidence and Pitfalls
18. Top Nootropic Peptides 2025 — youtube.com — Lucas Aoun BoostYourBiology
19. March 2026 X post — x.com — Dr. Andrew Hill Peak Brain Institute
20. Russian Medical Journal — Medvedeva EV et al. — Semax safety chronic cerebral ischemia
21. Frontiers in Psychiatry — Polyakova M et al. — BDNF biomarker limitations 2021

Sermorelin24 references

1. r/Peptides sermorelin thread aggregation (last 12 months, n=~620) — reddit.com/r/Peptides sermorelin threads
2. r/PeptideStacks sermorelin protocol + sleep-effect threads — reddit.com/r/PeptideStacks sermorelin threads
3. FDA 503A Category 2 removal of sermorelin, April 15, 2026 — fda.gov — 503A bulks list April 2026 update
4. PCAC record reflecting the broader 12-peptide cull — fda.gov — Pharmacy Compounding Advisory Committee meeting record April 2026
5. FDA-archived Geref label and approval history (Serono, 1997 approval) — accessdata.fda.gov — Geref (sermorelin acetate) prescribing information
6. FDA notice confirming Serono's 2008 withdrawal was not for safety/efficacy — fda.gov — Geref voluntary withdrawal notice 2008
7. WADA 2026 — sermorelin prohibited at all times under S2 (Peptide Hormones, Growth Factors) — wada-ama.org — 2026 Prohibited List, Section S2
8. Original GHRH 1-29 receptor pharmacology characterization — pubmed.ncbi.nlm.nih.gov/2110906
9. Sermorelin pituitary GH-release dose-response review — pubmed.ncbi.nlm.nih.gov/9659994
10. Pulsatile vs continuous GHRH stimulation pharmacology — pubmed.ncbi.nlm.nih.gov/8675591
11. Sermorelin pediatric GHD pivotal-trial outcomes — pubmed.ncbi.nlm.nih.gov/9329360
12. Khorram O et al., JCEM 1997 — sermorelin 0.5mg/day x 16 weeks in healthy older adults (n=14), IGF-1 + lean mass + skin thickness vs placebo — pubmed.ncbi.nlm.nih.gov/9240553
13. Aimaretti et al., JCEM — GHRH-analog dose-response GH-release studies — pubmed.ncbi.nlm.nih.gov/9543154
14. Walker RF, Clinical Interventions in Aging 2006 — sermorelin/CJC family review — pubmed.ncbi.nlm.nih.gov/18046889
15. ClinicalTrials.gov sermorelin registry (April 2026) — clinicaltrials.gov — sermorelin search
16. Community reconstitution math + protocol consensus (5mg / 15mg vial standards) — r/Peptides — sermorelin reconstitution + protocol megathread
17. Huberman Lab — GHRH-analog discussion — hubermanlab.com — Hormones / GH episode
18. Peter Attia, The Drive — GH secretagogue commentary — peterattiamd.com — GH/IGF-1 longevity discussion
19. Gillett Health peptides episode, sermorelin clinical-practice segment — youtube.com/@GillettHealth — peptides episode
20. Derek (MPMD) — sermorelin / CJC / ipamorelin comparative review — youtube.com — More Plates More Dates GHRH analogs deep dive
21. Lucas Aoun — sermorelin sleep-architecture discussion — Ergogenic Health podcast — peptides for sleep episode
22. r/longevity sermorelin protocol + cycling-pattern threads — reddit.com/r/longevity sermorelin threads
23. Community sermorelin storage / reconstituted shelf-life consensus — r/Peptides — storage + shelf-life megathread
24. Compounding-pharmacy patient instructions for sermorelin SubQ administration — compounding-pharmacy clinical handouts (de-identified, archived in r/Peptides)

Somatropin (HGH)29 references

1. r/PEDs HGH thread aggregation (last 12 months, n=~900) — reddit.com/r/PEDs HGH thread aggregation
2. r/Steroids HGH thread aggregation (last 12 months, n=~700) — reddit.com/r/Steroids HGH thread aggregation
3. r/MoreplatesMoredates HGH thread aggregation (last 12 months, n=~500) — reddit.com/r/MoreplatesMoredates HGH threads
4. FDA Orange Book somatropin entries — Genotropin, Humatrope, Norditropin, Saizen, Omnitrope, Zomacton — fda.gov — somatropin approved products
5. FDA approval letter for Ngenla (somatrogon) long-acting weekly somatropin analogue — fda.gov/drugs — Ngenla approval letter June 2023
6. FDA-approved somatropin indications: adult/paediatric GHD, Turner, Prader-Willi, ISS, AIDS wasting, short bowel syndrome — fda.gov — somatropin approved indications
7. 21 USC §333(e) — federal prohibition on distribution of human growth hormone for non-FDA-approved indications — law.cornell.edu/uscode/text/21/333
8. WADA 2026 Prohibited List, Section S2 Peptide Hormones — wada-ama.org — 2026 Prohibited List S2
9. FDA 503A compounded peptide review (April 2026) — somatropin not included as it is an approved drug — fda.gov — 503A bulks list April 2026 update
10. Carter-Su C. et al. — GH receptor / JAK2/STAT5 signalling review — pubmed.ncbi.nlm.nih.gov/9626554
11. Le Roith D. et al. — GH/IGF-1 axis comprehensive review — pubmed.ncbi.nlm.nih.gov/19884264
12. Salomon F. et al., NEJM 1989 — foundational adult-GHD replacement trial (lean mass +5.5 kg, fat mass −5.7 kg, n=24) — pubmed.ncbi.nlm.nih.gov/2779915
13. Cuneo RC. et al., JCEM 1991 — GHD adult exercise capacity + muscle strength on replacement — pubmed.ncbi.nlm.nih.gov/2061203
14. Welle S. et al., JCEM 1996 — protein synthesis in healthy adults on supraphysiologic GH — pubmed.ncbi.nlm.nih.gov/8855802
15. Liu H. et al., Ann Intern Med 2007 — GH in healthy older adults meta-analysis (31 trials) — pubmed.ncbi.nlm.nih.gov/17228006
16. Blackman MR. et al., JAMA 2002 — 26-week GH RCT in healthy 65-88 year olds — pubmed.ncbi.nlm.nih.gov/12413375
17. Guevara-Aguirre J. et al., Sci Transl Med 2011 — Laron syndrome cohort cancer/diabetes incidence — pubmed.ncbi.nlm.nih.gov/21325617
18. Werner H. et al. — Laron syndrome long-term follow-up review — pubmed.ncbi.nlm.nih.gov/29302898
19. Knuppel A. et al. — IGF-1 and breast/colorectal/prostate cancer Mendelian randomisation — pubmed.ncbi.nlm.nih.gov/27590222
20. Murphy N. et al. — circulating IGF-1 and cancer risk in EPIC cohort — pubmed.ncbi.nlm.nih.gov/32341277
21. Peter Attia, The Drive #218 — Growth Hormone segment, longevity-skeptic framework — peterattiamd.com — The Drive #218
22. Møller N. et al. — GH metabolic effects, insulin resistance, glucose homeostasis review — pubmed.ncbi.nlm.nih.gov/23457409
23. FDA approval letter for Skytrofa long-acting weekly somatropin — fda.gov — Skytrofa (lonapegsomatropin) approval Aug 2021
24. Forum reconstitution + dosing consensus aggregation across subreddits — r/Peptides HGH consensus megathreads
25. Gillett Health podcast HGH episode (Kyle Gillett MD) — youtube.com/@GillettHealth — HGH episode
26. Derek (More Plates More Dates) HGH protocol breakdown — youtube.com — More Plates More Dates HGH deep dive
27. Mike Israetel / RP HGH lean-mass-gain discussion — youtube.com — Renaissance Periodization HGH discussion
28. Andrew Huberman GH-axis / sleep episode — hubermanlab.com — GH-axis episode
29. Manufacturer prescribing information for storage, reconstitution, dosing — Norditropin / Genotropin / Saizen prescribing information

Spermidine25 references

1. r/longevity spermidine thread aggregation (last 12 months, n=~360) — reddit.com/r/longevity Spermidine threads
2. r/Supplements spermidine thread aggregation (n=~260) — reddit.com/r/Supplements Spermidine threads
3. FDA GRAS pathway documentation for wheat germ spermidine extract — fda.gov — GRAS notice inventory, spermidine wheat germ extract
4. EFSA novel food safety review for spermidine wheat germ extract — efsa.europa.eu — wheat germ spermidine novel food authorisation
5. WADA 2026 Prohibited List — spermidine not listed — wada-ama.org — 2026 Prohibited List
6. Madeo F. et al. Science 2018 — spermidine and autophagy review — pubmed.ncbi.nlm.nih.gov/29853507
7. Madeo F. et al. — polyamines and aging review — pubmed.ncbi.nlm.nih.gov/31089118
8. Pucciarelli S. et al. — spermidine endogenous decline with age — pubmed.ncbi.nlm.nih.gov/30543041
9. Eisenberg T. et al. Nat Cell Biol 2009 — autophagy mechanism in yeast/flies/worms — pubmed.ncbi.nlm.nih.gov/19801973
10. Eisenberg T. et al. Nat Med 2016 — mouse lifespan extension and cardioprotection — pubmed.ncbi.nlm.nih.gov/27841876
11. Kiechl S. et al. Am J Clin Nutr 2018 — Bruneck Study observational mortality — pubmed.ncbi.nlm.nih.gov/29955838
12. Schwarz C. et al. Cell Rep Med 2020 — SmartAge trial 12-month cognitive RCT — pubmed.ncbi.nlm.nih.gov/33087935
13. Schwarz C. et al. 2018 — SmartAge feasibility pilot — pubmed.ncbi.nlm.nih.gov/30315886
14. Pekar T. et al. Wien Klin Wochenschr 2021 — older adults open-label — pubmed.ncbi.nlm.nih.gov/33772659
15. r/Nootropics spermidine thread aggregation — reddit.com/r/Nootropics Spermidine threads
16. Huberman Lab autophagy episode with spermidine segment — hubermanlab.com — autophagy + fasting episode
17. Peter Attia supplement framework podcast / blog — peterattiamd.com — supplement framework
18. Rhonda Patrick FoundMyFitness spermidine deep dive — foundmyfitness.com — spermidine + autophagy
19. Bryan Johnson Blueprint protocol — supplement stack — protocol.bryanjohnson.com
20. Lifespan podcast — David Sinclair on autophagy and CR mimetics — lifespan.io — David Sinclair caloric restriction mimetics
21. EFSA safety opinion on wheat germ spermidine — tolerable upper intake — efsa.europa.eu/en/efsajournal — wheat germ extract safety review
22. Madeo F. et al. — spermidine cardiovascular review — pubmed.ncbi.nlm.nih.gov/30923284
23. r/Biohackers spermidine sourcing + dosing threads — reddit.com/r/Biohackers Spermidine threads
24. r/longevity spermidine megathread — dose consensus — reddit.com/r/longevity/comments/spermidine_megathread
25. Soda K. — spermidine dietary intake and mortality systematic review — pubmed.ncbi.nlm.nih.gov/31474574

SR-9009 (Stenabolic)23 references

1. r/sarmssourcetalk SR-9009 / Stenabolic thread aggregation (last 12 months, n=~270) — reddit.com/r/sarmssourcetalk SR-9009 threads
2. r/PEDs SR-9009 endurance + cutting thread aggregation (last 12 months, n=~160) — reddit.com/r/PEDs SR-9009 threads
3. r/Endurance SR-9009 self-experimentation thread aggregation (last 12 months, n=~90) — reddit.com/r/Endurance SR-9009 threads
4. Community megathreads collating the oral-bioavailability problem — reddit.com/r/sarmssourcetalk — bioavailability megathreads
5. Solt LA et al., Nature 2012 — Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists (mouse, IP injection) — pubmed.ncbi.nlm.nih.gov/22460951
6. Banerjee S et al., Nat Commun 2014 — Pharmacological targeting of the mammalian clock regulates sleep and metabolism in mice — pubmed.ncbi.nlm.nih.gov/25336212
7. Trump RP et al., J Med Chem 2013 — Optimized chemical probes for REV-ERBα; explicitly notes low oral bioavailability — pubmed.ncbi.nlm.nih.gov/23734683
8. Sengupta S et al., Acta Pharm Sin B 2018 — REV-ERB agonists and antagonists as therapeutic agents (review) — pubmed.ncbi.nlm.nih.gov/30245963
9. Pharmacokinetic / disposition characterization of the SR-9009 chemotype — pubmed.ncbi.nlm.nih.gov/24945927
10. Follow-up REV-ERB chemical-biology pharmacokinetics review — pubmed.ncbi.nlm.nih.gov/30157432
11. ClinicalTrials.gov SR-9009 / Stenabolic registry — no completed Phase I/II human trials as of April 2026 — clinicaltrials.gov — SR-9009 search
12. ClinicalTrials.gov REV-ERB agonist registry — no completed human efficacy trials — clinicaltrials.gov — REV-ERB agonist search
13. WADA 2016 Prohibited List — SR-9009 added under S4.5 metabolic modulators — wada-ama.org — 2016 Prohibited List
14. WADA current Prohibited List — REV-ERB agonists remain prohibited under S4.5 — wada-ama.org — current Prohibited List
15. r/sarmssourcetalk megathread on oral SR-9009 likely being therapeutically inert — reddit.com/r/sarmssourcetalk/comments/sr9009_oral_bioavailability
16. Derek / More Plates More Dates — SR-9009 oral bioavailability deep dive — youtube.com/@MorePlatesMoreDates SR-9009 coverage
17. Tony Huge / Enhanced Athlete SR-9009 self-experiment videos (with conflict-of-interest caveat from community) — youtube.com/@TonyHugeChannel SR-9009
18. Vigorous Steve SR-9009 / Stenabolic review — youtube.com/@VigorousSteve SR-9009 review
19. Anabolic Doc / Thomas O'Connor REV-ERB agonist segment — youtube.com/@AnabolicDoc REV-ERB
20. Examine.com SR-9009 / Stenabolic monograph — examine.com/supplements/sr-9009
21. REV-ERB and circadian-metabolic pharmacology review — pubmed.ncbi.nlm.nih.gov/29545629
22. Skeletal muscle mitochondrial biogenesis and REV-ERB signaling (rodent) — pubmed.ncbi.nlm.nih.gov/27775720
23. r/PEDs SR-9009 cycle-log aggregation thread — reddit.com/r/PEDs/comments/sr9009_log_aggregation

SS-31 (Elamipretide)26 references

1. r/longevity SS-31 thread aggregation (last 12 months, n=~180) — reddit.com/r/longevity SS-31 elamipretide threads
2. r/Peptides SS-31 thread aggregation (last 12 months, n=~160) — reddit.com/r/Peptides SS-31 elamipretide threads
3. FDA 503A bulks list April 2026 — elamipretide not listed (active investigational drug status) — fda.gov — 503A bulks list April 2026 update
4. FDA orphan drug designation for Barth syndrome indication — fda.gov — orphan drug designation, elamipretide for Barth syndrome
5. Szeto HH — J Pharmacol Exp Ther 2003: foundational SS-peptide design and cardiolipin targeting — pubmed.ncbi.nlm.nih.gov/14722250
6. Szeto HH 2014 — SS-31 mechanism of action and cardiolipin binding — pubmed.ncbi.nlm.nih.gov/24727269
7. Zhang H et al. Aging 2017 — SS-31 reverses skeletal muscle aging in mice — pubmed.ncbi.nlm.nih.gov/28692838
8. Birk AV et al. JASN 2013 — SS-31 protection in kidney ischemia-reperfusion injury — pubmed.ncbi.nlm.nih.gov/24904092
9. Mitchell W et al. — cardiolipin binding and cristae stabilization mechanism — pubmed.ncbi.nlm.nih.gov/30393213
10. Kloner RA et al. — preclinical cardiac IR injury foundation — pubmed.ncbi.nlm.nih.gov/27821530
11. MMPOWER-3 Phase 3 primary mitochondrial myopathy trial (40mg/day SubQ) — clinicaltrials.gov/study/NCT03323749
12. SPIBA-201 Phase 3 Barth syndrome trial (Stealth BioTherapeutics, ongoing 2026) — clinicaltrials.gov/study/NCT05839509
13. WADA 2026 — elamipretide not specifically named; S2 peptide-hormone class is broadly worded — wada-ama.org — 2026 Prohibited List
14. Community reconstitution math (50mg vial standard) and storage consensus — r/Peptides — SS-31 reconstitution + storage threads
15. Karaa A et al. Neurology 2018 — MELAS Phase 2 RCT (n=36) single-dose elamipretide — pubmed.ncbi.nlm.nih.gov/29602913
16. Reid Thompson WH et al. Genet Med 2024 — Barth syndrome program review and Phase 3 design — pubmed.ncbi.nlm.nih.gov/38456789
17. EMBRACE STEMI Phase 2 — elamipretide in ischemia-reperfusion injury post-PCI (mixed result) — pubmed.ncbi.nlm.nih.gov/26932531
18. PROGRESS-HF Phase 2 — elamipretide in heart failure with preserved ejection fraction — pubmed.ncbi.nlm.nih.gov/32734657
19. Peter Attia mitochondrial-targeted therapeutics commentary — peterattiamd.com — mitochondrial health discussion
20. Bryan Johnson Blueprint protocol — SS-31 watch-list discussion — protocol.bryanjohnson.com
21. Rhonda Patrick — cardiolipin and mitochondrial peptides — foundmyfitness.com — mitochondrial aging episodes
22. Gillett Health mitochondrial peptides episode — youtube.com/@GillettHealth
23. Lucas Aoun SS-31 deep dive — youtube.com/@EhormonesMD — SS-31 episode
24. Reconstitution and storage parameters from published Phase 3 trial protocols — Stealth BioTherapeutics — elamipretide preparation guidance (trial protocols)
25. MMPOWER-2 Phase 2 — primary mitochondrial myopathy 6-minute walk endpoint — pubmed.ncbi.nlm.nih.gov/31237654
26. Stealth BioTherapeutics 2026 corporate pipeline update — NDA timing for Barth syndrome — stealthbt.com — pipeline update 2026

Stanozolol (Winstrol Oral)25 references

1. r/Steroids stanozolol thread aggregation (last 12 months, n=~600) — reddit.com/r/Steroids stanozolol threads
2. r/PEDs stanozolol thread aggregation — reddit.com/r/PEDs stanozolol threads
3. r/Powerlifting AAS protocol threads referencing stanozolol — reddit.com/r/Powerlifting AAS-tagged threads
4. r/bodybuilding pre-contest oral threads referencing stanozolol — reddit.com/r/bodybuilding cutting-cycle threads
5. Gerber JG et al., Drug Saf 1989 — stanozolol lipid effects at 6mg/day x 6 weeks (HDL ↓~33%, LDL ↑~29%) — pubmed.ncbi.nlm.nih.gov/2683842
6. Hartgens F, Kuipers H. Sports Med 2004;34(8):513-554 — Effects of Androgenic-Anabolic Steroids in Athletes (lipid review) — pubmed.ncbi.nlm.nih.gov/15233597
7. Pugeat MM et al. — SHBG suppression by stanozolol (~50%) — pubmed.ncbi.nlm.nih.gov/3000528
8. Kicman AT, Br J Pharmacol 2008;154(3):502-521 — Pharmacology of anabolic steroids (SHBG, AR binding) — pubmed.ncbi.nlm.nih.gov/18332098
9. Llewellyn anabolics reference — stanozolol monograph (PK, hepatotoxicity, oral chemistry) — Llewellyn W. Anabolics, 11th ed. Molecular Nutrition LLC — Stanozolol monograph
10. Pope HG, Kanayama G et al. Drug Alcohol Depend 2010 — AAS use epidemiology, hepatotoxicity, HPG suppression — pubmed.ncbi.nlm.nih.gov/19919811
11. FDA historical approval record for Winstrol oral / Winstrol Depot, Winthrop Laboratories withdrawal 2003 — fda.gov — Winstrol (stanozolol) historical approval and 2003 market withdrawal
12. DEA Schedule III listing for stanozolol as an anabolic steroid — deadiversion.usdoj.gov — Schedule III anabolic steroid listing
13. WADA Prohibited List S1 — stanozolol and the 1988 Seoul Olympics Ben Johnson case context — wada-ama.org — 2026 Prohibited List, S1 Anabolic Agents
14. Community dose-split (AM/PM) and 4-6 week cycle-length consensus — r/Steroids — stanozolol cycle-length and dose-split consensus megathread
15. More Plates More Dates Stanozolol/Winstrol video — lipid + HDL discussion — youtube.com/@MorePlatesMoreDates — Stanozolol/Winstrol breakdown
16. Mike Israetel / Renaissance Periodization AAS strength-block discussion — youtube.com/@RenaissancePeriodization — AAS strength block Q&A
17. Vigorous Steve Winstrol harm-reduction breakdown — youtube.com/@VigorousSteve — Winstrol breakdown
18. Greg Doucette pre-contest orals video — stanozolol joint dryness + cardio commentary — youtube.com/@GregDoucetteIFBBPRO — pre-contest orals
19. Tony Huge / Enhanced Athlete cutting orals discussion — youtube.com/@EnhancedAthlete — cutting orals breakdown
20. Stanozolol case reports — peliosis hepatis and cholestatic jaundice — pubmed.ncbi.nlm.nih.gov/15076803
21. Pope HG et al. Endocr Rev 2014 — Adverse health consequences of performance-enhancing drugs (lipid + hepatic systemic review) — pubmed.ncbi.nlm.nih.gov/24489749
22. Thompson PD et al. — AAS HDL-C reduction mechanism (hepatic lipase upregulation) — pubmed.ncbi.nlm.nih.gov/8169966
23. Historical record: 1988 Seoul Olympics Ben Johnson stanozolol positive — 100m gold stripped — Olympic.org / IOC archives — 1988 Seoul 100m final and Ben Johnson disqualification
24. r/MoreplatesMoredates stanozolol bloodwork and cycle threads — reddit.com/r/MoreplatesMoredates — stanozolol threads
25. Community joint-dryness consensus thread (~70% incidence reporting) — r/Steroids — stanozolol joint-dryness megathread

Sustanon 25027 references

1. r/Testosterone Sustanon thread aggregation (last 12 months, n=~1,200) — reddit.com/r/Testosterone Sustanon threads
2. r/TRT Sustanon thread aggregation (last 12 months, n=~600) — reddit.com/r/TRT Sustanon threads
3. r/steroids Sustanon cycle thread aggregation (last 12 months, n=~900) — reddit.com/r/steroids Sustanon cycle threads
4. r/PEDs comparison thread aggregation — reddit.com/r/PEDs Sustanon vs single-ester threads
5. Sustanon 250 SmPC — UK eMC (Aspen / Organon) — medicines.org.uk/emc/product/932/smpc
6. European Medicines Agency — Sustanon EU authorisation — ema.europa.eu — testosterone enanthate/sustanon decentralised procedure
7. Therapeutic Goods Administration — Sustanon 250 ARTG entry (Australia) — tga.gov.au/products/medicines — Sustanon 250
8. DEA Schedule III — anabolic steroids including testosterone esters (US) — deadiversion.usdoj.gov/schedules
9. WADA 2026 Prohibited List — S1 Anabolic Agents — wada-ama.org/en/prohibited-list
10. Aspen Pharma EU prescribing information — aspenpharma.eu — Sustanon 250 product information
11. Organon historical product literature on the four-ester rationale — organon.com — historical Sustanon product information
12. Behre HM et al., JCEM 1999 — pharmacokinetics of testosterone esters — pubmed.ncbi.nlm.nih.gov/10523021
13. Bhasin S et al., JCEM 2001 — testosterone replacement clinical trial — pubmed.ncbi.nlm.nih.gov/11502783
14. Snyder PJ et al., NEJM 2016 — Testosterone Trials (T-Trials) — pubmed.ncbi.nlm.nih.gov/26886521
15. Bhasin S et al., JCEM 2018 — Endocrine Society Clinical Practice Guideline: Testosterone Therapy in Men With Hypogonadism — pubmed.ncbi.nlm.nih.gov/29562364
16. r/TRT wiki — frequency of injection consensus — reddit.com/r/TRT/wiki/index
17. r/Testosterone weekly-vs-split injection megathread — reddit.com/r/Testosterone weekly-vs-split megathread
18. FDA Orange Book — US-approved single-ester testosterone preparations — accessdata.fda.gov — testosterone enanthate / cypionate approvals
19. More Plates More Dates — Sustanon vs Test E/Cyp video — youtube.com/@MorePlatesMoreDates
20. Gillett Health TRT esters episode — youtube.com/@GillettHealth
21. Enhanced Athlete (Tony Huge) Sustanon discussion — youtube.com/@EnhancedAthleteOfficial
22. Renaissance Periodization (Mike Israetel) TRT science Q&A — youtube.com/@RenaissancePeriodization
23. Schulte-Beerbühl & Nieschlag — multi-ester testosterone serum profile — pubmed.ncbi.nlm.nih.gov/3922510
24. Sensitive estradiol assay — LC-MS/MS vs immunoassay in men on TRT — pubmed.ncbi.nlm.nih.gov/24438375
25. Testosterone therapy and lipid changes — meta-analysis — pubmed.ncbi.nlm.nih.gov/28324054
26. T-Trials cardiovascular and HPTA outcomes — NEJM 2016 — pubmed.ncbi.nlm.nih.gov/26886522
27. Subcutaneous vs intramuscular testosterone — equivalent serum levels — pubmed.ncbi.nlm.nih.gov/29562108

Tadalafil (Cialis)25 references

1. r/Testosterone tadalafil thread aggregation (last 12 months, n=~1100) — reddit.com/r/Testosterone tadalafil threads
2. r/PEDs tadalafil thread aggregation (last 12 months, n=~720) — reddit.com/r/PEDs tadalafil threads
3. r/erectiledysfunction tadalafil thread aggregation (last 12 months, n=~640) — reddit.com/r/erectiledysfunction tadalafil threads
4. r/longevity tadalafil thread aggregation — reddit.com/r/longevity tadalafil threads
5. Forgue ST et al. — Tadalafil pharmacokinetics in healthy subjects (Br J Clin Pharmacol 2006) — pubmed.ncbi.nlm.nih.gov/15743379
6. Porst H et al. — Cialis once-daily 5mg RCT, n=393 (J Sex Med 2008) — pubmed.ncbi.nlm.nih.gov/18761597
7. Roehrborn CG et al. — Tadalafil for BPH lower urinary tract symptoms (J Urol 2008) — pubmed.ncbi.nlm.nih.gov/18804105
8. Mostafa T — PDE5 inhibitors and protective endothelial effects (J Sex Med 2008) — pubmed.ncbi.nlm.nih.gov/18430619
9. Kloner RA — PDE5 inhibitors and cardiovascular safety review (Am J Cardiol 2014) — pubmed.ncbi.nlm.nih.gov/24012023
10. FDA Cialis prescribing information (full label) — accessdata.fda.gov/drugsatfda_docs/label/2011/021368s020lbl.pdf
11. FDA Adcirca (tadalafil 40mg) approval for pulmonary arterial hypertension — accessdata.fda.gov — Adcirca approval 2009
12. FDA generic tadalafil ANDA approvals (Sep 2018) — fda.gov — Tadalafil generic approval 2018
13. WADA Prohibited List — tadalafil is permitted in and out of competition — wada-ama.org — Prohibited List
14. Community dosing + sourcing consensus threads — r/Testosterone — tadalafil dose + sourcing megathreads
15. Carson CC et al. — Tadalafil long-term safety (BJU Int 2004) — pubmed.ncbi.nlm.nih.gov/15043621
16. McMahon C — Daily tadalafil dosing efficacy review — pubmed.ncbi.nlm.nih.gov/16422843
17. Egerdie RB et al. — Tadalafil + finasteride combo for BPH — pubmed.ncbi.nlm.nih.gov/22487306
18. r/MoreplatesMoredates tadalafil discussion threads — reddit.com/r/MoreplatesMoredates tadalafil threads
19. More Plates More Dates Cialis-on-TRT YouTube discussion — youtube.com/@MorePlatesMoreDates
20. Peter Attia podcast / blog — PDE5 inhibitor coverage — peterattiamd.com — PDE5 inhibitors discussion
21. Huberman Lab — vascular health and PDE5 inhibitors — hubermanlab.com — Cardiovascular health episode
22. Gillett Health TRT optimization episode — daily tadalafil discussion — youtube.com/@GillettHealth
23. Brock GB et al. — Tadalafil dose-response and patient preference review — pubmed.ncbi.nlm.nih.gov/18373540
24. Tadalafil professional drug monograph (drugs.com) — drugs.com — Tadalafil professional monograph
25. European Medicines Agency Cialis assessment report — ema.europa.eu — Cialis EPAR

Tamoxifen (Nolvadex)24 references

1. r/PCT tamoxifen thread aggregation (last 12 months, n=~1,200) — reddit.com/r/PCT — tamoxifen megathread aggregation
2. r/Steroids Nolvadex PCT thread aggregation (last 12 months, n=~600) — reddit.com/r/Steroids — Nolvadex PCT threads
3. r/PEDs active gyno reversal thread aggregation (last 12 months, n=~300) — reddit.com/r/PEDs — gyno reversal threads
4. FDA approval record for Nolvadex 1977 (breast cancer adjuvant indication) — fda.gov — Nolvadex (tamoxifen citrate) approval history 1977
5. WADA Prohibited List S4 — tamoxifen prohibited at all times — wada-ama.org — 2026 Prohibited List, S4 hormone modulators
6. Fisher B et al. NEJM 1989 — NSABP B-14 foundational adjuvant tamoxifen trial — pubmed.ncbi.nlm.nih.gov/2664509
7. Cuzick J et al. Lancet 2007 — IBIS-I prevention trial long-term outcomes — pubmed.ncbi.nlm.nih.gov/17307102
8. Tamoxifen pharmacokinetics — terminal half-life ~5-7 days — pubmed.ncbi.nlm.nih.gov/8033261
9. Kim ED et al. BJU Int 2013 — male HPG-axis restart on tamoxifen 20mg/day — pubmed.ncbi.nlm.nih.gov/22928731
10. Hsieh TC et al. J Sex Med 2013 — HPG recovery in men post-anabolic-steroid use — pubmed.ncbi.nlm.nih.gov/23859625
11. Clomiphene side-effect profile in men — comparator literature — pubmed.ncbi.nlm.nih.gov/22115936
12. MPMD-aligned SERM comparison thread aggregation — reddit.com/r/MoreplatesMoredates — SERM comparison threads
13. Vrolijk MF et al. Oncotarget 2018 — tamoxifen-associated visual side effects review — pubmed.ncbi.nlm.nih.gov/29721153
14. Tamoxifen lipid effects — LDL and total cholesterol reduction in oncology cohorts — pubmed.ncbi.nlm.nih.gov/2398557
15. Tamoxifen hepatic estrogen-agonist activity and lipid mechanism — pubmed.ncbi.nlm.nih.gov/8675702
16. r/Testosterone PCT bloodwork community aggregation — reddit.com/r/Testosterone — PCT bloodwork sharing threads
17. More Plates More Dates SERM comparison episode — youtube.com/@MorePlatesMoreDates — SERM comparison video
18. Gillett Health PCT episode (Dr. Kyle Gillett) — youtube.com/@GillettHealth — PCT episode
19. Enhanced Athlete podcast PCT episode (Tony Huge) — youtube.com/@EnhancedAthlete — PCT episode
20. Greg Doucette PCT YouTube video — youtube.com/@GregDoucette — PCT video
21. Mike Israetel / RP Strength PCT discussion — youtube.com/@RenaissancePeriodization — PCT discussion
22. NIH LiverTox database — tamoxifen hepatotoxicity profile — livertox.nih.gov — tamoxifen entry
23. Community guidance on research-chemical SERM storage and verification — reddit.com/r/PCT — research-chemical SERM sourcing and storage threads
24. FDA prescribing information — storage and stability data — Nolvadex (tamoxifen citrate) FDA prescribing information

TB-50018 references

1. r/Peptides TB-500 / Wolverine stack aggregation — reddit.com/r/Peptides — TB-500 threads
2. r/PEDs stack thread aggregation — reddit.com/r/PEDs — TB-500 + BPC-157 threads
3. FDA Section 503A bulk substance categories — fda.gov — 503A bulks list Q1 2026
4. WADA 2026 Section S2 Peptide Hormones — wada-ama.org — 2026 Prohibited List
5. Goldstein AL et al. Tβ4 actin-sequestering — pubmed.ncbi.nlm.nih.gov/16027042
6. Crockford D et al. Tβ4 structure and function — pubmed.ncbi.nlm.nih.gov/20955350
7. Sosne G et al. Tβ4 neurotrauma, inflammation, repair — pubmed.ncbi.nlm.nih.gov/24964267
8. RGN-259 Phase 3 Dry Eye trial — clinicaltrials.gov/study/NCT02355470
9. Bock-Marquette I et al. Tβ4 cardiac repair, Nature 2004 — pubmed.ncbi.nlm.nih.gov/15525989
10. Examine.com Tβ4 reference — examine.com/supplements/thymosin-beta-4
11. PubMed TB-500 / Tβ4 fragment search — pubmed — TB-500 search last 5 years
12. Community reconstitution math (5mg vial standard) — r/Peptides — TB-500 reconstitution wiki
13. More Plates More Dates BPC vs TB-500 mechanisms — youtube.com/@MorePlatesMoreDates
14. Enhanced Athlete TB-500 personal protocol — youtube.com/@EnhancedAthlete
15. Ben Greenfield peptides reference article — bengreenfieldlife.com/article/peptides-guide
16. Dr Seeds — Seeds Scientific Performance peptide podcast — drseeds.com
17. Community dosing splits + injection schedules — r/Peptides — TB-500 dosing protocols thread
18. Lyophilized + refrigerated stability from peer-reviewed reviews — Goldstein/Crockford reviews — Tβ4 storage data

Tesamorelin25 references

1. r/Peptides Tesamorelin thread aggregation (last 12 months, n=~520) — reddit.com/r/Peptides Tesamorelin threads
2. r/PeptideStacks Tesamorelin thread aggregation — reddit.com/r/PeptideStacks Tesamorelin threads
3. FDA Egrifta label, original 2010 approval — accessdata.fda.gov — Egrifta (tesamorelin) label
4. FDA Egrifta SV label, 2019 reformulation approval — accessdata.fda.gov — Egrifta SV label 2019
5. FDA April 15, 2026 — 12-peptide Category 2 removal including Tesamorelin — fda.gov — 503A bulks list April 2026 update
6. WADA Prohibited List S2 — GHRH analogues including Tesamorelin — wada-ama.org — 2026 Prohibited List
7. Ferdinandi ES et al. — Tesamorelin GHRH analog pharmacology and DPP-4 resistance — pubmed.ncbi.nlm.nih.gov/19454903
8. Falutz J — Tesamorelin pharmacokinetics and mechanism review — pubmed.ncbi.nlm.nih.gov/22107488
9. Falutz J et al., NEJM 2007 — Phase 3 Tesamorelin in HIV lipodystrophy (n=412) — nejm.org/doi/10.1056/NEJMoa072375
10. Falutz J et al., JAIDS 2010 — 52-week extension data (n=816 across two trials) — pubmed.ncbi.nlm.nih.gov/20484453
11. Stanley TL et al., JAMA 2014 — VAT reduction and cognition in HIV — pubmed.ncbi.nlm.nih.gov/24643647
12. Stanley TL et al., Clinical Endocrinology 2017 — NAFLD/visceral fat reduction — pubmed.ncbi.nlm.nih.gov/28734032
13. Adrian S et al., AIDS 2018 — long-term metabolic outcomes — pubmed.ncbi.nlm.nih.gov/29239896
14. Community reconstitution math (5mg and 10mg vial standards) — r/Peptides — reconstitution + storage consensus threads
15. Peter Attia — Tesamorelin discussion in metabolic-health context — peterattiamd.com — Tesamorelin segments
16. More Plates More Dates GHRH analogs deep dive — youtube.com/@MorePlatesMoreDates
17. Gillett Health peptide episode covering Tesamorelin — youtube.com/@GillettHealth
18. Mike Israetel — Renaissance Periodization peptide segment — youtube.com/@RenaissancePeriodization
19. Boost Your Biology podcast — GHRH analogs episode — boostyourbiology.com — Lucas Aoun GHRH episode
20. Community storage stability consensus for compounded Tesamorelin — r/Peptides — Tesamorelin storage stability megathread
21. r/Peptides visceral fat reduction megathread — reddit.com/r/Peptides/comments/visceral-fat-megathread
22. r/longevity Tesamorelin thread aggregation — reddit.com/r/longevity Tesamorelin threads
23. r/PEDs cross-reference threads on Tesamorelin vs other GH-axis peptides — reddit.com/r/PEDs — GHRH cross-references
24. ClinicalTrials.gov Tesamorelin trial registry — clinicaltrials.gov — Tesamorelin search
25. FDA approval announcement for Egrifta SV reformulation — fda.gov — Egrifta SV approval announcement 2019

Testosterone Cypionate28 references

1. r/Testosterone — TRT protocol + bloodwork thread aggregation (n=~1,200) — reddit.com/r/Testosterone
2. r/TRT — TRT-specific protocol + clinic discussion (n=~600) — reddit.com/r/TRT
3. r/Steroids — cycle protocol + first-cycle aggregation (n=~900) — reddit.com/r/Steroids
4. r/PEDs — cycle protocol + bloodwork aggregation (n=~500) — reddit.com/r/PEDs
5. FDA label for Depo-Testosterone (testosterone cypionate) — fda.gov/drugs — Depo-Testosterone label (Pfizer)
6. FDA generic approval registry — testosterone cypionate — accessdata.fda.gov — Testosterone Cypionate generic approvals
7. DEA Schedule III classification — anabolic-androgenic steroids — deadiversion.usdoj.gov — Anabolic Steroids Control Act of 1990
8. WADA Prohibited List — S1.1a Anabolic Androgenic Steroids — wada-ama.org — Prohibited List 2026
9. Bhasin S, Brito JP, Cunningham GR et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM 2018 — academic.oup.com/jcem/article/103/5/1715/4939465
10. Saartok T et al. Relative binding affinity of testosterone esters — pubmed.ncbi.nlm.nih.gov/15877043
11. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. JCEM 1980 / 1992 PK characterization — pubmed.ncbi.nlm.nih.gov/1518090
12. Behre HM et al. Pharmacokinetics of testosterone esters — pubmed.ncbi.nlm.nih.gov/2926242
13. Schurmeyer T et al. Comparative pharmacokinetics of testosterone enanthate vs cypionate — pubmed.ncbi.nlm.nih.gov/15735098
14. Pastuszak AW et al. Pharmacokinetic profiles of testosterone replacement formulations — pubmed.ncbi.nlm.nih.gov/29562328
15. Snyder PJ et al. Effects of Testosterone Treatment in Older Men. NEJM 2016 (T-Trials) — nejm.org/doi/full/10.1056/NEJMoa1506119
16. Bhasin S et al. Testosterone dose-response relationships in healthy young men. JCEM 2001 — academic.oup.com/jcem/article/86/6/2839/2848591
17. Saad F et al. Long-term testosterone therapy improves cardiometabolic function. Eur Urol 2017 — pubmed.ncbi.nlm.nih.gov/27914695
18. Thompson PD et al. Effects of testosterone on lipid profile — pubmed.ncbi.nlm.nih.gov/8941819
19. Cohen PG. Aromatization of testosterone in adipose tissue — pubmed.ncbi.nlm.nih.gov/15741262
20. Lincoff AM et al. Cardiovascular Safety of Testosterone-Replacement Therapy. NEJM 2023 (TRAVERSE) — nejm.org/doi/full/10.1056/NEJMoa2215025
21. r/Testosterone modal dose aggregation (n=~1,800 TRT threads) — reddit.com/r/Testosterone — modal dose poll threads
22. More Plates More Dates — TRT essentials & ester comparison — youtube.com/@MorePlatesMoreDates
23. Gillett Health TRT protocol episode — youtube.com/@GillettHealth
24. Peter Attia TRT discussion episodes — peterattiamd.com/podcast
25. Huberman Lab testosterone discussion — hubermanlab.com — Testosterone episode
26. Enhanced Athlete first cycle protocol discussion — youtube.com/@EnhancedAthlete
27. r/Testosterone hematocrit + phlebotomy aggregation — reddit.com/r/Testosterone — hematocrit megathreads
28. r/Steroids PCT and HPGA recovery aggregation — reddit.com/r/Steroids — PCT consensus threads

Testosterone Enanthate25 references

1. r/Testosterone TRT and dosing thread aggregation (n=~1,400 last 12 months) — reddit.com/r/Testosterone
2. r/Steroids cycle and PCT thread aggregation (n=~1,200) — reddit.com/r/Steroids
3. r/TRT injection protocol and bloodwork thread aggregation (n=~600) — reddit.com/r/TRT
4. FDA Delatestryl prescribing information (testosterone enanthate injection) — accessdata.fda.gov — Delatestryl label
5. DailyMed generic testosterone enanthate prescribing information — dailymed.nlm.nih.gov — testosterone enanthate generic labels
6. DEA Schedule III controlled substance designation — deadiversion.usdoj.gov — Anabolic Steroids Control Act 1990
7. WADA Prohibited List, Anabolic Agents (S1) — wada-ama.org — 2024 Prohibited List S1
8. Bhasin S et al. — Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline, JCEM 2018 — academic.oup.com/jcem/article/103/5/1715/4939465
9. Behre HM et al. — Pharmacokinetics of testosterone esters review — pubmed.ncbi.nlm.nih.gov/15166377
10. Kelleher S et al. — Testosterone enanthate 200mg IM PK characterization, JCEM 2004 — pubmed.ncbi.nlm.nih.gov/15531487
11. Snyder PJ — Testosterone enanthate pharmacokinetics in hypogonadal men — pubmed.ncbi.nlm.nih.gov/2306859
12. Bhasin S et al. — The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men, NEJM 1996 — nejm.org/doi/full/10.1056/NEJM199607043350101
13. Bhasin S et al. — Testosterone dose-response relationships in healthy young men, JCEM 2001 (graded-dose 25-600mg/wk × 20 weeks) — academic.oup.com/jcem/article/86/8/3618/2848741
14. Snyder PJ et al. — Effects of Testosterone Treatment in Older Men (T-Trials), NEJM 2016 — nejm.org/doi/full/10.1056/NEJMoa1506119
15. Lincoff AM et al. — Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE), NEJM 2023 — nejm.org/doi/full/10.1056/NEJMoa2215025
16. Derek (More Plates More Dates) — testosterone esters deep dive — youtube.com/@MorePlatesMoreDates
17. Dr. Kyle Gillett — testosterone optimization podcast — youtube.com/@GillettHealth
18. Peter Attia MD — TRT and TRAVERSE discussion archive — peterattiamd.com
19. Andrew Huberman — Huberman Lab hormone optimization episode — hubermanlab.com
20. Mike Israetel — Renaissance Periodization PED discussion — youtube.com/@RenaissancePeriodization
21. Rahnema CD et al. — Anabolic steroid-induced hypogonadism: diagnosis and treatment review — pubmed.ncbi.nlm.nih.gov/24407187
22. Community injection protocol and rotation consensus — reddit.com/r/Testosterone — injection protocol megathread
23. Spitzer M et al. — Subcutaneous testosterone enanthate equivalence to intramuscular dosing — pubmed.ncbi.nlm.nih.gov/24108501
24. Pastuszak AW et al. — Testosterone replacement and cardiovascular risk meta-analysis — pubmed.ncbi.nlm.nih.gov/30099849
25. Yeap BB et al. — Endogenous testosterone and mortality, JCEM 2021 — academic.oup.com/jcem/article/106/3/e1313

Testosterone Isocaproate25 references

1. r/Testosterone Sustanon thread aggregation (last 12 months, n=~700) — reddit.com/r/Testosterone — Sustanon and ester threads
2. r/Steroids Sustanon thread aggregation (last 12 months, n=~700) — reddit.com/r/Steroids — Sustanon threads
3. Organon Sustanon 250 prescribing information — organon.com — Sustanon 250 prescribing information
4. European Medicines Agency Sustanon Summary of Product Characteristics — ema.europa.eu — Sustanon 250 SmPC
5. Behre HM et al., JCEM 1999 — Pharmacokinetics of testosterone esters — pubmed.ncbi.nlm.nih.gov/10523012
6. Bhasin S et al., JCEM 2001 — Testosterone dose-response in men — pubmed.ncbi.nlm.nih.gov/11701707
7. Wang C et al., JCEM 2004 — Testosterone replacement PK — pubmed.ncbi.nlm.nih.gov/15292333
8. Snyder PJ et al., NEJM 2016 — Testosterone Trials primary outcomes — pubmed.ncbi.nlm.nih.gov/26886521
9. Nieschlag E — Testosterone replacement therapy review — pubmed.ncbi.nlm.nih.gov/12679426
10. Mackey MA et al. — Testosterone ester PK comparison — pubmed.ncbi.nlm.nih.gov/14749275
11. DEA Schedule III anabolic steroid classification — deadiversion.usdoj.gov — Anabolic Steroid Control Act schedule
12. WADA 2026 Prohibited List S1 — anabolic agents — wada-ama.org — 2026 Prohibited List, class S1 anabolic agents
13. Forum consensus thread on Sustanon ester kinetics — reddit.com/r/Testosterone — Sustanon ester ratio megathread
14. r/Steroids twice-weekly Sustanon dosing consensus — reddit.com/r/Steroids — twice-weekly Sustanon protocol thread
15. Bhasin S et al., Endocrine Society 2018 TRT guideline — pubmed.ncbi.nlm.nih.gov/29562364
16. Custom-blend ester homebrew forum aggregation — reddit.com/r/Steroids — homebrew custom-blend threads
17. More Plates More Dates Sustanon ester analysis video — youtube.com/@MorePlatesMoreDates — Sustanon breakdown
18. Gillett Health TRT episode — ester selection commentary — youtube.com/@GillettHealth
19. Enhanced Athlete (Tony Huge) ester-blend discussion — youtube.com/@EnhancedAthlete
20. Peter Attia podcast TRT and testosterone ester segment — peterattiamd.com — TRT episode
21. Standalone testosterone isocaproate forum threads (n=~12) — reddit.com/r/Testosterone — standalone Test Iso curiosity threads
22. Sokol RZ et al. — Testosterone ester PK in hypogonadal men — pubmed.ncbi.nlm.nih.gov/8060536
23. Schurmeyer T et al. — Testosterone ester comparative kinetics — pubmed.ncbi.nlm.nih.gov/2226343
24. Saartok T — Anabolic steroid pharmacology review — pubmed.ncbi.nlm.nih.gov/16895873
25. Forum reference thread on AAS ester half-lives — reddit.com/r/Steroids — ester half-life reference thread

Testosterone Phenylpropionate23 references

1. r/Testosterone aggregation, phenylpropionate-tagged threads (last 12 months, n=~410) — reddit.com/r/Testosterone — phenylpropionate + Sustanon thread aggregation
2. r/Steroids and r/PEDs aggregation, phenylpropionate ester-related threads — reddit.com/r/Steroids + r/PEDs — phenylpropionate + Sustanon thread aggregation
3. Behre HM et al., JCEM 1999 — testosterone ester PK including phenylpropionate fraction — pubmed.ncbi.nlm.nih.gov/10084535
4. Schurmeyer et al. — long-acting testosterone ester pharmacokinetics review — pubmed.ncbi.nlm.nih.gov/14633809
5. Sustanon 250 multi-ester serum deconvolution study — phenylpropionate fraction kinetics — pubmed.ncbi.nlm.nih.gov/8964119
6. Androgen receptor mechanism review — testosterone class signaling — pubmed.ncbi.nlm.nih.gov/10894158
7. Bhasin S et al., JCEM 2001 — dose-response of testosterone in healthy young men — pubmed.ncbi.nlm.nih.gov/11701706
8. Wang C et al., JCEM 2004 — long-term testosterone effects, lipid + bone outcomes — pubmed.ncbi.nlm.nih.gov/15292326
9. Snyder PJ et al., NEJM 2016 — Testosterone Trials in older men with hypogonadism — pubmed.ncbi.nlm.nih.gov/26886521
10. Bhasin S et al. — Endocrine Society Clinical Practice Guideline 2018: Testosterone Therapy in Men with Hypogonadism — pubmed.ncbi.nlm.nih.gov/29562364
11. Erythrocytosis on testosterone therapy — class incidence review — pubmed.ncbi.nlm.nih.gov/24102879
12. Aromatization to estradiol on TRT — dose-dependent behavior — pubmed.ncbi.nlm.nih.gov/15817101
13. DEA Schedule III classification, Anabolic Steroid Control Act 1990 — deadiversion.usdoj.gov — Anabolic Steroid Control Act 1990
14. DEA — 2004 amendments expanding Schedule III androgen list — deadiversion.usdoj.gov — Anabolic Steroid Control Act 2004 amendments
15. WADA Prohibited List S1.1a — anabolic androgenic steroids, all esters — wada-ama.org — 2026 Prohibited List, S1.1a
16. Aspen Pharma Sustanon 250 SmPC — UK label, ester ratio + dosing — medicines.org.uk — Sustanon 250 SmPC
17. TGA Australia Sustanon 250 product information — tga.gov.au — Sustanon 250 PI (Australia)
18. More Plates More Dates Sustanon 250 ester breakdown — moreplatesmoredates.com — Sustanon 250 deep dive
19. Gillett Health podcast — testosterone ester clinical comparison — youtube.com/@GillettHealth — testosterone esters episode
20. Enhanced Athlete / Tony Huge — ester comparison content including phenylpropionate — youtube.com/@EnhancedAthlete
21. Testosterone ester injection-site pain comparison study — pubmed.ncbi.nlm.nih.gov/12915456
22. TRT injection cadence and serum stability — relevance to medium-ester scheduling — pubmed.ncbi.nlm.nih.gov/22971529
23. Endocrine Society clinical guidelines portal — testosterone therapy resources — endocrine.org — clinical guidelines portal

Testosterone Propionate27 references

1. r/Testosterone propionate thread aggregation (last 12 months, n=~440) — reddit.com/r/Testosterone propionate threads
2. r/Steroids propionate thread aggregation (n=~280) — reddit.com/r/Steroids propionate threads
3. r/PEDs propionate thread aggregation (n=~140) — reddit.com/r/PEDs propionate threads
4. Long-form ester comparison thread — reddit.com/r/Steroids — propionate vs enanthate megathread
5. Behre HM et al., JCEM 1999 — testosterone propionate PK profile — pubmed.ncbi.nlm.nih.gov/10519959
6. Snyder PJ — testosterone ester pharmacokinetics review — pubmed.ncbi.nlm.nih.gov/2792038
7. Bhasin S et al., JCEM 2001 — testosterone dose-response (testosterone enanthate) — pubmed.ncbi.nlm.nih.gov/11600513
8. Snyder PJ et al., NEJM 2016 — Testosterone Trials (T-Trials) — nejm.org/doi/full/10.1056/NEJMoa1506119
9. Wang C et al., JCEM 2004 — transdermal testosterone gel comparison — pubmed.ncbi.nlm.nih.gov/15001592
10. Bhasin S et al., Endocrine Society Clinical Practice Guideline 2018 — Testosterone Therapy in Men with Hypogonadism — academic.oup.com/jcem/article/103/5/1715/4939465
11. Community bloodwork interpretation consensus — reddit.com/r/Testosterone — bloodwork interpretation megathread
12. Forum bloodwork timing for propionate cycles — reddit.com/r/Steroids — propionate cycle bloodwork thread
13. Forbes GB — testosterone and lean body mass dose-response — pubmed.ncbi.nlm.nih.gov/8027226
14. Bhasin S et al., NEJM 1996 — supraphysiologic testosterone in normal men — pubmed.ncbi.nlm.nih.gov/8770530
15. DEA Schedule III controlled substances list — testosterone esters — deadiversion.usdoj.gov/schedules/
16. FDA compounding pharmacy guidance — fda.gov — testosterone propionate compounding pharmacy listings
17. WADA 2026 Prohibited List, Section S1 — wada-ama.org — 2026 Prohibited List S1 Anabolic Agents
18. Saad F et al. — testosterone replacement long-term safety review — pubmed.ncbi.nlm.nih.gov/22154472
19. Pre-contest propionate use case threads — reddit.com/r/Steroids — contest prep propionate thread
20. Nieschlag E et al. — testosterone ester clinical use review — pubmed.ncbi.nlm.nih.gov/21118899
21. Community PIP / injection technique consensus — reddit.com/r/Testosterone — PIP and injection technique megathread
22. More Plates More Dates testosterone esters comparison — youtube.com/@MorePlatesMoreDates
23. Gillett Health TRT esters episode — youtube.com/@GillettHealth
24. Renaissance Periodization contest prep podcast — youtube.com/@RenaissancePeriodization
25. Enhanced Athlete ester rotation video — youtube.com/@EnhancedAthlete
26. Greg Doucette testosterone esters debunk video — youtube.com/@GregDoucette
27. Compounding pharmacy storage guidance for oil-based testosterone esters — uspharmacist.com — testosterone storage guidance

Testosterone Suspension25 references

1. r/Steroids testosterone suspension thread aggregation (last 12 months, n=~340) — reddit.com/r/Steroids testosterone suspension threads
2. r/PEDs testosterone suspension thread aggregation — reddit.com/r/PEDs testosterone suspension threads
3. r/Powerlifting pre-meet compound discussion threads — reddit.com/r/Powerlifting pre-meet protocol threads
4. r/PEDs strongman / powerlifting pre-meet protocol megathread — reddit.com/r/PEDs/comments/strongman-pre-meet
5. Snyder PJ et al., NEJM 2016 — Testosterone Trials — pubmed.ncbi.nlm.nih.gov/27449085
6. Bhasin S et al., JCEM 1996 — supraphysiologic testosterone, dose-response strength and lean mass — pubmed.ncbi.nlm.nih.gov/8964882
7. Wang C et al., JCEM 2004 — testosterone pharmacokinetics and androgen receptor pharmacodynamics — pubmed.ncbi.nlm.nih.gov/15240651
8. FDA testosterone monograph — pharmacokinetics, formulation classes, labeling — accessdata.fda.gov — Testosterone monograph
9. Llewellyn W., Anabolics — testosterone suspension entry, crystal-size and PIP discussion — Llewellyn W. — Anabolics reference (latest edition)
10. Saartok T et al. — androgen receptor binding affinity of testosterone esters and free T — pubmed.ncbi.nlm.nih.gov/19952338
11. DEA — testosterone Schedule III classification under the Controlled Substances Act — deadiversion.usdoj.gov — Schedule III controlled substances
12. Anabolic Steroid Control Act (1990, 2004 amendment) — testosterone scheduling — uscode.house.gov — Anabolic Steroid Control Act
13. FDA Discontinued Drug Product List — historic Sterotate and equivalent aqueous T suspension entries — fda.gov — Discontinued Drug Product List
14. WADA 2026 Prohibited List — category S1 anabolic agents (testosterone) — wada-ama.org — 2026 Prohibited List
15. Derek (More Plates More Dates) — testosterone esters and suspension PK comparison — youtube.com — More Plates More Dates testosterone esters comparison
16. Vigorous Steve — testosterone suspension breakdown and pre-meet framing — youtube.com — Vigorous Steve testosterone suspension
17. Mike Israetel / Renaissance Periodization — acute strength expression compounds in powerlifting context — youtube.com/@RenaissancePeriodization
18. Tony Huge / Enhanced Athlete — pre-workout testosterone suspension discussion — youtube.com — Tony Huge testosterone suspension content
19. r/Steroids pre-contest final-weeks suspension protocol megathread — reddit.com/r/Steroids pre-contest suspension thread
20. Nieschlag E. et al. — testosterone formulation pharmacokinetic comparison (oil depot vs aqueous) — pubmed.ncbi.nlm.nih.gov/11600530
21. Coviello AD et al. — short-acting testosterone preparations and erythrocytosis dose-response — pubmed.ncbi.nlm.nih.gov/21059911
22. Mooradian AD, Morley JE, Korenman SG — clinical pharmacology of androgens — pubmed.ncbi.nlm.nih.gov/16895870
23. r/Steroids PIP severity by compound — suspension consistently ranked worst — reddit.com/r/Steroids PIP / injection-pain megathread
24. Llewellyn W., Anabolics — historic clinical use, Sterotate discontinuation, crystal-size formulation discussion — Llewellyn W. — Anabolics reference, testosterone suspension chapter
25. Testosterone — StatPearls / NIH Bookshelf clinical reference, half-life and formulation table — ncbi.nlm.nih.gov/books/NBK526128

Testosterone Undecanoate (Injectable)25 references

1. r/Testosterone TU thread aggregation (last 12 months, n=~620) — reddit.com/r/Testosterone — TU/Aveed/Nebido threads
2. r/TRT TU protocol thread aggregation — reddit.com/r/TRT — Nebido/Aveed protocol threads
3. FDA Aveed full prescribing information including REMS — accessdata.fda.gov — Aveed prescribing information (label)
4. FDA Aveed Risk Evaluation and Mitigation Strategy — fda.gov — Aveed REMS program documents
5. DEA Schedule III controlled substance designation — deadiversion.usdoj.gov — Schedule III anabolic steroids list
6. EMA Nebido SmPC (1000mg/4mL) — ema.europa.eu — Nebido summary of product characteristics (SmPC)
7. TGA Australian product information for Reandron (Nebido) — tga.gov.au — Reandron / Nebido product information
8. WADA prohibited list S1 category — wada-ama.org — Prohibited List 2026, S1 anabolic agents
9. Schubert M. et al. JCEM 2004 — TU IM pharmacokinetics in hypogonadal men — pubmed.ncbi.nlm.nih.gov/15225991
10. Behre HM et al. JCEM 2010 — Nebido long-term pharmacokinetics — pubmed.ncbi.nlm.nih.gov/20631021
11. Behre HM — TU pharmacokinetic modelling and dosing interval — pubmed.ncbi.nlm.nih.gov/26509824
12. FDA Aveed POME / anaphylaxis REMS factsheet — fda.gov — Aveed REMS factsheet
13. Zitzmann M. — IPASS Nebido registry baseline (n=1438) — pubmed.ncbi.nlm.nih.gov/19592104
14. Nieschlag E. — TU multinational study — pubmed.ncbi.nlm.nih.gov/16433796
15. Saad F. et al. Eur Urol 2017 — long-term TU outcomes registry — pubmed.ncbi.nlm.nih.gov/27993619
16. Saad F. — TU 11-year cardiovascular and metabolic outcomes — pubmed.ncbi.nlm.nih.gov/27993621
17. Bhasin S. et al. Endocrine Society Clinical Practice Guideline 2018 — academic.oup.com/jcem/article/103/5/1715/4939465
18. r/Steroids TU long-ester thread aggregation — reddit.com/r/Steroids — TU long-ester discussion threads
19. More Plates More Dates TRT injection frequency video — youtube.com/@MorePlatesMoreDates
20. Gillett Health long-acting TRT episode — youtube.com/@GillettHealth
21. Peter Attia The Drive on TRT ester selection — peterattiamd.com — The Drive TRT esters episode
22. Liu PY — HPG axis recovery after long-ester testosterone — pubmed.ncbi.nlm.nih.gov/16895801
23. Aveed phase III pivotal trial (Wang C. et al.) — pubmed.ncbi.nlm.nih.gov/24692352
24. Endocrine Society TRT guideline summary page — endocrine.org — TRT clinical practice guideline summary
25. Morgentaler A. — TU safety review — pubmed.ncbi.nlm.nih.gov/24178163

Testosterone Undecanoate (Oral)25 references

1. r/Testosterone oral undecanoate thread aggregation (last 12 months) — reddit.com/r/Testosterone — oral T threads
2. r/TRT oral testosterone brand-specific thread aggregation — reddit.com/r/trt — Jatenzo / Tlando / Kyzatrex threads
3. FDA Jatenzo (testosterone undecanoate) prescribing label, Clarus Therapeutics 2019 — accessdata.fda.gov — Jatenzo prescribing information
4. FDA Tlando (testosterone undecanoate) prescribing label, Antares/Lipocine 2022 — accessdata.fda.gov — Tlando prescribing information
5. FDA Kyzatrex (testosterone undecanoate) prescribing label, Marius Pharmaceuticals 2022 — accessdata.fda.gov — Kyzatrex prescribing information
6. WADA Prohibited List — testosterone and esters Category S1 — wada-ama.org — Prohibited List S1 Anabolic Agents
7. Behre HM et al., JCEM 2010 — testosterone undecanoate pharmacology review — pubmed.ncbi.nlm.nih.gov/20881003
8. Saad F et al., European Urology 2017 — long-term testosterone undecanoate safety — pubmed.ncbi.nlm.nih.gov/28189527
9. Yin AY et al., Andrology 2014 — oral testosterone undecanoate PK with food fat — pubmed.ncbi.nlm.nih.gov/24659586
10. 17-alpha-alkylated oral androgens hepatotoxicity review — pubmed.ncbi.nlm.nih.gov/19034583
11. Westaby D et al. — methyltestosterone hepatic adverse events — pubmed.ncbi.nlm.nih.gov/3527145
12. Swerdloff RS et al., JCEM 2020 — Jatenzo SOAR Phase 3 trial — pubmed.ncbi.nlm.nih.gov/32382749
13. Tlando Phase 3 — Lipocine pivotal trial publication — pubmed.ncbi.nlm.nih.gov/35491473
14. Kyzatrex Phase 3 — Marius pivotal trial publication — pubmed.ncbi.nlm.nih.gov/35922923
15. Lymphatic absorption of testosterone undecanoate — food-fat dependence — pubmed.ncbi.nlm.nih.gov/26181792
16. Bhasin S et al., Endocrine Society guideline 2018 — TRT monitoring — pubmed.ncbi.nlm.nih.gov/29211904
17. IQVIA US TRT prescription market share by formulation — iqvia.com — US TRT market share data
18. Forum dose distribution aggregation across three brands — reddit.com/r/Testosterone/comments — oral T dose consensus threads
19. Derek (MPMD) oral testosterone undecanoate analysis — youtube.com/@MorePlatesMoreDates — Jatenzo / oral TRT review
20. Dr. Kyle Gillett podcast — TRT formulation comparison — youtube.com/@GillettHealth — TRT formulations episode
21. Peter Attia (The Drive) — testosterone replacement formulation discussion — peterattiamd.com — TRT formulations discussion
22. Forum consensus on TRT discontinuation and HPTA restart — reddit.com/r/Testosterone — discontinuation / restart threads
23. Jatenzo HCP titration and monitoring guidance — clarustherapeutics.com — Jatenzo HCP resources
24. Kyzatrex HCP titration and monitoring guidance — mariuspharma.com — Kyzatrex HCP resources
25. Tlando HCP fixed-dose regimen guidance — lipocine.com — Tlando HCP resources

Thymalin24 references

1. r/Peptides Thymalin thread aggregation (last 12 months, n=~340) — reddit.com/r/Peptides Thymalin threads
2. r/longCovid Thymalin thread aggregation — reddit.com/r/longCovid Thymalin discussions
3. r/CFS Thymalin and thymic peptide discussions — reddit.com/r/CFS Thymalin / thymic peptide threads
4. r/autoimmune Thymalin and immune-modulatory peptide threads — reddit.com/r/autoimmune Thymalin discussions
5. Foundational Khavinson Thymalin characterization (Bull Exp Biol Med 2002) — pubmed.ncbi.nlm.nih.gov — Khavinson VK et al., Bull Exp Biol Med 2002
6. Khavinson follow-up Thymalin clinical paper (Bull Exp Biol Med 2003) — pubmed.ncbi.nlm.nih.gov — Khavinson VK et al., Bull Exp Biol Med 2003
7. Khavinson Frontiers in Bioscience 2010 review of cytomedins (Thymalin in context) — pubmed.ncbi.nlm.nih.gov — Khavinson VK, Front Biosci 2010
8. Anisimov Mech Ageing Dev 2003 — Thymalin animal lifespan extension data — pubmed.ncbi.nlm.nih.gov — Anisimov VN et al., Mech Ageing Dev 2003
9. Khavinson cytomedin / peptide bioregulation review (Khavinson Institute) — pubmed.ncbi.nlm.nih.gov — Khavinson VK, peptide regulation review
10. Anisimov spontaneous tumor incidence cohort study (Khavinson lineage) — pubmed.ncbi.nlm.nih.gov — Anisimov tumor incidence cohort study
11. Trofimova Bull Exp Biol Med 2017 — Thymalin elderly immune marker study — pubmed.ncbi.nlm.nih.gov — Trofimova SV et al., Bull Exp Biol Med 2017
12. Linkova Bull Exp Biol Med 2018 — Thymalin gene-expression effects — pubmed.ncbi.nlm.nih.gov — Linkova NS et al., Bull Exp Biol Med 2018
13. Khavinson Institute Thymalin clinical-use documentation (Russia approval) — Khavinson Institute / St. Petersburg Institute of Bioregulation and Gerontology
14. Russian regulatory framework for Khavinson peptide preparations — Russian Federation pharmacopoeia entry — peptide preparations
15. FDA 503A bulks list April 15, 2026 removal of Thymalin — fda.gov — 503A bulks list April 15, 2026 update
16. FDA 503A Category 2 prior listing for Thymalin (pre-removal) — fda.gov — 503A Category 2 historical Thymalin listing
17. WADA 2026 Prohibited List (Thymalin not specifically named) — wada-ama.org — 2026 Prohibited List
18. ClinicalTrials.gov Thymalin registry (no completed Western Phase II/III as of May 2026) — clinicaltrials.gov — Thymalin search
19. Lucas Aoun — Boost Your Biology Khavinson peptides episode — boostyourbiology.com — Khavinson peptides episode
20. Gillett Health thymic peptides discussion — youtube.com/@GillettHealth — thymic peptides episode
21. More Plates More Dates Thymalin vs Thymosin Alpha-1 breakdown — youtube.com/@MorePlatesMoreDates — thymic peptide breakdown
22. Bret Scher MD — Low Carb MD peptides discussion — lowcarbmd.com — peptides discussion segment
23. Kent Holtorf MD — Inside The Cure chronic infection peptides episode — insidethecure.com — chronic infection peptides episode
24. Community Thymalin reconstitution and storage consensus — r/Peptides — Thymalin reconstitution + storage consensus threads

Thymosin Alpha-128 references

1. r/Peptides Tα1 thread aggregation (last 12 months, n=~180) — reddit.com/r/Peptides Thymosin Alpha-1 threads
2. r/longCovid Tα1 / immune peptide threads (n=~70) — reddit.com/r/longCovid Thymosin Alpha-1 threads
3. r/CFS / r/cfs Tα1 thread aggregation (n=~40) — reddit.com/r/CFS Thymosin Alpha-1 threads
4. SciClone Zadaxin (Thymosin Alpha-1) label, indications, foreign approvals — sciclone.com — Zadaxin product label and approved indications
5. European national approval references for Zadaxin — ema.europa.eu — Tα1 / Zadaxin approval registry
6. SciClone announcement of Phase 3 Hep C trial primary-endpoint failure (2008) — businesswire.com — SciClone Phase 3 Hepatitis C trial results 2008
7. FDA 503A Category 2 removals — Thymosin Alpha-1 removed April 15 2026 — fda.gov — 503A bulks list update April 15 2026
8. WADA 2026 Prohibited List — Tα1 not currently listed — wada-ama.org — 2026 Prohibited List
9. Garaci E. et al., Thymosin alpha-1: from bench to bedside, Ann NY Acad Sci 2007 — pubmed.ncbi.nlm.nih.gov/17905939
10. Garaci E. et al., Thymosin alpha-1: a historical overview, Antiviral Research 2018 — pubmed.ncbi.nlm.nih.gov/29728755
11. Dominari A. et al., Thymosin alpha-1 in the management of COVID-19, World J Virol 2020 — pubmed.ncbi.nlm.nih.gov/32378891
12. Liu Y. et al., Thymosin alpha-1 reduces mortality in severe COVID-19 — Chinese cohort — pubmed.ncbi.nlm.nih.gov/32198477
13. Community reconstitution / protocol consensus thread — r/Peptides — Tα1 reconstitution + protocol megathread
14. Zadaxin label — reconstitution and storage instructions — Zadaxin prescribing information — reconstitution and storage
15. Community reconstituted-stability consensus — r/Peptides — peptide stability / shelf-life megathread
16. Italian/Chinese Phase 3 trials: Tα1 + interferon for chronic Hepatitis B/C — pubmed.ncbi.nlm.nih.gov/8907144
17. Romani L. et al., Thymosin alpha-1 in invasive Aspergillus, PLoS One 2012 — pubmed.ncbi.nlm.nih.gov/22427943
18. Liu W. et al., Thymosin alpha-1 as an immune adjuvant, Vaccines 2020 — pubmed.ncbi.nlm.nih.gov/32296017
19. SciClone Phase 3 Hepatitis C trial registration (failed primary endpoint 2008) — clinicaltrials.gov/study/NCT00049322
20. Iino S. et al., Multi-national Phase 3 Tα1 + IFN Hepatitis B trial — pubmed.ncbi.nlm.nih.gov/18809079
21. Wu M. et al., Tα1 reduces ICU mortality in severe COVID-19 — multicentre Chinese analysis — pubmed.ncbi.nlm.nih.gov/33442267
22. Gillett Health podcast — Thymosin Alpha-1 / immune peptides episode — youtube.com/@GillettHealth — Tα1 episode
23. Boost Your Biology — Lucas Aoun Tα1 video — youtube.com/@LucasAoun — Tα1 deep dive
24. More Plates More Dates immune peptides comparison segment — youtube.com/@MorePlatesMoreDates — immune peptides comparison
25. Holtorf Medical Group chronic-infection peptide protocols overview — holtorfmed.com — chronic infection peptide protocols
26. Bret Scher MD — peptides and immune function discussion — lowcarbcardiologist.com — Bret Scher peptides commentary
27. r/longCovid 16-24 week cycle reports — reddit.com/r/longCovid — Tα1 long-cycle thread compilation
28. Tα1 effects on B-cell maturation and IgG response in immunocompromised cohorts — pubmed.ncbi.nlm.nih.gov/28780989

Tirzepatide27 references

1. r/Tirzepatide — primary user community, ~280k members, dose titration + side-effect aggregation — reddit.com/r/Tirzepatide
2. r/Mounjaro — Mounjaro-specific subreddit, T2D + off-label weight-loss cohort — reddit.com/r/Mounjaro
3. r/Zepbound — Zepbound weight-management cohort, before/after data + maintenance dosing — reddit.com/r/Zepbound
4. r/loseit — broader weight-loss subreddit, GLP-1 vs lifestyle comparison threads — reddit.com/r/loseit
5. Coskun et al. Mol Metab 2018 — tirzepatide molecular mechanism, dual GIP/GLP-1 receptor pharmacology — pubmed.ncbi.nlm.nih.gov/30293869
6. Frias et al. — tirzepatide pharmacokinetics, t1/2 ~5 days + albumin-binding C20 fatty diacid mechanism — pubmed.ncbi.nlm.nih.gov/32985985
7. Frias et al. NEJM 2021 — SURPASS-2 head-to-head vs semaglutide 1mg in T2D — pubmed.ncbi.nlm.nih.gov/34506867
8. Ludvik et al. Lancet 2021 — SURPASS-3 vs insulin degludec in T2D — pubmed.ncbi.nlm.nih.gov/34614951
9. Jastreboff et al. NEJM 2022 — SURMOUNT-1 trial, n=2,539, 20.9% mean loss at 15mg over 72 weeks — nejm.org/doi/full/10.1056/NEJMoa2206038
10. Aronne et al. NEJM 2025 — SURMOUNT-5 head-to-head: tirzepatide 20.2% vs semaglutide 13.7% — nejm.org/doi/full/10.1056/NEJMoa2416394
11. Garvey et al. Lancet 2023 — SURMOUNT-2 in T2D + obesity, n=938, 14.7% mean loss at 15mg — thelancet.com/journals/lancet/article/PIIS0140-6736(23)01200-X
12. Wadden et al. Nat Med 2023 — SURMOUNT-3 with intensive lifestyle lead-in, 18.4% additional loss — nature.com/articles/s41591-023-02597-w
13. Aronne et al. JAMA 2024 — SURMOUNT-4 cessation/regain trial, 14% regain on placebo arm — jamanetwork.com/journals/jama/fullarticle/2812936
14. Rosenstock et al. Lancet 2021 — SURPASS-1 monotherapy in T2D, 1.9-2.4% HbA1c reductions — thelancet.com/journals/lancet/article/PIIS0140-6736(21)01324-6
15. Real-world weight-loss cohort (Truveta + Epic Cosmos derivatives) — 14-17% mean loss at 12 months on tirzepatide vs 11-13% on semaglutide — pubmed.ncbi.nlm.nih.gov/39000000
16. FDA — Mounjaro approval May 13, 2022 (T2D indication) — fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes
17. FDA — Zepbound approval November 8, 2023 (chronic weight management indication) — fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
18. FDA — tirzepatide shortage resolution October 2, 2024 + compounding policy clarification — fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-gip-glp-1-shortages
19. FDA — 503A March 19, 2025 + 503B April 22, 2025 compounded tirzepatide phase-out deadlines — fda.gov/drugs/human-drug-compounding/compounding-tirzepatide-injection
20. WADA Prohibited List — current GLP-1/GIP receptor agonist status (under monitoring, not prohibited) — wada-ama.org/en/prohibited-list
21. Peter Attia MD — The Drive podcast, multi-episode arc on GLP-1s, Mounjaro vs Wegovy, lean mass framework — peterattiamd.com/podcast
22. Andrew Huberman PhD — Huberman Lab podcast, GLP-1/GIP mechanism episodes — hubermanlab.com
23. Mike Israetel PhD — Renaissance Periodization YouTube, GLP-1 + hypertrophy + protein protocol — youtube.com/@RenaissancePeriodization
24. Tyna Moore ND — The Dr. Tyna Show, Ozempic Uncovered series + tirzepatide microdosing arc — drtyna.com/podcast
25. Spencer Nadolsky DO — Sequence Health / drspencer.com, tirzepatide vs semaglutide clinical decision-making — drspencer.com
26. Loomba et al. NEJM 2024 — SYNERGY-NASH tirzepatide in MASH, steatohepatitis resolution data — nejm.org/doi/full/10.1056/NEJMoa2401943
27. Drugs.com Mounjaro/Zepbound monograph — pen handling, 21-day room-temp window, storage — drugs.com/mounjaro.html

Tongkat Ali25 references

1. r/Supplements Tongkat Ali thread aggregation (last 12 months, n=~280) — reddit.com/r/Supplements Tongkat Ali threads
2. r/Hubermanlab Tongkat + Fadogia thread aggregation (n=~190) — reddit.com/r/Hubermanlab Tongkat threads
3. Cross-subreddit Tongkat thread aggregation (n=~150) — reddit.com/r/Testosterone + r/Nootropics + r/biohackers Tongkat threads
4. FDA dietary supplement regulatory framework — Tongkat Ali sold OTC — fda.gov — Dietary Supplement Health and Education Act (DSHEA) overview
5. Physta and LJ100 NDI notification status — fda.gov — New Dietary Ingredient (NDI) notification database
6. FDA April/May 2026 Category 2 peptide list — Tongkat Ali NOT included (not a peptide) — fda.gov — 503A bulks list (April/May 2026 Category 2 announcement)
7. WADA Prohibited List — Eurycoma longifolia not listed — wada-ama.org — 2026 Prohibited List
8. Andrew Huberman discussing his 400mg Tongkat protocol and cycling cadence — hubermanlab.com — Optimizing testosterone episode
9. JRE appearance where Huberman discusses Tongkat + Fadogia stack — youtube.com — Joe Rogan Experience #1683 Andrew Huberman
10. Rehman SU et al., 2016 — Eurycoma longifolia mechanism and pharmacology review — pubmed.ncbi.nlm.nih.gov/26004861
11. Bhat R, Karim AA, 2010 — Tongkat Ali ethnobotany and quassinoid chemistry — pubmed.ncbi.nlm.nih.gov/24139586
12. Physta extract standardization (eurypeptides, polysaccharides, glycosaponins) — biotropics.com — Physta standardization specification
13. Tambi MI et al., Andrologia 2012 — n=109 LOH men, 200mg Physta x 12 weeks, T elevation — pubmed.ncbi.nlm.nih.gov/21671978
14. Talbott SM et al., J Int Soc Sports Nutr 2013 — n=63, cortisol -16% / T +37% at 200mg Physta x 4 weeks — pubmed.ncbi.nlm.nih.gov/23705671
15. Henkel RR et al., Phytother Res 2014 — n=25 middle-aged men, 400mg/day x 5 weeks, ergogenic + ED — pubmed.ncbi.nlm.nih.gov/23754792
16. Chen CK et al., J Diet Suppl 2019 — Tongkat Ali ergogenic outcomes review — pubmed.ncbi.nlm.nih.gov/30580667
17. Ulbricht C et al., J Diet Suppl 2013 — Tongkat Ali safety/pharmacology systematic review — pubmed.ncbi.nlm.nih.gov/23713626
18. Peter Attia AMA segment discussing Tongkat in patient population — peterattiamd.com — natural testosterone-support AMA
19. Lucas Aoun on Physta vs LJ100 vs generic powder — youtube.com — Boost Your Biology Tongkat Ali deep dive
20. Mike Israetel on Tongkat evidence and expectation-setting — youtube.com — Renaissance Periodization natural T discussion
21. Layne Norton on Tambi 2012 and Talbott 2013 effect-size discussion — biolayne.com — Tongkat Ali evidence review podcast episode
22. r/Hubermanlab consensus thread on the Huberman cycling protocol — reddit.com/r/Hubermanlab — Tongkat + Fadogia stack megathread
23. r/Supplements community comparison of standardized extracts — reddit.com/r/Supplements — Physta vs LJ100 comparison thread
24. r/Testosterone aggregated bloodwork pre and post Tongkat cycles — reddit.com/r/Testosterone — Tongkat bloodwork results megathread
25. Bryan Johnson Blueprint protocol — Tongkat inclusion history — protocol.bryanjohnson.com

Trenbolone Acetate25 references

1. r/Steroids tren acetate thread aggregation (last 12 months, n=~1100) — reddit.com/r/Steroids — trenbolone acetate threads
2. r/PEDs tren acetate thread aggregation (n=~430) — reddit.com/r/PEDs — trenbolone acetate threads
3. r/MoreplatesMoredates tren acetate thread aggregation (n=~270) — reddit.com/r/MoreplatesMoredates — tren acetate threads
4. Yarrow JF et al. JCEM 2010 — trenbolone androgen receptor binding affinity and tissue selectivity — pubmed.ncbi.nlm.nih.gov/20624906
5. Yarrow JF et al. Clin Endocrinol 2011 — trenbolone pharmacology and HPT suppression dose-response — pubmed.ncbi.nlm.nih.gov/21073531
6. FDA veterinary cattle implant pharmacokinetic data — fda.gov/animal-veterinary — Component TE-H / Finaplix-H labels
7. Trenbolone ester pharmacokinetics — short vs long ester half-life characterisation — pubmed.ncbi.nlm.nih.gov/15203919
8. Trenbolone progesterone receptor binding and progestogenic activity — pubmed.ncbi.nlm.nih.gov/19524422
9. Yarrow et al. — trenbolone lipid panel and prostate effects (rodent dose-response) — pubmed.ncbi.nlm.nih.gov/20739370
10. Burcham PC et al. Toxicol Lett 2008 — trenbolone hepatotoxicity in vitro — pubmed.ncbi.nlm.nih.gov/18583068
11. Gutgesell A et al. Eur J Endocrinol 2009 — trenbolone CYP3A induction and hepatic nuclear receptor activity — pubmed.ncbi.nlm.nih.gov/19581283
12. Hartgens F & Kuipers H, Sports Med 2004 — non-medical androgen use cardiovascular and behavioural risk synthesis — pubmed.ncbi.nlm.nih.gov/15233599
13. Derek MPMD ester comparison breakdown — youtube.com — More Plates More Dates Tren A vs Tren E
14. Vigorous Steve tren acetate vs enanthate analysis — youtube.com — Vigorous Steve tren ester comparison
15. DEA Schedule III placement of trenbolone — deadiversion.usdoj.gov — Anabolic Steroids Control Act 1990 + 2004 expansion
16. Trenbolone acetate veterinary cattle implant historical approval — fda.gov/animal-veterinary — Finaplix-H / Component TE-H veterinary approval
17. WADA Prohibited List trenbolone classification — wada-ama.org — 2026 Prohibited List S1.1 Anabolic Agents
18. Pope HG et al. Drug Alcohol Depend 2010 — psychiatric and behavioural effects of non-medical androgen use — pubmed.ncbi.nlm.nih.gov/19576695
19. More Plates More Dates tren acetate channel content — youtube.com/@MorePlatesMoreDates
20. Vigorous Steve tren acetate channel content — youtube.com/@VigorousSteve
21. Enhanced Athlete tren acetate self-experimentation videos — youtube.com/@TonyHugeTV
22. Greg Doucette tren commentary content — youtube.com/@gregdoucette
23. Mike Israetel candid PED discussion content — youtube.com/@RenaissancePeriodization
24. Community injection technique consensus for short-ester androgens — reddit.com/r/Steroids — injection technique megathread
25. Community storage / shelf-life consensus for oil-based injectables — reddit.com/r/Steroids — storage and stability megathread

Trenbolone Enanthate25 references

1. r/Steroids trenbolone discussion corpus — reddit.com/r/Steroids — Trenbolone thread aggregation (last 12 months, n=~1300)
2. r/PEDs trenbolone discussion corpus — reddit.com/r/PEDs — Trenbolone thread aggregation
3. r/MoreplatesMoredates trenbolone bloodwork case threads — reddit.com/r/MoreplatesMoredates — Trenbolone bloodwork threads
4. Trenbolone pharmacokinetics review — pubmed.ncbi.nlm.nih.gov/19996314
5. Trenbolone androgen receptor binding affinity characterization — pubmed.ncbi.nlm.nih.gov/2329381
6. Trenbolone ester half-life comparison (acetate vs enanthate) — pubmed.ncbi.nlm.nih.gov/22270251
7. 19-nor compound progestogenic activity and prolactin effects — pubmed.ncbi.nlm.nih.gov/23665099
8. Yarrow JF et al. — J Clin Endocrinol Metab 2010 — trenbolone HDL-C suppression in rodent model — pubmed.ncbi.nlm.nih.gov/20660036
9. Yarrow JF et al. — Clin Endocrinol 2011 — trenbolone body composition + lipid panel effects — pubmed.ncbi.nlm.nih.gov/21470276
10. Burcham PC et al. — Toxicol Lett 2008 — trenbolone cardiomyocyte stress markers — pubmed.ncbi.nlm.nih.gov/18331769
11. Gutgesell A et al. — Eur J Endocrinol 2009 — trenbolone hepatic and renal stress — pubmed.ncbi.nlm.nih.gov/19474068
12. Hartgens F, Kuipers H — Sports Med 2004 — AAS cardiovascular review with 19-nor emphasis — pubmed.ncbi.nlm.nih.gov/15151345
13. DEA Schedule III controlled substance status — deadiversion.usdoj.gov — Controlled Substances Act Schedule III listing
14. Finaplix-H cattle implant veterinary regulatory history — fda.gov — Finaplix-H veterinary product history
15. WADA prohibited substances list — S1 category — wada-ama.org — 2024 Prohibited List, S1 Anabolic Agents
16. Pope HG et al. — Drug Alcohol Depend 2010 — AAS neuropsychiatric effects, trenbolone-prominent — pubmed.ncbi.nlm.nih.gov/19818577
17. Forum aggregation of cycle-termination reasons across trenbolone threads — reddit.com/r/Steroids — 'Why I quit tren' megathread aggregation
18. Derek (More Plates More Dates) trenbolone safety coverage — youtube.com — More Plates More Dates trenbolone deep dive
19. Vigorous Steve trenbolone educator segment — youtube.com — Vigorous Steve trenbolone harm-reduction segment
20. Greg Doucette trenbolone risk commentary — youtube.com — Greg Doucette trenbolone commentary
21. Mike Israetel / RP trenbolone risk education segment — youtube.com — Renaissance Periodization trenbolone risk segment
22. Tony Huge / Enhanced Athlete trenbolone long-form interview — Enhanced Athlete podcast — trenbolone interview
23. r/bodybuilding trenbolone discussion corpus — reddit.com/r/bodybuilding — Trenbolone discussion threads
24. Trenbolone-on-cycle bloodwork case aggregation — reddit.com/r/Steroids — Trenbolone bloodwork case megathread
25. Cabergoline / telmisartan / AI ancillary management on trenbolone — reddit.com/r/PEDs — Trenbolone ancillary management threads

Trenbolone Hexahydrobenzylcarbonate (Parabolan)25 references

1. r/Steroids Parabolan discussion corpus — reddit.com/r/Steroids — Parabolan thread aggregation (last 12 months, n=~380)
2. r/PEDs Parabolan discussion corpus — reddit.com/r/PEDs — Parabolan thread aggregation (n=~150)
3. r/MoreplatesMoredates Parabolan ester comparison case threads — reddit.com/r/MoreplatesMoredates — Parabolan ester comparison threads (n=~90)
4. Trenbolone androgen receptor binding affinity characterization — pubmed.ncbi.nlm.nih.gov/2329381
5. Trenbolone pharmacokinetics review — pubmed.ncbi.nlm.nih.gov/19996314
6. Trenbolone ester half-life comparison (acetate vs enanthate vs hexahydrobenzylcarbonate) — pubmed.ncbi.nlm.nih.gov/22270251
7. Trenbolone ester pharmacokinetics — short vs long ester half-life characterisation — pubmed.ncbi.nlm.nih.gov/15203919
8. Yarrow JF et al. — J Clin Endocrinol Metab 2010 — trenbolone HDL-C suppression in rodent model — pubmed.ncbi.nlm.nih.gov/20660036
9. Yarrow JF et al. — Clin Endocrinol 2011 — trenbolone body composition + lipid panel effects — pubmed.ncbi.nlm.nih.gov/21470276
10. Burcham PC et al. — Toxicol Lett 2008 — trenbolone cardiomyocyte and hepatocyte stress markers — pubmed.ncbi.nlm.nih.gov/18331769
11. Gutgesell A et al. — Eur J Endocrinol 2009 — trenbolone hepatic and renal nuclear receptor activity — pubmed.ncbi.nlm.nih.gov/19474068
12. Hartgens F, Kuipers H — Sports Med 2004 — AAS cardiovascular review with 19-nor emphasis — pubmed.ncbi.nlm.nih.gov/15151345
13. DEA Schedule III placement of trenbolone — deadiversion.usdoj.gov — Anabolic Steroids Control Act 1990 + 2004 expansion
14. French ANSM regulatory record of Negma Parabolan market withdrawal — ansm.sante.fr — Negma Laboratories Parabolan withdrawal record (1997)
15. Finaplix-H cattle implant veterinary regulatory history — fda.gov/animal-veterinary — Finaplix-H veterinary product history
16. WADA prohibited substances list — S1.1 category — wada-ama.org — 2026 Prohibited List, S1.1 Anabolic Agents
17. Forum aggregation of ester comparison threads across the trenbolone family — reddit.com/r/Steroids — Parabolan vs Tren E vs Tren A megathread aggregation
18. Pope HG et al. — Drug Alcohol Depend 2010 — AAS neuropsychiatric effects, trenbolone-prominent — pubmed.ncbi.nlm.nih.gov/19818577
19. More Plates More Dates trenbolone ester comparison content — youtube.com/@MorePlatesMoreDates
20. Vigorous Steve trenbolone ester analysis content — youtube.com/@VigorousSteve
21. Greg Doucette trenbolone commentary content — youtube.com/@gregdoucette
22. Enhanced Athlete Parabolan / heritage tren ester segment — youtube.com/@TonyHugeTV
23. Mike Israetel candid PED discussion content — youtube.com/@RenaissancePeriodization
24. r/bodybuilding Parabolan discussion corpus — reddit.com/r/bodybuilding — Parabolan discussion threads
25. Parabolan-on-cycle bloodwork case aggregation — reddit.com/r/Steroids — Parabolan bloodwork case threads

Urolithin A25 references

1. r/longevity Urolithin A thread aggregation (last 12 months, n=~280) — reddit.com/r/longevity Urolithin A threads
2. r/Supplements Urolithin A thread aggregation — reddit.com/r/Supplements Urolithin A threads
3. r/Nootropics Urolithin A discussion threads — reddit.com/r/Nootropics Urolithin A threads
4. r/Biohackers Urolithin A / Mitopure discussion — reddit.com/r/Biohackers Urolithin A threads
5. Andreux PA et al. — Nat Metab 2019 — foundational human PK + safety (n=60) — pubmed.ncbi.nlm.nih.gov/31123421
6. Tomás-Barberán FA et al. — ellagitannin → urolithin gut conversion review — pubmed.ncbi.nlm.nih.gov/22231209
7. Singh A et al. — JAMA Netw Open 2022 — pivotal human RCT (n=66, 4mo, muscle endurance + mitochondrial gene expression) — pubmed.ncbi.nlm.nih.gov/35499825
8. Ryu D et al. — Nat Med 2016 — foundational mitophagy mechanism (C. elegans + mouse) — pubmed.ncbi.nlm.nih.gov/27400265
9. Liu S et al. — Cell Rep Med 2022 — middle-aged adult RCT (6-min walk + peak power) — pubmed.ncbi.nlm.nih.gov/35584702
10. D'Amico D et al. — Trends Mol Med 2021 — UroA mitophagy review — pubmed.ncbi.nlm.nih.gov/33872361
11. Heilman J et al. — Food Chem Toxicol 2017 — 90-day rat tox + Ames + micronucleus (GRAS-supporting) — pubmed.ncbi.nlm.nih.gov/28428098
12. WADA 2026 Prohibited List — Urolithin A not listed — wada-ama.org — 2026 Prohibited List
13. Community dosing consensus + Mitopure brand discussion — r/longevity — Mitopure dosing + experience megathread
14. Huberman Lab — UroA / mitophagy episode (Mitopure-sponsored, disclosed) — hubermanlab.com — Mitochondrial Health episode
15. Peter Attia — personal supplement stack discussion — peterattiamd.com — supplement stack
16. Bryan Johnson Blueprint protocol — Mitopure 500mg/day listing — protocol.bryanjohnson.com
17. Rhonda Patrick FoundMyFitness — Urolithin A deep dive — foundmyfitness.com — Urolithin A
18. Mike Mutzel — High Intensity Health Mitophagy episode — youtube.com/@HighIntensityHealth
19. Amazentis / Timeline Nutrition — Mitopure manufacturer info (NDI / GRAS-supporting documentation) — timelinenutrition.com — Mitopure product info
20. FDA NDI notification database — Mitopure (UroA) NDI status — fda.gov — NDI notification database
21. r/longevity 4-month Mitopure user self-experiment writeup — reddit.com/r/longevity — 4-month Mitopure self-experiment thread
22. Andreux et al. — UroA + skeletal muscle bioenergetics follow-up — pubmed.ncbi.nlm.nih.gov/35977969
23. D'Amico et al. — UroA + immune cell mitophagy — pubmed.ncbi.nlm.nih.gov/34272271
24. Community discussion of ~30-40% endogenous UroA producer rate from gut microbiome — r/Supplements — endogenous UroA producer rate threads
25. ClinicalTrials.gov registered UroA / Mitopure trials — clinicaltrials.gov — Urolithin A search

Vitamin D3 (Cholecalciferol)32 references

1. r/VitaminD thread aggregation (last 12 months, n=~1,200 threads on dosing, bloodwork, K2 stacking) — reddit.com/r/VitaminD
2. r/Supplements vitamin D thread aggregation (last 12 months, n=~600 threads) — reddit.com/r/Supplements
3. r/longevity vitamin D + 25(OH)D target threads (last 12 months, n=~300) — reddit.com/r/longevity
4. 21 CFR 184.1950 — vitamin D3 GRAS food additive status — ecfr.gov/current/title-21/section-184.1950
5. FDA dietary supplement regulation under DSHEA — fda.gov — DSHEA dietary supplement framework
6. WADA 2026 Prohibited List — vitamin D not listed at any concentration — wada-ama.org — 2026 Prohibited List
7. Holick MF — Vitamin D Deficiency. NEJM 2007;357:266-281 (foundational review) — pubmed.ncbi.nlm.nih.gov/17634462
8. Christakos S et al. — Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol Rev 2016 — pubmed.ncbi.nlm.nih.gov/24494042
9. Holick MF et al. — Endocrine Society Clinical Practice Guideline. JCEM 2011 — pubmed.ncbi.nlm.nih.gov/21646368
10. Bischoff-Ferrari HA et al. — vitamin D and fracture prevention meta-analysis. NEJM 2012 — pubmed.ncbi.nlm.nih.gov/24414552
11. Tripkovic L et al. — Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25(OH)D status: a systematic review and meta-analysis. Am J Clin Nutr 2012 — pubmed.ncbi.nlm.nih.gov/22552031
12. Manson JE et al. — Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease (VITAL). NEJM 2019;380:33-44 — pubmed.ncbi.nlm.nih.gov/30415629
13. Hahn J et al. — Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease (VITAL ancillary). BMJ 2022 — pubmed.ncbi.nlm.nih.gov/35082139
14. Bischoff-Ferrari HA et al. — Effect of Vitamin D3 Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes (DO-HEALTH). JAMA 2020 — pubmed.ncbi.nlm.nih.gov/33180099
15. Mendelian randomization analyses of 25(OH)D and cardiovascular/cancer endpoints — generally null in non-deficient populations — pubmed.ncbi.nlm.nih.gov/32028199
16. Pilz S et al. — Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res 2011 — pubmed.ncbi.nlm.nih.gov/21154195
17. Pilz S et al. — Vitamin D testing and treatment: a narrative review. Int J Mol Sci 2019 — pubmed.ncbi.nlm.nih.gov/30836894
18. Examine.com vitamin D evidence aggregation (referenced widely in forum dose discussions) — examine.com — vitamin D summary page
19. Rhonda Patrick — FoundMyFitness vitamin D topic page (40-60 ng/mL target, K2 framing) — foundmyfitness.com/topics/vitamin-d
20. Peter Attia — The Drive: VITAL trial and vitamin D supplementation reassessment — peterattiamd.com — VITAL trial discussion
21. Andrew Huberman — Huberman Lab episode on supplementation, vitamin D segment — hubermanlab.com — supplementation episode
22. Mark Hyman — Doctor's Pharmacy podcast, vitamin D as hormone framing — drhyman.com — vitamin D content
23. Bryan Johnson Blueprint published supplement stack (vitamin D3 2000 IU, K2-MK7 100 mcg) — protocol.bryanjohnson.com
24. IOM 2011 — Dietary Reference Intakes for Calcium and Vitamin D (UL 4000 IU/day for adults) — pubmed.ncbi.nlm.nih.gov/21118827
25. Vitamin D toxicity case report literature review — toxicity at chronic >40,000 IU/day — pubmed.ncbi.nlm.nih.gov/29346035
26. Endocrine Society clinical practice guideline — 30-50 ng/mL optimal range — endocrine.org — clinical practice guideline summary
27. PTH suppression as functional marker of vitamin D adequacy — pubmed.ncbi.nlm.nih.gov/22611157
28. Uwitonze AM, Razzaque MS — Role of Magnesium in Vitamin D Activation and Function. JAOA 2018 — pubmed.ncbi.nlm.nih.gov/29093983
29. Vitamin K2 (MK-7) and bone/cardiovascular endpoints — current evidence base summary — pubmed.ncbi.nlm.nih.gov/24489547
30. Examine.com — capsule, softgel, drops dosage form comparison — examine.com — vitamin D dosage forms
31. Mulligan GB, Licata A — Taking vitamin D with the largest meal improves absorption. J Bone Miner Res 2010 — pubmed.ncbi.nlm.nih.gov/20200983
32. Community storage / shelf-life consensus for fat-soluble vitamins — r/Supplements — storage and shelf-life consensus threads

YK-1127 references

1. r/sarmssourcetalk YK-11 thread aggregation (last 12 months, n=~420) — reddit.com/r/sarmssourcetalk YK-11 threads
2. r/PEDs YK-11 thread aggregation (last 12 months, n=~200) — reddit.com/r/PEDs YK-11 threads
3. FDA tainted body-building products enforcement category — fda.gov — Tainted Body-Building Products warning list
4. FDA warning letters to research-chemical vendors marketing SARMs / YK-11 — fda.gov — SARM warning letters to vendors
5. Kanno Y. et al., Biol Pharm Bull 2011 — YK-11 anabolic activity in C2C12 myoblasts (foundational paper) — pubmed.ncbi.nlm.nih.gov/21415556
6. Kanno Y. et al., Biol Pharm Bull 2013 — YK-11 follistatin upregulation / myostatin pathway — pubmed.ncbi.nlm.nih.gov/23994076
7. Structural characterization of YK-11 as a 17α-methylated DHT derivative — pubmed.ncbi.nlm.nih.gov/27697772
8. Kanno Y. et al. — YK-11 effects on osteogenic differentiation — pubmed.ncbi.nlm.nih.gov/28245459
9. Sakuma S. et al. — extended myogenic-marker characterization — pubmed.ncbi.nlm.nih.gov/29452146
10. Review — selective androgen receptor modulators classification context — pubmed.ncbi.nlm.nih.gov/30620925
11. ClinicalTrials.gov YK-11 registry (zero completed trials as of May 2026) — clinicaltrials.gov — YK-11 search
12. Review — anabolic-androgenic steroids vs SARMs structural-classification overview — pubmed.ncbi.nlm.nih.gov/30414835
13. WADA 2018 — YK-11 added to S1 anabolic agents — wada-ama.org — Prohibited List 2018
14. WADA 2026 Prohibited List — S1 anabolic agents (YK-11 retained) — wada-ama.org — Prohibited List 2026
15. Review — 17α-alkylated oral anabolic steroids and hepatotoxicity — pubmed.ncbi.nlm.nih.gov/19877123
16. Case report — drug-induced liver injury attributed to YK-11 — pubmed.ncbi.nlm.nih.gov/35119872
17. Case report — cholestatic hepatitis associated with YK-11 use — pubmed.ncbi.nlm.nih.gov/36045132
18. Case series — androgen suppression and liver injury in SARM/YK-11 users — pubmed.ncbi.nlm.nih.gov/37210512
19. LiverTox monograph — 17α-alkylated androgens hepatotoxicity — ncbi.nlm.nih.gov/books/NBK548931 — LiverTox: 17-alpha-alkylated steroids
20. FDA warning-letter database, research-chemical vendors — fda.gov — warning letters database (SARMs/YK-11)
21. r/sarmssourcetalk YK-11 cycle log megathread — reddit.com/r/sarmssourcetalk — YK-11 cycle log megathread
22. More Plates More Dates YK-11 deep dive (Derek) — youtube.com — More Plates More Dates YK-11 video
23. Tony Huge / Enhanced Athlete YK-11 commentary — youtube.com — Enhanced Athlete YK-11 commentary
24. Vigorous Steve YK-11 classification review — youtube.com — Vigorous Steve YK-11 review
25. Coach Greg Doucette SARMs / YK-11 marketing critique — youtube.com — Greg Doucette SARMs commentary
26. r/PEDs bloodwork-compilation thread for YK-11 cycles — reddit.com/r/PEDs — YK-11 bloodwork compilation thread
27. r/sarmssourcetalk YK-11 vendor concentration + storage discussion — reddit.com/r/sarmssourcetalk — vendor concentration / storage thread

13 · Limitations

• Population-average parameters. Pharmacokinetic parameters are population means from peer-reviewed literature. Individual responses vary with body composition, metabolism, injection technique, reconstitution accuracy, and dozens of factors not captured by population data.
• Quantitative output is anchored to compounds with published popPK + clinical-trial data. Receptor-occupancy bands, Monte‑Carlo confidence intervals, and trajectory bands are computed only for the three GLP-1RA reference compounds. Compounds outside this set receive qualitative analysis with explicit hedging — never fabricated quantitative output.
• Closed-form pharmacokinetics assume linear elimination. Closed-form Bateman superposition is correct for the linear PK regime that covers the substantial majority of consumer doses. Non-linear elimination cases are integrated numerically; compounds without published non-linear data carry observational dose-range cohorts only.
• Self-reported frequencies carry selection bias. Real-world reporting skews toward novelty and complaint, not steady-state experience. Per-compound research profiles split clinical (trial-derived) vs forum (self-reported) frequencies and never conflate the two.
• Real-world cohort means run below trial means. Retrospective claims-data cohorts (Truveta, Epic Cosmos derivatives) report 11–13 % mean weight loss at 12 months on semaglutide vs the trial mean of 14.9 %. The gap reflects observational adherence and titration patterns vs the controlled trial environment.
• Observational, not prescriptive. The dataset describes what compounds do, what users report, and what literature anchors. It does not prescribe what any individual should do. Decisions involving any compound on this list belong with a qualified clinician.

14 · Updates & contact

This page is the public technical contract for Milligram’s data and reasoning layer. Every formula on this page corresponds to a function in the production engine; every constant on this page corresponds to a literal in the production reference data set; every reference on this page resolves to a verifiable peer-reviewed citation, regulatory document, or named-source URL. Updates are made in lockstep with the production data pipeline.

For dataset access discussions, methodology questions, partnership inquiries, or corrections: support@milligramapp.com.

Last updated 9 May 2026 · 2,833 cited references